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For the 9th Edition of the “Cancer in Germany” 
report, data from the whole of Germany is available 
for the first time covering the years 2009 and 2010. 
With the exception of the Baden-Württemberg Can-
cer Register, which was established in 2009 and 
which, because of its gradual development, is not in 
a position to deliver reliable data for the purposes of 
epidemiological research for the period 2009-2010, 
reliable data is available for all other federal states. 
This means that an important milestone in the his-
tory of cancer registry in Germany has been reached. 
A history that encompasses almost a hundred years 
from the initial beginnings of population-based can-
cer registration in 1920’s Hamburg, via the estab-
lishment of the National Cancer Registry in the 
GDR in 1953 and the Saarland Cancer Registry in 
1967 through to the current achievement of national 
coverage.
Germany is now going another step further fol-
lowing this development, which although initially 
slow, has been consistently driven forward over the 
past almost two decades by the Federal Government, 
Federal States and a whole number of committed 
staff within the Cancer Registries themselves: Last 
Spring, within the framework of the National Can-
cer Plan, a law was passed – the Cancer Screening 
and Cancer Registries Act (KFRG) – which also puts 
clinical cancer registration nationwide on a legal 
footing. One of the particular tasks of clinical cancer 
registration is the quality control of oncological care, 
which requires much more detailed clinical docu-
mentation of recorded new cases of cancer. Epide-
miological and clinical cancer registration can only 
succeed if both forms of registration work together 
closely in spite of their different funding models, by 
coordinating registration channels and data-flows, 
sharing the data recorded and experience gained or 
even by merging – along the lines of the Dutch 
model  – to form “integrated” clinical-epidemiologi-
cal cancer registries.
It is already obvious now that clinical cancer 
registration in many regions will require a start-up 
period spanning many years. This means that the 
deadline target set in the Act for the end of 2017 may 
seem somewhat ambitious – at least for those regi-
ons starting from “scratch” with their clinical cancer 
registration. It will therefore still be a number of 
years until German, nationwide clinical data is sci-
entifically usable. 
However, from an epidemiological and public 
health point of view, even the data that has been 
available to date from the epidemiological cancer 
registries is extremely valuable. On the one hand it 
shows a need for epidemiological research, based on 
the example of those types of cancer with increasing 
incidence rates such as carcinomas of the liver, thy-
roid and vulva. On the other, it helps to evaluate cur-
rent and future measures for cancer screening, 
which forms a second focus of the National Cancer 
Plan and of the KFR. Furthermore, initial examples 
reveal that even under the very strict restrictions on 
the part of data protection in Germany, a compa-
rison of data from epidemiological studies with data 
in cancer registries is indeed possible, which in a 
few years will also come to benefit the “National 
Cohorts”, a broad-scale, nationwide cohort study 
to research the causes of all chronic diseases. Even 
without a direct link to other data, many scientific 
issues can be processed using the data, as many 
publications based on German Cancer Registry data 
meanwhile show. 
With the establishment of the Centre for Cancer 
Registry Data (ZfKD) at the Robert Koch Institute in 
2010 the possibility now exists of being able to 
obtain the data of all German population-based can-
cer registries for substantiated purposes on applica-
tion, centrally, from one office. 
Amongst other things, one of the tasks of the 
Advisory Committee is to make recommendations 
regarding applications for use [of data].  
The well-known high regard for cancer registries 
in Scandinavia stems from the fact that important 
findings have been derived from the data contained 
therein. I would therefore like to encourage those 
who read this to use the data and results from the 
German Cancer Registry for the ultimate objective 
of public health: “Maintaining and improving the 
state of health of the population”. 
Prof. Andreas Stang, MPH
Chairman of the Advisory Committee of the Centre 
for Cancer Registry Data 
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important parameter for assessing the effectiveness 
of diagnosis, therapy and aftercare of cancers.
Because of the demographic development in Ger-
many, it is expected that there will be more than a 
20 % increase in new cases of cancer between 2010 
and 2030.
The prediction of the future number of new cancer 
cases is an important aspect of requirement plan-
ning within the health service. The population-
based cancer registries provide the baseline data 
needed for this. 
The data from population-based cancer registries is 
also used for scientific research into the causes of 
cancer or for health services research. Such studies 
(case-control studies, cohort studies, etc.) investiga-
te issues such as:
 ▶ What are the causes of childhood leukaemia?
 ▶ Do women who take hormone-replacement the-
rapy for menopausal problems have a higher 
risk of developing breast cancer?
 ▶ Does lung cancer develop more frequently in 
people in certain occupational groups? 
 ▶ Are diagnosis, therapy and aftercare being car-
ried out according to the latest standards?
Population-based cancer registries make it possible 
for all cases of the disease that have occurred in a 
defined population to be taken into account in 
research projects. If as many patients as possible 
participate in the project, it can be broadly guaran-
teed that the findings of such studies do not only 
apply to a specific group of patients (for example, in 
a specific study or a particular hospital). Population-
based case-control studies and cohort studies conse-
quently use data from population-based cancer 
registries for research into the causes and risks of 
cancer.
Further or specific issues may also be analysed 
using the registry data. Examples include:
 ▶ Detailed analyses regarding survival prospects 
following diagnosis of cancer
 ▶ Examination of oncological care and long-term 
quality of life of cancer patients
 ▶ Evaluation of pilot projects concerning mammo-
graphy-screening, quality assured breast-scree-
ning and diagnostic services and skin-cancer 
screening
Population-based (epidemiological) cancer regis-
tries are institutions for the collection, storage, pro-
cessing, analysis and interpretation of data on the 
incidence and prevalence of cancers within defined 
registration areas (e.g. one German federal state). 
The data from the cancer registries also forms an 
indispensable basis for further studies into the cau-
ses of carcinogenesis, the assessment of early detec-
tion measures and population-based care of tumour 
patients.
Findings from population-based cancer regist-
ries include:
The prostate, bowel and lungs are the most common 
cancer sites among men.
The incidence of cancers (i.e. how frequently they 
occur annually in a certain population group) can be 
described using the data from population-based can-
cer registries. The incidence is calculated according 
to cancer type, patient age and gender, as well as 
other characteristics. Reliable information regar-
ding incidence is indispensable for depicting the 
extent and type of the burden that cancer places on a 
population.
For some years there have been just as many new 
cases of lung cancer among women under the age of 
forty as among men of the same age.
Only by using data from the population-based can-
cer registries can the development of incidence over 
time (trends) can be observed. The registries have a 
key function for health reporting in this context.
Regional differences in the incidence of malignant 
melanoma of the skin can be observed in Europe 
and in Germany.
Population-based cancer registries can analyse the 
regional distribution of various types of cancer. It is 
also within their remit to investigate any cancer clus-
ters observed. Further clarification of these clusters 
with regard to possible causes usually involves targe-
ted analytical studies.
In recent years, the survival prospects following dia-
gnosis with cancer have largely converged in both 
the western and eastern federal states.
Population-based cancer registries conduct survival-
time analyses of all cancer patients in their registra-
tion region. Population-based survival rates are an 
1 Epidemiological cancer registration in Germany
1.1 Aims and tasks of population-based cancer registries
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commencement of registration in Baden-Wuerttem-
berg in 2009. The Federal Cancer Registry Data Act, 
which came into force in the same year, further 
improved the scope for collection and evaluation of 
anonymised cancer registry data at the national level 
via the newly established German Centre for Cancer 
Registry Data at the Robert Koch Institute.
In order to be able to pool information about an 
individual's cancer condition from different sources, 
data is collected in such a way that multiple reports 
on the same person are identifiable. For research 
purposes it has to be possible to re-establish the link 
between the data and the individual. However in 
order to safeguard patients‘ privacy and their right to 
control what happens to their data, all population-
based registries are required under state legislation 
to adopt extensive precautions to protect and secure 
personal data.
Undistorted evaluation of the data is only possible 
if more than 90 % of all new cancer cases are regis-
tered. The cooperation of all physicians and dentists 
involved in diagnosis, treatment and aftercare is 
therefore crucial to the significance of data from a 
population-based cancer registry. Patients are also 
requested to take an active part in cancer registra-
tion. Ask your doctor to report your case to the appro-
priate cancer registry! This way you too can contri-
bute to improved evaluation of cancer-related deve-
lopments, cancer research and also help to improve 
cancer detection, treatment and aftercare.
1.2 Current developments in cancer  
registration in Germany
Since 2009, all new cases of cancer nationwide are 
being systematically registered across the whole of 
Germany on the basis of regional legislation. As a 
consequence, the current situation for population-
based cancer registration is to be viewed as very 
good. In nine federal states the estimated degree of 
registration for 2010 is over 90 %. This means we 
now have reliable data on new cases of cancer for a 
population of more than 50 million. Across Germa-
ny approximately 90 % of the estimated new cases 
for 2010 have actually been recorded in the registries 
– ten years previously the figure was still under 
40 %. In the next few years of reporting, this percen-
tage will increase further solely because of the 
phased establishment of the Baden-Wuerttemberg 
cancer registry up to the end of 2011. Internationally, 
barely any other country of comparable population 
size has achieved such a high rate of registration to 
date.
Numerous individual initiatives in the federal 
states to improve cancer registration have contribu-
ted to this great result. Population-based cancer 
registration has also continued to receive support 
 ▶ Study of the connection between social strata 
and cancer incidence and mortality
 ▶ Cooperation with the cancer centres, e.g. in the 
assessment of the long-term survival of treated 
patients
 ▶ Study on the effectiveness of colonoscopy scree-
ning
A detailed list can be found at: www.gekid.de.
In the years to come, the evaluation of the screening 
measures introduced in Germany will present a par-
ticular challenge for the population-based cancer 
registries. Using the data provided by the registries, 
it will be possible to assess whether screening has 
had the desired effect of reducing the number of 
advanced cancers within the population. By linking 
the registry data with the respective screening pro-
gramme it should also be possible to demonstrate 
reduction in mortality among participants in such 
measures.
One initial focus in this regard has been the assess-
ment of mammography screening, which had been 
introduced nationwide by 2009. The population-
based cancer registries have already provided detailed 
basic data for the first evaluation reports on mammo-
graphy screening (www.mammo-programm.de), and 
this is being used for quality assurance and an initial 
assessment of the programme. A new task scheduled 
here is the identification of interval carcinomas (inci-
dence of breast cancer following negative screening 
examination).
In 2008, the statutory health insurers introduced 
screening for skin cancer, the effects of which on the 
incidence of skin cancer and related mortality can 
also be investigated using the data from the cancer 
registries. The National Cancer Plan once again 
emphasised the central role of cancer registration in 
assessing the effects of organised programmes for 
the early detection of cancer. A number of imple-
mentational recommendations were adopted in the 
plan, which may ensure improved coordination in 
the future between the early recognition program-
mes and the information collected in the cancer 
registries.
A longer-term task of the population-based cancer 
registries is also to examine the effectiveness of the 
vaccination programme for girls between 12 and 17 
years of age against human papilloma viruses (HPV) 
with the aim of significantly reducing the number of 
new cases of cervical cancer.
In order to fulfil the stated objectives and tasks of 
the cancer registries it does not suffice to operate 
population-based cancer registries in selected regi-
ons of Germany. To achieve this it is necessary to 
operate cancer registries in all federal states nation-
wide. This has been achieved in the meantime with 
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research data and cancer registry data have also 
resulted from further research projects. Informa-
tion with regard to further research work and cur-
rent publications can be found on the GEKID home-
page and in the annex to this report.
These examples show clearly that the focus of 
cancer registration in Germany is currently shifting 
away from the mere collection of data towards the 
active scientific utilisation of the data. This develop-
ment is of essential importance because without in-
depth scientific analysis the knowledge gained from 
the laboriously gathered data would be limited. 
Finally, the pooled anonymised datasets from all 
registries can now also be used by external scientists 
(on application to the German Centre for Cancer 
Registry Data), an opportunity which has increasin-
gly been made use of recently. Even from the point 
of view of health reporting, the numerous contribu-
tions from the cancer registries have, in the mean-
time, become an important component.
Within the framework of the National Cancer 
Plan, the population-based cancer registries together 
with GEKID and the German Centre for Cancer 
Registry Data, have taken active roles in various 
bodies. (See Federal Ministry of Health website at 
www.bundesgesundheitsministerium.de for NCP 
objectives). The passing of the Cancer Screening 
and Registration Act (KFRG) at the beginning of 
2013 can be viewed as a major success of the Natio-
nal Cancer Plan. Through this law and following 
epidemiological registration, clinical cancer regist-
ration has also been introduced on a mandatory 
basis, which includes – amongst other things – 
recording of detailed data pertaining to therapy 
and progress. In conjunction with the German 
Tumour Centres Working Group (ADT) the federal 
states are currently working on an implementation 
programme, which also includes the development 
of a uniform basic dataset for cancer registration.
A completely new era is dawning with the intro-
duction of clinical cancer registries. The data from 
cancer registries will therefore be useful for purpo-
ses of comprehensive quality-assurance and for 
health services research. This will consequently 
result in an increase in the significance of cancer 
registration for oncological research and care and in 
the benefits for patients with cancer.
Viewed overall, the current development in can-
cer registration and usage of data for cancer-related 
matters in Germany is to be seen very positively and 
has considerable future prospects. If the doctors and 
patients remain willing to report, and given the 
appropriate financial and political support for can-
cer registries, the goal of a comprehensive, nation-
wide system of cancer registration in Germany will 
soon be reached.
from the Federal Government with the Federal Can-
cer Registry Data Act of 2009 and the establishment 
of the German Centre for Cancer Registry Data 
(ZfKD) within the Robert Koch Institute. Since the 
end of 2011, all regional cancer registries have been 
supplying their depersonalised data annually to the 
ZfKD in a uniform format. This collective data 
forms the basis of the analyses carried out by the 
ZfKD which are presented in this, the 9th edition of 
“Cancer in Germany”.
For 2014, the International Agency for Research 
on Cancer at the World Health Organisation in 
Lyon, France is planning a new edition of the pub-
lication “Cancer Incidence in Five Continents 
(Vol. X)”. Once again the German cancer registries 
were asked to actively participate and have transfer-
red their anonymised data sets on new cases of can-
cer to the IARC. Since in the last edition data was 
presented from seven German cancer registries, it is 
to be assumed that due to the quality of the data 
gathered in Germany it will now be possible for 
additional state cancer registries to meet the strict 
criteria of the IARC and qualify for inclusion in this 
central publication series of the WHO.
Data from the German cancer registries together 
with data from other European countries can already 
be found today on the European Network for Cancer 
Registries’ website (http://eco.iarc.fr). Here the Ger-
man data can easily be compared with the details 
from other European registries.
The Association of Population-based Cancer 
Registries in Germany (GEKID), which has cancer 
epidemiologists as members in addition to all the 
population-based cancer registries, has continued to 
work intensively over the past two years on the 
improved use of the cancer registry data. An impor-
tant result is the GEKID’s new interactive cancer 
atlas on current cancer prevalence and mortality in 
Germany. The atlas is available on the GEKID web-
site (www.gekid.de), with maps offering interactive 
regional comparisons for 23 cancer sites. Important 
agreements were also reached on the methodology 
for calculating survival rates, with the aim of impro-
ving the transparency and comparability of this 
important parameter.
In addition to purely presenting cancer registry 
data, the population-based cancer registries and 
GEKID have also been involved in planning and car-
rying out epidemiological cancer research projects. 
A particular area of emphasis here was the German 
Cancer Aid (Deutsche Krebshilfe) funding pro-
gramme focussing on “Cancer epidemiology.” 
Together with the German Cancer Research Centre 
in Heidelberg it was possible to investigate in detail 
survival data following cancer and publish the fin-
dings internationally. Several important, internatio-
nal publications, for example on the link between 
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projects, the ZfKD receives support from an Advisory 
Committee, which is also consulted regarding ZfKD 
publications. Finally, and in conjunction with univer-
sity teaching staff from various universities, the 
ZfKD is currently advising on several Doctoral and 
Master’s theses.
The clinical cancer registries, which are to be int-
roduced in all federal states in accordance with the 
Cancer Screening and Registration Act (KFRG), 
should contribute with their data and analyses in the 
future toward guaranteeing or further improving the 
quality of care for those suffering from cancer in Ger-
many. For the implementation of the National Can-
cer Plan, however, nationwide, population-based 
(epidemiological) data is also indispensable: the ana-
lysis of temporal trends, regional differences and not 
least the comparison thereof with international 
results all contribute significantly toward highligh-
ting advances, but also deficits in the fight against 
cancer. This is especially valid with regard to the 
assessment of the effects of cancer screening, which 
constitutes a second focus of the National Cancer 
Plan and the Cancer Screening and Registration Act.
In the next few years, in addition to the tasks out-
lined in the above, the ZfKD will increasingly be tur-
ning its attention to further scientific and methodo-
logical issues. In January 2014, the Federal Health 
Gazette will publish a special booklet on “Epidemio-
logical Cancer Registration” to which authors from 
within the registries, the ZfKD, the German Cancer 
Research Centre and university institutions will con-
tribute. This booklet will offer a summary of the 
multitude of possible uses of cancer registry data in 
Germany. In 2015 the second ZfKD report series - 
initiated via the Federal Cancer Registry Data Act 
(BKRG) - will start. As part of this, comprehensive 
reports about the cancer situation in Germany will 
be published every five years using additional data 
sources. Information concerning current projects 
and activities can be found on the ZfKD website 
(www.krebsdaten.de).
2 Methodological Aspects
2.1 Estimating the degree of capture in 
the epidemiological cancer registries 
(Estimation of Completeness) 
The usefulness of population-based data with regard 
to cancer largely depends on the level of complete-
ness with which new cancer cases are registered. 
Therefore the Centre for Cancer Registry Data 
(ZfKD) annually checks the completeness of the 
data from the population-based cancer registries in 
Germany, and 2010 marked the first year of diagno-
sis this was done in all federal states. The estimation 
is made with the help of an internationally accepted 
1.3 Current main foci of the Centre for  
 Cancer Registry Data (ZfKD)
Almost four years have passed since the ZfKD was 
established, building on the former working group 
Federal Cancer Surveillance Unit. One important the-
me during this period has been the development of 
an interactive evaluation tool at www.krebsdaten.de 
supplementary to the results contained in this 
report. Compared to previous editions, the presenta-
tion of the results in “Cancer in Germany” has 
become considerably more extensive and detailed: 
In the meantime, ten additional cancer sites have 
been added to the 16 presented in the 1997 first edi-
tion, and these have now been supplemented for the 
first time with an overview of rarer tumour diseases 
and of non-melanoma skin cancer. In addition to 
details regarding incidence and mortality for the 
individual disease types, analysis results are presen-
ted pertaining to prevalence, distribution of tumour 
stages and to the survival rates according to cancer 
type. This development is not only an expression of 
what is now a marked improvement in the data 
available, but also necessary to do the complex phe-
nomenon of ‘cancer’ justice. Also, especially with 
regard to rarer forms of cancer together affecting 
several thousand people every year in Germany, the 
ZfKD nationwide collective dataset permits conside-
rably more reliable statements to be made than 
would have been possible from the results of indivi-
dual registries.
Another ZfKD focus has been the collaboration 
with GEKID on further standardisation of data acqui-
sition in the registries. Simply because of the fact 
that the nationwide dataset can be made available to 
third parties on application, the need arises for any 
differences in registration practice and data quality 
that still exist to be further minimised or documen-
ted. However, a coordinated implementation is also 
required for changes in international disease classi-
fication, as most recently in the case of leukaemia 
and lymphoma as part of an ICD10 update by the 
WHO. The same currently applies for amended data-
protection requirements with regard to encryption 
methods used in the registries. In these fields too, 
the ZfKD and GEKID are working together intensi-
vely and even representatives from the clinical can-
cer registries are already being included to some 
extent.
The contributions of the ZfKD to the increased 
scientific use of the data already mentioned in Sec-
tion 1.2 are manifold: in addition to its own publica-
tions and conference papers, the ZfKD supports 
external scientists by answering queries and provi-
ding results, as well as – if appropriate – planning 
and executing evaluation projects using the ‘Scienti-
fic Use File’. When processing applications for such 
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the real ratio of mortality to incidence differs bet-
ween the regions. This may, for example, be the case 
if early detection measures are utilised to varying 
degrees in the federal states or if they are introduced 
at different points in time, as was the case with 
mammography-screening.
According to the current estimation, nine federal 
states are already achieving an estimated complete-
ness of at least 90 % for 2010, with seven of the sta-
tes even achieving over 95 % in relation to the afore-
mentioned reference registries. In the last ten years, 
the degree of capture has consequently increased 
considerably (Illustration 2.1.1). Any deficits that still 
exist can in part be explained by the fact that the for-
warding of data regarding patients treated outside 
their state of residence is not yet satisfactorily regu-
lated in all areas. Planned adaptations to regional 
laws and the development of technical solutions 
should lead to further improvements in the next few 
years. The stepwise implementation of the cancer 
registry in Baden-Wuerttemberg did not reach com-
pletion until during the course of 2011, which means 
that comprehensive capture cannot be expected 
until the diagnosis year 2012 at the earliest. Accor-
ding to ZfKD estimates, the greatest deficits still 
exist for cancers of the liver, gall bladder and pan-
creas, as well as leukaemias and lymphoma. In each, 
only five federal states and the administrative dis-
trict of Münster have achieved an estimated degree 
of capture of at least 90 %. In contrast, for the majo-
rity of diagnosis groups examined, at least ten fede-
ral states can already be classified as having compre-
hensive coverage.
2.2 Estimating national incidence for  
Germany
The estimation of incidence rates for Germany are 
based on the results of completeness estimation as 
explained in 2.1. The estimated nationwide figures 
for new cases for the individual diagnoses and years 
arise from the summation of the results from the 
registries with a degree of capture of at least 90 % 
and the expected value from the completeness esti-
mation for those regions that were not (yet) deemed 
to be comprehensive for the respective year. The 
DCO (Death Certificate Only) cases were included 
for the comprehensive registries from the sixth year 
of nationwide registration. For the first five years 
and for the non-comprehensive registers the DCO-
rates from the five reference registries were taken 
into the calculation (according to site, age and gen-
der). Because of the varying stages of development, 
North Rhine-Westphalia was divided into three regi-
ons for the time being (the administrative district of 
Münster, Düsseldorf/Cologne and Arnsberg/Det-
mold).
indicator of completeness, namely the ratio of mor-
tality to incidence. This ratio (M/I Index) can largely 
be assumed to be regionally constant for the respec-
tive cancer diagnosis, provided there are no funda-
mental differences in diagnosis and therapy and 
therefore also in the survival prospects of cancer 
patients in Germany. With the help of the M/I-Index 
in a particular reference region where registration is 
known to be comprehensive and by using regional 
mortality figures, the incidence in the respective 
region examined can be estimated and compared 
with the actual recorded data. Cases identified 
through death certificate only (DCO) are not taken 
into account here. The completeness of the refe-
rence region register is also estimated by means of 
comparison with the expected values.
The following inclusion criteria were established 
for the reference region in 2010.
 ▶ Comprehensive cancer registration for a period 
of at least ten years
 ▶ Completeness of more than 90 % for cancer ove-
rall over the past ten years (using the previous 
RKI estimation method) and more than 80 % for 
all individual years
 ▶ Proportion of DCO-cases of less than 15 % for 
cancer overall over the past ten years or at least 
from the sixth year since the beginning of regis-
tration
These criteria were met by the registries in Saarland, 
Hamburg, Bremen, Saxony and the administrative 
district of Münster (North Rhine-Westphalia). It is 
expected that this pool will grow to include further 
registries in the next few years.
According to the principle described in the above, 
expected values are calculated for six age groups for 
men and women respectively and for 18 diagnosis 
groups. In order to compensate for random fluctua-
tions the observed and expected values were smoo-
thed using log-linear models.
If mortality in the region being studied is too low 
(less than five cases of death per year on average) the 
modelled (smoothed) incidence in the reference 
region is used instead of the quotients derived from 
incidence and mortality for the appropriate age 
group in order to calculate the expected number of 
new cases. The estimated degree of completeness 
for each diagnosis group is the result of the ratio of 
observed and expected case figures accumulated 
across all age groups. The completeness for cancer 
overall is again estimated by summing the observed 
and expected values for all diagnosis groups.
The procedure described has limitations, espe-
cially if the mortality for one type of cancer is low in 
absolute terms or relative to incidence (testicular 
cancer, malignant melanoma, thyroid cancer), or if 
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period before 2002 for instance. Although the same 
methodology was used in each case, estimates for 
recent years can generally be viewed as more reliable.
Assuming that the levels of completeness within 
the diagnosis groups do not differ significantly, esti-
mations were conducted for the first time for rarer 
types of cancer according to the same principle. The 
results are shown in Chapter 3.28 and in even more 
detail on the website at www.krebsdaten.de.
An estimation of the incidence of non-melanoma 
skin cancers (C44) is not possible using the method 
described, amongst other things due to the low mor-
tality. Experience shows that the acquisition of data 
pertaining to these diseases in population-based 
cancer registries is difficult since treatment is often 
on a purely out-patient basis. Consequently, even in 
an international context there is very little reliable 
data. However, in recent years some registries in 
Germany have made successful efforts to also 
include registered dermatologists in the registration 
Because the entire dataset is analysed anew for 
every estimation of incidence, this may result in 
changes (usually slight) in the incidence rates from 
estimation to estimation, which partly can be caused 
by delayed notification of incident cases and partly 
by the methodology of the estimation itself. Conse-
quently the current estimations for 2008 for laryn-
geal and oesophageal cancer are up to 5 % lower 
than two years ago whilst the estimated number of 
cases of Non-Hodgkin lymphomas are around 10 % 
higher. With regard to most sites, slight increases 
resulted of around 2-3 % on average, which approxi-
mately corresponds to the number of late registra-
tions in the registries.
This report presents estimated trends over time 
since 1999. Since the population-based cancer regis-
tries in the densely populated federal states did not 
commence data capture until between 2002 and 
2009, the estimations for recent years are based on 
a significantly broader data basis than those for the 
Figure 2.1.1
Development of the estimated completeness of the population-based cancer registries in Germany 2000 to 2002 and 2010,  
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Cancer incidence and mortality risks 
Age-specific incidence rates and mortality rates may 
be interpreted as measures for the age- and gender-
specific risks of developing and dying from a speci-
fic malignant tumour within a year. In addition, age 
and sex specific risks of developing or dying from a 
specific form of cancer within the next ten years or 
at some point in the future were calculated. The 
results are presented both as a percentage and as 
one in N individuals of the same age and sex. So-
called “competing risks” were also taken into consi-
deration, e.g. the probability of a 75-year-old man to 
die from some other disease within the next ten 
years. Similarly, the “lifetime risk” was calculated, 
i.e. the risk of developing a tumour at some point 
during an entire lifespan. However, only the respec-
tive current rates (incidence and mortality rates and 
general life expectancy) are used in the calculations. 
No prediction is therefore made regarding the future 
development of these values. Furthermore, these 
results are to be viewed as average values for the 
entire German population and individual risks may 
differ considerably due to the presence or absence of 
specific risk factors. The DevCan programme deve-
loped by the US National Cancer Institute was used 
to perform the calculations.
International comparison
In order to be able to classify the estimated cancer 
incidence and cancer mortality in Germany 
in an international context, current age-standar-
dised incidence and mortality rates in the countries 
bordering on Germany as well as the United King-
dom, Finland, and the USA (see Annex for sources). 
Where figures were available by the editorial dead-
line, these results refer to the mean value for 2009 
and 2010, otherwise the latest available data or esti-
mations were used for the comparison. For some 
types of cancer (e.g. bladder cancer, renal cancer) the 
grouping of diagnoses in accordance with ICD-10 
differs somewhat in individual countries from that 
used in Germany, which slightly limits comparabili-
ty in some cases (see appropriate footnote).
The international results were accepted without che-
cking completeness or plausibility. Therefore it is 
not possible to rule out an underestimation of inci-
dence in particular for individual countries (due to 
underreporting of new cases). As a rule, a significant 
deviation in the ratio of mortality to incidence - com-
pared to other countries represented - can be consi-
dered an indication of underestimation; just as an 
incidence rate for individual cancer types below the 
corresponding mortality rate would indicate under-
reporting.
process. This first-time estimation of nationwide 
incidence figures is thus based on the data of those 
registries where the age-standardised incidence rate 
in the past two years deviated by less than 25 % from 
the federal state with the highest recorded incidence 
(Schleswig-Holstein, Lower Saxony, North Rhine-
Westphalia, Hesse and the Rhineland Palatinate). 
The calculation was performed by projecting the 
pooled, age-specific incidence rates in these states 
onto the entire German population. However, a 
great degree of uncertainty still surrounds the inci-
dence estimates for non-melanoma skin cancers 
and these do not yet allow any reliable statements to 
be made regarding trends over time, which is why 
they are not presented in their own chapter. With 
regard to the presentation of the incidence of cancer 
in general (chapter 3.1) non-melanoma skin cancers 
have not, as in previous years, been included for rea-
sons of comparability.
2.3 Indicators and graphical presen-
tations
The following section provides explanations of the 
measured values used in the results chapters and in 
the graphical presentations.
Age-specific rates
The age-specific rate is determined by dividing the 
number of cases of cancer and deaths in a certain 
age group by the corresponding number of men or 
women in this age group within the population. The 
graphical presentation of these rates shows the rela-
tionship between age and incidence by gender. The 
age-specific incidence rates are expressed as the 
annual number of new cases per 100,000 inhabi-
tants for the respective age group and year.
Age-standardised rates
As the presentation of the age-specific incidence for 
men and women in this report shows, the cancer 
incidence rate usually increases considerably with 
age, so that before comparing incidence or mortality 
in different states and regions, or within the same 
population at different times, differences in the age 
structure of the compared populations must first be 
removed with the help of age-standardisation. This 
is achieved through weighting and subsequent sum-
ming of the observed age-specific rates. An age-stan-
dardised rate indicates the incidence of a type of ill-
ness or cause of death in a total of 100,000 people in 
a pre-defined age structure (standard population). In 
this report the old European Standard Population 
has been used.
 Cancer in Germany 13
vant population (in this case the residential popula-
tion of Germany). The result is expressed as the 
number of new diagnoses or deaths per 100,000 
residents per year. In contrast to the age-standar-
dised rates, crude rates are highly dependent on the 
age-structure of a population, particularly in the case 
of cancer.
Survival rates
The results of survival analyses in this report descri-
be the average survival prospects of patients over the 
age of 15 years at the time of diagnosis given a speci-
fic cancer type. Absolute and relative survival rates 
have been calculated for this purpose. Absolute sur-
vival rates represent the proportion of patients who 
are still alive at a certain time after their diagnosis. 
For example, an absolute 5-year survival rate of 80 % 
means that 80 people out of 100 diagnosed with a 
specific type of cancer have survived the first five 
years after their diagnosis.
Relative survival rates show cancer-related morta-
lity in terms of the ratio of absolute survival of the 
cancer patients to the expected survival in the gene-
ral population of the same age and gender. For 
example, a relative 5-year survival rate of 100 % 
means that within 5 years of cancer diagnosis, just 
as many persons affected have died as would have 
been expected even without diagnosis. The relative 
survival rate is always higher than the correspon-
ding absolute rate. It has been calculated using the 
so called “Ederer II method” using the federal Ger-
man mortality tables from the Federal Statistical 
Office. 
In order to make the most up-to-date estimates of 
survival prospects possible, the so-called “period 
method” was used. This takes into account the sur-
vival of people with cancer who have been alive 
during a specific period (in this case 2009-2010). 
Because the accuracy of the survival analyses is 
highly dependent on the quality of the underlying 
data, only those registries were included for the cur-
rent calculations, which met two criteria. Firstly, 
DCO cases should account for no more than 15 % 
across all malignant cancers (C00-C97 not inclu-
ding C44) for the period under consideration. The 
fact that there is no diagnosis date for a DCO case, 
i.e. a case of the illness which is only recorded 
because of the death certificate, inevitably means 
they have to be excluded from the survival analysis. 
This causes a potential over-estimation of survival 
rates since according to the results of many studies, 
DCO cases tend to represent a selection of patients 
with shorter survival times.
The second criterion concerns the quality of the 
determination of the vital status of patients included 
in registry data during their lifetime. International 
studies indicate that patients diagnosed with pan-
Median age at diagnosis
The median age at which a specific cancer develops 
according to cancer site and gender was calculated 
for all cases diagnosed in 2009 and 2010. The inclu-
sion of DCO cases, for which the age at death is used 
instead of age at diagnosis, inevitably leads to a 
slight overestimation of this value.
Mortality
Cancer mortality is based on number of deaths in 
any one year due to cancer according to the official 
cause-of-death statistics. The deaths are attributed 
to the underlying cause of death and grouped 
in terms of age and sex. The mortality rate is 
expressed as the relationship of the annual number 
of deaths to the size of the population. The rates are 
relative to 100,000 people. In this report, the abso-
lute number of deaths, as well as crude and the age-
standardised mortality rates from 1999 to 2010 
(European Standard) are presented. More up-to-
date figures are already available from the German 
Federal Statistical Office (www.gbe-bund.de) and at 
www.krebsdaten.de.
Prediction of incidence for 2014
The incidence rates were predicted for 2014 by deter-
mining linear trends in estimated age-, gender- and 
site-specific logarithmic incidence rates for Germa-
ny over the past ten years, and continuing these 
trends through to 2014 drawing on the current 
demographic projections from the German Federal 
Statistical Office. In variation from the above, cons-
tant incidence rates were assumed in the case of pro-
state cancer for all age groups and for female breast 
cancer for the 50 to 69 year age group (target group 
for mammography screening).
Regional comparison
The mean age-standardised incidence rates for 
2009 and 2010 (European Standard) from the fede-
ral states are expressed in comparison with the cor-
responding estimates for Germany. Any estimated 
capture rates of less than 90 % for 2010 are indica-
ted by highlighting the incidence bar. Age-standar-
dised mortality according to site and sex for all fede-
ral states is shown in comparison to nationwide 
mortality in Germany for the same period, using 
figures from the German Federal Statistical Office 
(www.gbe-bund.de).
Crude rates
A crude rate of incidence or mortality for a specific 
cancer site and population is calculated by dividing 
the total number of all new cases of cancer reported 
(incidence) or the number of deaths due to cancer 
(mortality) in a pre-determined time period by the 
total number of all women and/or men in the rele-
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med that the estimated survival rates quoted for Ger-
many are slightly over-estimated, at least for those 
types of cancer with worse prognoses, but this is 
probably the case for most of the international 
results published too.
Distribution of stages of tumours
The extent of a solid malignant tumour at the point 
of diagnosis in the years 2009-2010 was evaluated 
using the TNM-classification, though given the data 
situation, only the distribution of T stages (tumour 
size) are presented here. For those cancer sites, for 
which the definition of the T-stages have been amen-
ded in the 7th Edition of the TNM-classification, 
valid since the beginning of 2010, only data from 
2010 were used that were not explicitly coded accor-
ding to the 6th Edition. For the respective sites, tho-
se registries were included in the evaluation where 
the proportion of missing values (including DCO-
cases) was less than 50 %. For sites where fewer than 
four federal states were able to fulfil this criterion, 
the stages have not been presented.
5-year prevalence
The 5-year prevalence refers to the number of people 
living at a given time (here 31 December 2010) who 
had been newly diagnosed with cancer within the 
previous five years, i.e. between 2006 and 2010. The 
prevalence is calculated using the Pisani method 
from the estimated incidence rates for Germany 
and the absolute survival rates calculated using the 
Kaplan-Meier method (according to age, sex, site, 
and calendar year) for the regions listed under ‘sur-
vival rates’ (see above).
creatic cancer or lung cancer with metastases have a 
very poor prognosis. Furthermore, the average sur-
vival prospects for patients with such diagnoses 
have not changed substantially over a long period. 
Consequently, any high proportion of surviving pati-
ents with these types of cancer established by cancer 
registries could be an indication of deficiencies in 
the quality of the data (a relevant proportion of 
‘missed’ deaths). Therefore, only those registries 
were included in the evaluation in which patients 
diagnosed with pancreatic cancer or metastasised 
lung cancer showed a relative 5-year survival rate of 
no more than 7.5 % on average.
After applying these two criteria, the cancer regis-
tries of Hamburg, Lower Saxony, Bremen, the Rhi-
neland Palatinate and Saarland, as well as the data 
from the Joint Cancer Registry for Brandenburg, 
Mecklenburg-Western Pomerania, Saxony and Thu-
ringia were used in the evaluations. The range quo-
ted for five year survival represents the lowest and 
highest values in the individual regions included, 
though for these purposes only regions with case 
figures of at least 50 patients were taken into account 
in the analysis. If this criterion was not met by at 
least five regions, no range details have been presen-
ted. Presumably, the presented range only to a small 
extent reflects ‘real’ differences in the quality of care. 
Differences in data quality or in the proportion of 
DCO cases may play a role, as well as random fluc-
tuations, especially for smaller federal states. Metho-
dological differences between registries may also 
influence results, in particular efforts to conduct 
trace-back research on DCO cases, which is not per-
formed in all federal states. Overall, it can be assu-
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Table 3.0.1
Estimated numbers of incident cancer cases in Germany 2010
No. of incident cases Incidence rate¹
Cancer site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 - C14 9,340 3,490 18 2 5 9
Oesophagus C15 4,890 1,420 8 9 2 1
Stomach C16 9,150 6,690 15 7 8 5
Colon and rectum C18 - C21 33,800 28,630 57 8 36 8
Liver C22 5,850 2,480 10 1 3 2
Gallbladder and biliary tract C23, C24 2,240 3,070 3 8 3 7
Pancreas C25 8,020 8,060 13 8 10 0
Larynx C32 3,230 460 6 0 0 8
Lung C33, C34 35,040 17,030 60 7 26 5
Malignant melanoma of the skin C43 9,640 9,580 18 0 17 8
Mesothelioma C45 1,320 350 2 1 0 5
Breast C50 610 70,340 1 1 119 6
Vulva C51 3,190 4 6
Cervix C53 4,660 9 3
Uterus C54, C55 11,550 17 7
Ovaries C56 7,790 12 1
Prostate C61 65,830 111 4
Testis C62 3,820 9 4
Kidney C64 8,950 5,570 16 2 8 2
Bladder C67 11,350 4,150 18 9 5 0
Central nervous system C70 - C72 3,890 3,030 7 9 5 2
Thyroid gland C73 1,690 4,220 3 5 8 7
Hodgkin's lymphoma C81 1,260 940 2 9 2 2
Non-Hodgkin lymphomas C82 - C85 8,590 7,640 15 5 11 2
Multiple myeloma C90 3,360 2,780 5 7 3 7
Leukaemias C91 - C95 6,640 4,920 12 5 7 7
Other cancer sites 13,890 12,880 24 9 18 4
Total cancer² C00-C97 w/o. C44 252,390 224,910 445.0 349.1
1 age-standardised (European standard)  2 not including non-melanoma skin cancer (C44)
Figure 3.0.1
Most frequent tumour sites as a percentage of all new cancer cases in Germany 2010 
(not including non-melanoma skin cancer)
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3.0 Overview of incident cancer cases and cancer deaths
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Table 3.0.2
Number of deaths from cancer in Germany 2010
Source: Official cause of death statistics, Federal Statistical Office, Wiesbaden
No. of deaths Mortality rate¹
Cancer Site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 - C14 3,816 1,204 7 2 1 8
Oesophagus C15 3,837 1,142 6 9 1 5
Stomach C16 5,777 4,400 9 7 5 1
Colon and rectum C18 - C21 13,489 12,510 22 3 13 9
Liver C22 4,856 2,534 8 1 3 0
Gallbladder and biliary tract C23, C24 1,234 2,041 2 1 2 3
Pancreas C25 7,537 7,950 12 8 9 5
Larynx C32 1,261 188 2 2 0 3
Lung C33, C34 29,381 13,627 49 9 19 8
Malignant melanoma of the skin C43 1,568 1,143 2 7 1 6
Mesothelioma C45 1,099 298 1 8 0 4
Breast C50 107 17,466 0 2 24 0
Vulva C51 749 0 8
Cervix C53 1,524 2 5
Uterus C54, C55 2,432 3 0
Ovaries C56 5,599 7 5
Prostate C61 12,676 20 0
Testis C62 166 0 4
Kidney C64 3,096 2,151 5 2 2 4
Bladder C67 3,631 1,885 5 9 1 9
Central nervous system C70 - C72 3,087 2,559 5 8 3 9
Thyroid gland C73 275 431 0 5 0 5
Hodgkin's lymphoma C81 169 147 0 3 0 2
Non-Hodgkin lymphomas C82 - C85 3,082 2,921 5 1 3 3
Multiple myeloma C90 1,981 1,850 3 2 2 2
Leukaemias C91 - C95 3,942 3,304 6 5 4 0
Other cancer sites 11,788 10,348 19 9 12 4
Total cancer² C00 - C97 w/o. C44 117,855 100,403 198.7 127.9
1 age-standardised (European standard)  2 not including non-melanoma skin cancer (C44)
Figure 3.0.2
Most frequent tumour sites when cancer was the cause of death in Germany 2010
Source: Official cause of death statistics, Federal Statistical Office, Wiesbaden
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Epidemiology
‘All cancer sites’ refers here to all malignant neo-
plasms including lymphomas and leukaemias. In 
line with normal international practice, non-melano-
ma skin cancers (white skin cancer) are not included 
in the above. Estimates regarding the frequency of 
this widespread yet seldom life-threatening disease 
can be found in chapter 3.28. 
According to our estimates a total of approxi-
mately 477,300 new cases of cancer were diagnosed 
in Germany in 2010. Of these, approximately 
252,400 were in men and 224,900 in women. 
Just over half of all cases relate to the mammary 
gland (71,000), the prostate (65,800), the bowel 
(62,400) or the lungs (52,100). 
Between 2000 and 2010 the number of new can-
cer cases increased among men by around 21 % and 
in women by 14 %. The decisive factor influencing 
this was the changing demographic structure of the 
population (increase in the proportion of older peo-
ple), which was more pronounced among men than 
women. The development in age-standardised inci-
dence rates indicates that without these changes 
there would have been no increase in incidence figu-
res among men and only a slight increase of around 
7 % in women. The latter can be explained to a sig-
nificant extent by the changes in breast cancer, 
where the introduction of mammography screening 
between 2005 and 2009 has played a significant 
role (cf. Chapter 3.13). Apart from breast cancer, the 
age-standardised incidence rates in women have 
increased for malignant melanoma and for malig-
nant tumours of the lung, thyroid, vulva, oral cavity 
and pharynx, yet only in the cases of lung cancer and 
vulvar carcinoma there was also an associated incre-
ase in mortality rates. Declining incidence and mor-
tality rates were observed above all in cancers of the 
stomach, of the gall bladder and bile duct, the bowel 
and the ovaries, whilst in the case of breast cancer, 
carcinoma of the thyroid and malignant tumours of 
the uterus and cervix, as well as of the kidneys and 
the bladder, the mortality rate has fallen by at least 
15 % despite incidence rates increasing or remaining 
constant.
In men, incidence rates since the year 2000 have 
only increased by more than 10 % for malignant 
melanoma, prostate cancer and carcinoma of the 
liver and only the latter showed an increase in mor-
tality rate. Incidence and mortality rates declined 
significantly for malignant tumours of the stomach, 
lungs, larynx and bladder. The mortality rates also 
fell for cancers of the bowel, gall bladder, prostate 
and kidney.
In the last decade the age-standardised incidence 
rates for cancer among men have fallen by 17 % and 
in women by 11 %, somewhat greater reductions 
than in the European Union overall (13 % and 9 % 
respectively). The absolute number of deaths caused 
by cancer increased among men in Germany by 
around 8 % and remained largely unchanged in 
women.
Due to the demographic change, the median age 
at diagnosis for men has increased from 67 to 69 
years, though the incidence rates among those over 
70 years old have fallen slightly whilst increasing 
slightly in younger years. There tends to be a similar 
picture for women although the median age at diag-
nosis remains unchanged at 69. 
Currently every second man (51 %) and 43 % of all 
women can be expected to develop cancer in the 
3.1 All cancer sites
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 253,100 228,500 252,400 224,900 264,700 236,200
Crude incidence rate1 630 6 547 3 629 4 539 9 666 5 573 3
Standardised incidence rate1,² 453 2 357 4 445 0 349 1 436 8 356 2
Median age at diagnosis 69 69 69 69
Deaths 116,381 99,152 117,855 100,403
Crude mortality rate1 290 0 237 5 293 9 241 0
Standardised mortality rate1,² 201 4 128 6 198 7 127 9
5-year prevalence 759,500 743,200 770,000 753,200
Absolute 5-year survival rate (2009-2010)3 52 (45-56) 59 (55-63)
Relative 5-year survival rate (2009-2010)3 61 (54-66) 67 (62-71)
Table 3.1.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C97 without C44
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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course of their life. Every fourth man and every fifth 
woman dies of cancer. The relationship between can-
cer incidence and age varies between men and 
women. Women under the age of 55 years reveal hig-
her incidence rates than men of the same age. In the 
higher age groups this relationship reverses. In the 
over 65 year age group the incidence rates among 
men are almost twice as high as those among 
women.
Cancer can occur in all kinds of organs in the body 
and can originate from different types of cell. The 
origin of most types of cancers are the internal or 
external body surfaces. Approximately 70 % are ade-
nocarcinomas originating in glandular tissue. 
Around a further 15 % are squamous-cell carcinomas, 
malignant tumours of the transitional epithelium 
(urothelium carcinoma) and small-cell carcinoma, 
which occur for example in the lung. Alongside leu-
kaemias and lymphomas, malignant tumours also 
have their origins, for example, in the support cells of 
the nervous system (glia cells) or under pigment-pro-
ducing cells (melanomas). Rarer forms of cancer 
include those originating in connective tissue, such 
as mesothelioma and various sarcomas.
The relative 5-year survival rates range from above 
90 % for malignant melanoma of the skin, testicular 
cancer, and now also prostate cancer, through to 
survival rates of less than 20 % for lung and oeso-
phageal cancer. In the case of malignant tumours of 
the pancreas and mesothelioma, the relative 5-year 
survival rates are below 10 % (Figure 3.1.0). Compa-
red to patient survival rates from the 1980s in Saar-
land (50 % to 53 % for women and 38 % to 40 % for 
men), the prognosis for cancer patients in Germany 
overall has improved considerably. Current estima-
tions using the period method and only the most 
recent data show 5-year relative survival rates of 61 % 
for men and 67 % for women in patients diagnosed 
in 2009 and 2010. This means that the survival rates 
for both genders are converging overall. The impro-
ved overall cancer survival rates are due in part to 
shifts in the localisation spectrum, for example the 
decline in cases of stomach cancer and lung cancer 
among men (for which the prognoses are poor) and 
a larger proportion of colorectal, breast, and prostate 
cancer with better prognoses. The most obvious 
improvements in the survival rates of adult cancer 
patients over the last 25 years have been achieved in 
malignant tumours of the mammary gland, the 
bowel and the prostate.
Risk factors and early detection 
The aetiology of many cancers is not known, and in 
other cases, known risk factors cannot be influ-
enced. Prevention strategies are therefore only 
available for a few tumour types. However, these 
include types of cancer which affect large numbers 
of people. The World Health Organization estimates 
that more than 30 % of all cancer cases could be avo-
ided with preventive measures.
Among avoidable risk factors, tobacco consump-
tion is the most important. According to estimates 
by the Centre for Cancer Registry Data, a total of 
around 15 % of all cancer cases in Germany in 2008 
were to be attributed to smoking. Also the roles of 
excess weight and lack of exercise have long been 
known from observational epidemiological investi-
gations. Possible underlying biological mechanisms 
are becoming clearer due to the most recent research 
into the metabolic syndrome. This chronic “metabo-
lic imbalance” is linked with hypertension, high 
blood cholesterol and hyperglycaemia. Inflamm-
atory processes in adipose tissue are also suspected 
of being involved in the development of cancer. 
Among individual nutrition-related factors, alco-
hol consumption plays an important role. Low quan-
tities of fruit, vegetables, and dietary fibre, often 
combined with a high intake of red meat, have been 
identified as risk factors for a number of frequently 
occurring types of cancer. However it has not always 
been possible in observational studies to separate 
the influence of specific foodstuffs and their consti-
tuents from that of the energy balance.
Also among the avoidable risk factors for develo-
ping cancer is the ultraviolet fraction of sunlight 
(UV radiation). Many people, particularly in Ger-
many, overestimate the influence of hazardous sub-
stances and impurities in foodstuffs, as well as envi-
ronmental factors or toxic exposure at the work-
place. However, in certain individual cases these 
factors can also play a substantial role in the deve-
lopment of cancer, even here. Examples here are 
radon, the regionally occurring noble gas, which is 
thought to be responsible for up to nine per cent of 
lung cancer cases in Germany, or earlier occupatio-
nal exposure to asbestos, which because of the long 
latency period is still causing mesothelioma of the 
pleura or peritoneum even today. Even medical pro-
cedures may impact on the cancer risk in individual 
cases. Potential risks include diagnostic procedures 
and therapies involving exposure to radiation, cyto-
static agents used in chemotherapy, and hormone 
replacement therapy for menopausal women, 
which has been identified as a risk factor for breast 
cancer.
Chronic infections are now known to be risk fac-
tors for some widespread forms of cancer. Vaccina-
tions or the treatment of causal factors can contri-
bute to the reduction of cancer risk. This has been 
established for vaccinations against hepatitis viruses 
as a risk factor for liver cancer, and it is hoped that 
vaccination against human papilloma viruses will 
have a similar effect reducing the incidence rate for 
cervical carcinoma.
20
In addition to avoidable risk factors, genetic cau-
ses may also increase the risk of developing cancer. 
To date, however, only very few of these genetic muta-
tions have been clearly identified. The respective 
relevant risk factors for specific types of cancer are 
presented in more detail in the individual sections.
The early detection programmes supported by the 
statutory health insurance companies in Germany 
screen for cancer of the skin and bowel, as well as 
breast and cervical cancer in women, and prostate 
cancer for men. These early detection measures are 
presented in the individual sections.
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Relative 5-year survival rates, by tumour site and sex, Germany 2009 – 2010 (period analysis)
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C00 – C97 without C44, Germany 1999 – 2010
Figure 3.1.1a
Age-standardised incidence and mortality rates, by sex,
ICD-10 C00 – C97 without C44, Germany 1999 – 2010
per 100,000 (European standard)
Figure 3.1.2















22 Cancer in Germany | All cancer sites

















Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C00 – C97 without C44, Germany 2009 – 2010
Figure 3.1.4b
Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C00 – C97 without C44, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 1 2 % (1 in 86) 51 0 % (1 in 2) 0 3 % (1 in 390) 26 1 % (1 in 4)
45 years 3 5 % (1 in 29) 51 0 % (1 in 2) 1 2 % (1 in 81) 26 2 % (1 in 4)
55 years 10 5 % (1 in 10) 50 6 % (1 in 2) 3 8 % (1 in 26) 26 0 % (1 in 4)
65 years 21 0 % (1 in 5) 47 9 % (1 in 2) 8 0 % (1 in 13) 24 6 % (1 in 4)
75 years 27 6 % (1 in 4) 40 4 % (1 in 2) 12 9 % (1 in 8) 21 1 % (1 in 5)
Lifetime risk 50 8 % (1 in 2) 25 8 % (1 in 4)
Women aged in the next ten years ever in the next ten years ever
35 years 2 1 % (1 in 48) 42 5 % (1 in 2) 0 3 % (1 in 310) 20 3 % (1 in 5)
45 years 4 8 % (1 in 21) 41 5 % (1 in 2) 1 1 % (1 in 92) 20 1 % (1 in 5)
55 years 8 8 % (1 in 11) 39 0 % (1 in 3) 2 6 % (1 in 38) 19 4 % (1 in 5)
65 years 13 0 % (1 in 8) 34 0 % (1 in 3) 4 9 % (1 in 20) 17 7 % (1 in 6)
75 years 16 2 % (1 in 6) 26 1 % (1 in 4) 8 1 % (1 in 12) 14 6 % (1 in 7)
Lifetime risk 42 9 % (1 in 2) 20 2 % (1 in 5)
Table 3.1.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C97 without C44, database 2010
Figure 3.1.3
Distribution of T-stages at first diagnosis by sex
Not included because tumour stages are site-specific.
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Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C00 – C97 without C44, 2009 – 2010
per 100,000 (European standard)
Figure 3.1.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C00 – C97 without C44, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
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Epidemiology
Cancer of the oral cavity and the pharynx is made up 
of a heterogeneous group of malignant neoplasms. 
In addition to squamous-cell carcinomas, somewhat 
more than 5 % of cases are adenocarcinomas, for 
example of the salivary glands.
Men are significantly more frequently affected 
and given a median age at diagnosis of 61 years, 
somewhat earlier than women too (65 years). 
Incidence and mortality rates for men from can-
cer of the oral cavity and pharynx have been decli-
ning since the turn of the millennium, whilst among 
women there is still a slight increase in both inci-
dence and mortality rates in Germany. The number 
of cases among men is currently no longer increa-
sing and in women the increase is slight. The high-
est incidence and mortality rates for women in Ger-
many continue to be reported from Hamburg and 
Bremen, and for men in Mecklenburg-Western 
Pomerania. In an international comparison, the 
highest incidence rate among men is in France, and 
for women in Denmark.
Depending on site, the survival prospects vary 
greatly within this disease group. Favourable 5-year-
survival rates are associated with carcinoma of the 
lips and salivary glands, whereas comparatively 
unfavourable prognoses exist for malignant tumours 
of the pharynx. These differences partly also account 
for the low survival rates of men (48 %) compared to 
women (61 %). Approximately 40 % of the tumours 
in women are diagnosed at an early stage (T1), but 
only around 30 % in men.
Risk factors
The most important triggers for cancer of the oral 
cavity and pharynx are tobacco and alcohol con-
sumption. The combination of both factors is parti-
cularly harmful. Further possible risk factors can be 
a one-sided, vitamin deficient diet with excessive 
meat consumption. Inadequate oral hygiene and 
mechanical irritations, for example due to poorly fit-
ting dentures, are also possible risk factors. Exposu-
re to sunlight can contribute to carcinoma of the 
lips. Contact with sawdust or some chemicals – 
mostly in an occupational context - can increase the 
risk of developing tumours, especially in the naso-
pharynx.  An infection with human papilloma virus 
(HPV) is a risk factor for tumours of the pharynx. 
The role of HPV in the origins of cancer of the oral 
cavity has not yet been completely clarified. Epstein-
Barr viruses are regarded as a further viral risk fac-
tor, in particular for nasopharyngeal carcinoma. Peo-
ple with type 2 diabetes, a marked immunodeficien-
cy or rare pre-existing conditions may also have an 
increased risk. There are also clear indications that a 
genetic pre-disposition plays a role in the develop-
ment of carcinoma in the head and neck areas.
 Cancer in Germany | Oral cavity and pharynx
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 9,480 3,480 9,340 3,490 9,900 3,900
Crude incidence rate1 23 6 8 3 23 3 8 4 24 9 9 5
Standardised incidence rate1,² 18 8 5 9 18 2 5 9 18 3 6 4
Median age at diagnosis 61 64 61 65
Deaths 3,813 1,169 3,816 1,204
Crude mortality rate1 9 5 2 8 9 5 2 9
Standardised mortality rate1,² 7 4 1 8 7 2 1 8
5-year prevalence 27,800 11,300 27,900 11,500
Absolute 5-year survival rate (2009-2010)3 44 (40-46) 55 (49-66)
Relative 5-year survival rate (2009-2010)3 48 (44-50) 61 (55-72)
Table 3.2.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C14
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.2  Oral cavity and pharynx
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C00 – C14, Germany 1999 – 2010
Figure 3.2.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C00 – C14, Germany 1999 – 2010
per 100,000 (European standard)
Figure 3.2.2
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Table 3.2.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C14, database 2010
Figure 3.2.4b
Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C00 – C14, Germany 2009 – 2010
Figure 3.2.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C00 – C14, Germany 2009 – 2010

















Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C00 – C14, Germany 2010
41 % 28 % 15 % 16 %
30 % 30 % 19 % 21 %





T1       T2       T3       T4       
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,500) 1 7 % (1 in 59) <0 1 % (1 in 6,800) 0 7 % (1 in 140)
45 years 0 3 % (1 in 320) 1 6 % (1 in 61) 0 1 % (1 in 930) 0 7 % (1 in 140)
55 years 0 6 % (1 in 170) 1 4 % (1 in 72) 0 2 % (1 in 440) 0 6 % (1 in 160)
65 years 0 5 % (1 in 190) 0 9 % (1 in 110) 0 2 % (1 in 410) 0 4 % (1 in 220)
75 years 0 3 % (1 in 300) 0 5 % (1 in 220) 0 2 % (1 in 560) 0 3 % (1 in 380)
Lifetime risk 1 7 % (1 in 60) 0 7 % (1 in 140)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 4,600) 0 6 % (1 in 160) <0 1 % (1 in 22,000) 0 2 % (1 in 430)
45 years 0 1 % (1 in 1,100) 0 6 % (1 in 160) <0 1 % (1 in 4,200) 0 2 % (1 in 430)
55 years 0 2 % (1 in 530) 0 5 % (1 in 180) 0 1 % (1 in 2,000) 0 2 % (1 in 470)
65 years 0 2 % (1 in 570) 0 4 % (1 in 260) 0 1 % (1 in 1,700) 0 2 % (1 in 590)
75 years 0 1 % (1 in 730) 0 2 % (1 in 430) 0 1 % (1 in 1,500) 0 1 % (1 in 790)
Lifetime risk 0 7 % (1 in 150) 0 2 % (1 in 430)
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Figure 3.2.6 
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C00 – C14, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)

































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C00 – C14, 2009 – 2010
per 100,000 (European standard)










































28 Cancer in Germany | Oesophagus
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 4,880 1,370 4,890 1,420 5,400 1,500
Crude incidence rate1 12 1 3 3 12 2 3 4 13 6 3 7
Standardised incidence rate1,² 9 0 2 0 8 9 2 1 9 1 2 2
Median age at diagnosis 67 71 66 70
Deaths 3,776 1,161 3,837 1,142
Crude mortality rate1 9 4 2 8 9 6 2 7
Standardised mortality rate1,² 6 8 1 6 6 9 1 5
5-year prevalence 8,000 2,200 8,100 2,300
Absolute 5-year survival rate (2009-2010)3 18 (15-24) 19 (10-29)
Relative 5-year survival rate (2009-2010)3 21 (17-27) 22 (12-31)
Table 3.3.1
Overview of key epidemiological parameters for Germany, ICD-10 C15
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.3  Oesophagus
Epidemiology
Men are diagnosed approximately three to four 
times more frequently than women with cancer of 
the oesophagus and contributing to this is the grea-
ter distribution of major risk factors, i.e. alcohol and 
tobacco consumption, among men.  
Squamous-cell carcinomas account for 50 % to 
60 % of all cases of cancer of the oesophagus. In 
recent years, the proportion of adenocarcinomas, 
which are mainly found in the lower section of the 
oesophagus, has risen to approximately one third of 
cases. 
Following considerable improvements, the survi-
val prospects of patients with oesophageal cancer 
are still just a little less favourable than with sto-
mach cancer. Currently, the relative 5-year survival 
rates for both men and women are over 20 %. Only 
one in eight cases is diagnosed at an early stage (T1). 
The age-standardised incidence and mortality 
rates have remained virtually unchanged since the 
turn of the millennium, whilst the absolute number 
of cases in both sexes is increasing. 
The highest incidence rates in Germany are being 
recorded in the northern federal states. Internatio-
nally, high incidence and mortality rates are apparent 
in the Netherlands and in the United Kingdom.
 
Risk factors
The most important risk factors for the development 
of the more frequent squamous-cell carcinoma in 
the oesophagus include alcohol and tobacco con-
sumption. In combination, the two factors reinforce 
one another. Studies have also shown that those 
affected, often eat little fruit and vegetables. 
Adenocarcinomas, which are somewhat less fre-
quent, often originate in combination with a gastro-
oesophageal reflux disease (long-term flow of gastric 
juices back into the oesophagus, chronic heartburn). 
This leads to changes to the mucous lining of the 
lower part of the oesophagus, causing a Barrett´s 
oesophagus, which is regarded as a precursor to can-
cer. Also in the case of adenocarcinoma, a consump-
tion below the average of fruit and vegetables incre-
ases the risk of developing the disease.
Recently, adenocarcinomas of the oesophagus 
have been associated with smoking, being over-
weight and possibly also with type 2 diabetes. Family 
clusters of cases are known, but these may possibly 
be attributable to shared lifestyle risks.
The possible influence of the human papilloma 
viruses is a topic of controversial debate.
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Figure 3.3.1b
Absolute numbers of incident cases and deaths, by sex,
ICD-10 C15, Germany 1999 – 2010



































Age-standardised incidence and mortality rates, by sex, 
ICD-10 C15, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C15 | Cancer in Germany 
Figure 3.3.2

















Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C15, database 2010
 Cancer in Germany | Oesophagus

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C15, Germany 2009 – 2010
Figure 3.3.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C15, Germany 2009 – 2010
12 % 16 % 56 % 16 %
12 % 16 % 53 % 19 %





T1       T2       T3       T4       
Figure 3.3.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C15, Germany 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 5,200) 0 9 % (1 in 110) <0 1 % (1 in 10,000) 0 8 % (1 in 130)
45 years 0 1 % (1 in 930) 0 9 % (1 in 110) 0 1 % (1 in 1,400) 0 7 % (1 in 130)
55 years 0 3 % (1 in 380) 0 9 % (1 in 120) 0 2 % (1 in 520) 0 7 % (1 in 140)
65 years 0 3 % (1 in 290) 0 7 % (1 in 150) 0 3 % (1 in 370) 0 6 % (1 in 170)
75 years 0 3 % (1 in 340) 0 4 % (1 in 240) 0 3 % (1 in 370) 0 4 % (1 in 250)
Lifetime risk 0 9 % (1 in 110) 0 8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 26,000) 0 3 % (1 in 360) <0 1 % (1 in 65,000) 0 2 % (1 in 440)
45 years <0 1 % (1 in 4,800) 0 3 % (1 in 360) <0 1 % (1 in 8,300) 0 2 % (1 in 440)
55 years 0 1 % (1 in 1,700) 0 3 % (1 in 390) <0 1 % (1 in 2,300) 0 2 % (1 in 450)
65 years 0 1 % (1 in 1,200) 0 2 % (1 in 470) 0 1 % (1 in 1,500) 0 2 % (1 in 530)
75 years 0 1 % (1 in 1,100) 0 1 % (1 in 390) 0 1 % (1 in 1,300) 0 1 % (1 in 720)
Lifetime risk 0 3 % (1 in 360) 0 2 % (1 in 440)
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¹ no comparable data for incidence
Figure 3.3.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C15, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C15, 2009 – 2010
per 100,000 (European standard)
 ICD-10 C15 | Cancer in Germany 
32 Cancer in Germany | Stomach
Epidemiology
For more than 30 years in Germany – as in other 
industrialised nations – there has been a steady dec-
line in the incidence and mortality rates for stomach 
cancer. This decline is ongoing. International and 
regional comparisons show that in Europe and 
within Germany the rates are higher in the east than 
in the west. The highest of the incidence rates inclu-
ded here were found in Poland and the Czech Repu-
blic. The incidence rates for all eastern federal states 
in Germany except Berlin are higher than for wes-
tern federal states.
The median age for developing stomach cancer is 
comparatively high at 71 years of age for men and 75 
for women. One in every 74 women and one in every 
52 men can still expect to develop stomach cancer 
during their lifetime.
Although the 5-year survival rate for stomach 
cancer has recently improved to 33 %, it is still unfa-
vourable in comparison to other forms of cancer.
Due to changes in the 7th edition of the TNM 
classification system and thus to the associated hete-
rogeneity of data for the current period of observa-
tion, no interpretation of tumour stages is included 
in this edition of the report.
Histologically, various forms of adenocarcino-
mas predominate in the stomach. Particularly note-
worthy are the (mucosa-associated) MALT lympho-
mas originating in the stomach mucosa.
Risk factors
A bacterial infection of the stomach with Helicobac-
ter pylori is the most important risk factor for sto-
mach cancer, as this can probably reinforce the 
effects of other risks. Smoking and excessive alcohol 
consumption also increase the risk of stomach can-
cer. The relationships between dietary factors and 
the risk of stomach cancer are complex. In general, a 
diet with a low fruit and vegetable content and high 
animal product content is associated with a higher 
risk. There are indications that chronic heartburn or 
gastro-oesophageal reflux increases the risk for cer-
tain forms of tumour at the transition from the sto-
mach to the oesophagus. Being overweight can also 
promote these carcinomas. Low socio-economic sta-
tus and past stomach surgery continue to be associa-
ted with an increased frequency of stomach cancer.
First-degree relatives of patients have a risk two to 
three times higher than the general population. It is 
not always clear whether this is due to a shared life-
style, to the transmission of Helicobacter pylori 
within the family, or to hereditary gene mutations. In 
the case of young patients, it can be useful for relati-
ves to receive genetic advice. The same applies for 
members of families with rare hereditary colorectal 
cancer (HNPCC, Lynch syndrome).
Pernicious anaemia and several other pre-existing 
diseases constitute risk factors that affect only com-
paratively few people. Among the mostly benign sto-
mach polyps, only the rare adenoma is regarded as a 
precursor to cancer.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 9,500 6,650 9,150 6,690 9,100 6,200
Crude incidence rate1 23 7 15 9 22 8 16 1 22 8 15 2
Standardised incidence rate1,² 16 6 8 6 15 7 8 5 14 3 7 7
Median age at diagnosis 71 75 71 75
Deaths 5,783 4,461 5,777 4,400
Crude mortality rate1 14 5 11 1 14 7 10 9
Standardised mortality rate1,² 10 0 5 4 9 7 5 2
5-year prevalence 19,700 14,000 19,500 13,800
Absolute 5-year survival rate (2009-2010)3 27 (21-30) 27 (22-31)
Relative 5-year survival rate (2009-2010)3 33 (25-36) 33 (26-36)
Table 3.4.1
Overview of key epidemiological parameters for Germany, ICD-10 C16
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.4  Stomach
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C16, Germany 1999 – 2010
Figure 3.4.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C16, Germany 1999 – 2010
per 100,000 (European standard)
WomenMen
Age group












Age-specific incidence rates by sex, ICD-10 C16, Germany 2009 – 2010
per 100,000
34 Cancer in Germany | Stomach
Table 3.4.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C16, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C16, Germany 2009 – 2010
Figure 3.4.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C16, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 2,500) 2 0 % (1 in 51) <0 1 % (1 in 5,400) 1 3 % (1 in 77)
45 years 0 1 % (1 in 760) 1 9 % (1 in 51) 0 1 % (1 in 1,500) 1 3 % (1 in 77)
55 years 0 3 % (1 in 310) 1 8 % (1 in 53) 0 2 % (1 in 560) 1 3 % (1 in 78)
65 years 0 6 % (1 in 170) 1 7 % (1 in 57) 0 4 % (1 in 280) 1 2 % (1 in 82)
75 years 0 9 % (1 in 110) 1 4 % (1 in 69) 0 7 % (1 in 150) 1 1 % (1 in 91)
Lifetime risk 1 9 % (1 in 52) 1 3 % (1 in 78)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 3,300) 1 3 % (1 in 74) <0 1 % (1 in 6,700) 0 9 % (1 in 110)
45 years 0 1 % (1 in 1,200) 1 3 % (1 in 75) <0 1 % (1 in 2,400) 0 9 % (1 in 110)
55 years 0 2 % (1 in 640) 1 3 % (1 in 78) 0 1 % (1 in 1,200) 0 9 % (1 in 110)
65 years 0 3 % (1 in 330) 1 2 % (1 in 85) 0 2 % (1 in 570) 0 8 % (1 in 120)
75 years 0 5 % (1 in 180) 1 0 % (1 in 100) 0 4 % (1 in 270) 0 8 % (1 in 130)
Lifetime risk 1 3 % (1 in 74) 0 9 % (1 in 110)
Figure 3.4.3
Distribution of T-stages at first diagnosis by sex
Not presented due to the large proportion of missing data.
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C16, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C16, 2009 – 2010
per 100,000 (European standard)
36 Cancer in Germany | Colon and rectum
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 34,770 29,540 33,800 28,620 35,500 28,400
Crude incidence rate1 86 6 70 8 84 3 68 7 89 5 68 9
Standardised incidence rate1,² 60 7 38 3 57 8 36 8 56 2 34 9
Median age at diagnosis 71 74 71 75
Deaths 13,572 12,504 13,489 12,510
Crude mortality rate1 33 8 30 0 33 6 30 0
Standardised mortality rate1,² 23 2 14 2 22 3 13 9
5-year prevalence 116,800 99,700 116,200 98,100
Absolute 5-year survival rate (2009-2010)3 53 (47-58) 53 (48-58)
Relative 5-year survival rate (2009-2010)3 64 (57-68) 65 (58-68)
Table 3.5.1
Overview of key epidemiological parameters for Germany, ICD-10 C18 – C21
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.5  Colon and rectum
Epidemiology
About every seventh case of cancer in Germany 
affects the colon or rectum. In 2010 almost 34,000 
men and 29,000 women were diagnosed. In additi-
on, there were nearly 5,000 in situ tumours. Almost 
two thirds of tumours were located in the large 
intestine, some 30 % affected the rectum, while the 
remainder were located at the junction between the 
colon and the rectum (rectosigmoid), i.e. the anal 
canal. The rare cases of cancer of the upper intestine 
(C17) are not included here, in line with internatio-
nal practice. Histologically, besides squamous-cell 
carcinomas of the anus and rare neuroendrocrinal 
tumours (approx. 1 %), almost all tumours are ade-
nocarcinomas (approx. 85 %).
The risk of developing the disease increases stea-
dily with advancing age. Correspondingly the 
median age at diagnosis is 71 years for men and 75 
years for women. More than half of those affected 
were diagnosed after the age of 70 years, with only 
about 10 % before 55 years of age, i.e. before qualify-
ing for the colonoscopy offered in the early detection 
programme. The age-standardised incidence rates 
for women and men have recently shown a slight 
downward trend. Despite a demographic change, 
the absolute number of cases of colorectal cancer 
has recently not further increased. The age-standar-
dised mortality rates for men and women have dec-
lined by more than 20 % in the past 10 years. Colo-
rectal cancer has a moderately good prognosis, and 
five years after diagnosis about half of the patients 
are still alive. The relative survival rates are approxi-
mately 65 % for men and for women.
Risk factors and early detection
A number of factors increase the risk of colorectal 
cancer. Smoking and being overweight are the prin-
cipal risk factors, followed by insufficient exercise 
and a diet low in fibre. People who regularly consu-
me alcohol or eat a lot of red meat or processed meats 
made from red meat are more prone to develop colo-
rectal cancer. First-degree relatives of colorectal can-
cer patients are themselves affected with an above-
average frequency. There is a very high risk of deve-
loping colorectal cancer early in life in the case of 
rare inherited diseases such as familial adenomatous 
polyposis (FAP) or Lynch syndrome (hereditary non-
polyposis colorectal cancer, HNPCC).
Chronic inflammatory bowel diseases also slightly 
increase the risk of developing this cancer.
As part of the early detection directive, people bet-
ween 50 and 54 years of age with statutory health 
insurance can have an annual test for blood in the 
stool. From the age of 55 years they are entitled to a 
colonoscopy examination, in the course of which 
colon polyps, which may develop into malignant 
tumours, can also be removed. If there are no patho-
logical findings, they are entitled to a further colono-
scopy ten years later. As an alternative to colono-
scopy, insured persons can have the above-menti-
oned stool test every two years, with entitlement to a 
follow-up colonoscopy where clarification is requi-
red. Special provisions are made for people with an 
increased risk.
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C18 – C21, Germany 1999 – 2010
Figure 3.5.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C18 – C21, Germany 1999 – 2010
per 100,000 (European standard)
WomenMen
Age group












Age-specific incidence rates by sex, ICD-10 C18 – C21, Germany 2009 – 2010
per 100,000
38 Cancer in Germany | Colon and rectum
Table 3.5.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C18 – C21, database 2010
















13% 16% 52% 20%
15 % 16 % 54 % 15 %
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Figure 3.5.4b
Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C18 – C21, Germany 2009 – 2010
Figure 3.5.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C18 – C21, Germany 2009 – 2010
Figure 3.5.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C18 – C21, Germany 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 920) 7 1 % (1 in 14) <0 1 % (1 in 4,200) 3 1 % (1 in 32)
45 years 0 4 % (1 in 240) 7 1 % (1 in 14) 0 1 % (1 in 860) 3 1 % (1 in 32)
55 years 1 3 % (1 in 79) 7 0 % (1 in 14) 0 4 % (1 in 260) 3 1 % (1 in 32)
65 years 2 4 % (1 in 41) 6 4 % (1 in 16) 0 9 % (1 in 110) 3 0 % (1 in 33)
75 years 3 4 % (1 in 29) 5 1 % (1 in 20) 1 6 % (1 in 63) 2 7 % (1 in 37)
Lifetime risk 7 0 % (1 in 14) 3 0 % (1 in 33)
Women aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,000) 5 7 % (1 in 17) <0 1 % (1 in 4,000) 2 6 % (1 in 38)
45 years 0 3 % (1 in 300) 5 7 % (1 in 18) 0 1 % (1 in 1,200) 2 6 % (1 in 38)
55 years 0 7 % (1 in 140) 5 5 % (1 in 18) 0 2 % (1 in 460) 2 6 % (1 in 38)
65 years 1 4 % (1 in 69) 5 0 % (1 in 20) 0 5 % (1 in 190) 2 5 % (1 in 40)
75 years 2 4 % (1 in 42) 4 1 % (1 in 24) 1 1 % (1 in 91) 2 3 % (1 in 44)
Lifetime risk 5 7 % (1 in 17) 2 6 % (1 in 38)
39 ICD-10 C18 – C21 | Cancer in Germany 






























¹ data for mortality without C21
Figure 3.5.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C18 – C21, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C18 – C21, 2009 – 2010
per 100,000 (European standard)
40 Cancer in Germany | Liver
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 5,630 2,390 5,850 2,480 6,200 2,700
Crude incidence rate1 14 0 5 7 14 6 5 9 15 7 6 6
Standardised incidence rate1,² 9 9 3 1 10 1 3 2 10 0 3 3
Median age at diagnosis 70 74 70 74
Deaths 4,738 2,493 4,856 2,534
Crude mortality rate1 11 8 6 0 12 1 6 1
Standardised mortality rate1,² 8 1 3 0 8 1 3 0
5-year prevalence 7,400 2,700 7,600 2,800
Absolute 5-year survival rate (2009-2010)3 13 (10-17) 11 (5-16)
Relative 5-year survival rate (2009-2010)3 15 (11-20) 12 (6-19)
Table 3.6.1
Overview of key epidemiological parameters for Germany, ICD-10 C22
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.6  Liver
Epidemiology 
Liver cancer is relatively uncommon, but in view of 
its poor prognosis it ranks among the ten most fre-
quent causes of death due to cancer for both men 
and women. There are approximately 8,300 new 
cases in Germany every year, and roughly the same 
number of deaths. The median age at diagnosis is 
70 years for men and 74 years for women. Only 
about 4 % of cases are diagnosed before 45 years of 
age. One in 86 men and one in 200 women in Ger-
many develop a malignant liver tumour in the 
course of their life. 
Some 65 % of malignant tumours develop from 
liver cells (hepatocellular carcinoma), and almost 
25 % from cells in the intrahepatic bile ducts (chol-
angiocarcinoma). This proportion is significantly 
higher for women.
Since 1980, the mortality rate for men has risen 
steadily by a total of 52 %, even after age-standardi-
sation, while it has remained more or less unchanged 
for women in the same period. The increased mor-
tality rate in men was independent of the histology 
of the tumour.  The age-standardised incidence rate 
for liver cancer in men has also increased slightly 
over the past 10 years.
Currently, incidence and mortality rates in the 
north-western federal states are somewhat lower 
than in the rest of Germany.
The survival prospects for liver cancer depend on 
the stage of the tumour at diagnosis and on the con-
dition of the liver (cirrhosis). Only just over 10 % of 
patients survive the first five years after diagnosis. 
Risk factors and early detection
Proven risk factors for liver cancer are chronic infec-
tion with hepatitis-B or hepatitis-C virus. There is 
also a relationship between regular high alcohol 
consumption and the risk of developing liver cancer. 
Foodstuffs contaminated with aflatoxin B1 (produ-
ced by the fungi Aspergillus parasiticus and A. fla-
vus) constitute a further risk factor. Tobacco con-
sumption is also associated with an increased risk. 
From the lifestyle-related risk factors, type 2 diabe-
tes mellitus and obesity are also associated with an 
increased risk of liver cancer. Finally, hereditary 
metabolic diseases such as haemochromatosis can 
also increase this risk.
Early detection examinations for the general 
population are not included in the statutory health 
insurance. It is recommended that regular examina-
tions should be undertaken by all patients with cir-
rhosis of the liver, with long-standing hepatitis infec-
tions, and with nonalcoholic fatty liver disease. Ult-
rasound examination is suitable for this, while blood 
tests (for alpha-fetoprotein) are only of minor rele-
vance.
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Figure 3.6.1b
Absolute numbers of incident cases and deaths, by sex,
ICD-10 C22, Germany 1999 – 2010
Figure 3.6.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C22, Germany 1999 – 2010
per 100,000 (European standard)
WomenMen
Age group












Age-specific incidence rates by sex, ICD-10 C22, Germany 2009 – 2010
per 100,000
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Table 3.6.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C22, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C22, Germany 2009 – 2010
Figure 3.6.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C22, Germany 2009 – 2010
Figure 3.6.3
Distribution of T-stages at first diagnosis by sex
Not presented due to the large proportion of missing data.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 6,700) 1 2 % (1 in 85) <0 1 % (1 in 15,000) 1 0 % (1 in 98)
45 years 0 1 % (1 in 1,400) 1 2 % (1 in 85) <0 1 % (1 in 2,100) 1 0 % (1 in 98)
55 years 0 3 % (1 in 390) 1 2 % (1 in 87) 0 2 % (1 in 590) 1 0 % (1 in 98)
65 years 0 4 % (1 in 220) 1 0 % (1 in 100) 0 4 % (1 in 260) 0 9 % (1 in 110)
75 years 0 5 % (1 in 190) 0 7 % (1 in 140) 0 5 % (1 in 200) 0 7 % (1 in 140)
Lifetime risk 1 2 % (1 in 86) 1 0 % (1 in 100)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 22,000) 0 5 % (1 in 200) <0 1 % (1 in 22,000) 0 5 % (1 in 190)
45 years <0 1 % (1 in 4,900) 0 5 % (1 in 200) <0 1 % (1 in 5,900) 0 5 % (1 in 190)
55 years 0 1 % (1 in 1,400) 0 4 % (1 in 210) 0 1 % (1 in 1,800) 0 5 % (1 in 200)
65 years 0 1 % (1 in 740) 0 4 % (1 in 230) 0 1 % (1 in 780) 0 5 % (1 in 210)
75 years 0 2 % (1 in 510) 0 3 % (1 in 290) 0 2 % (1 in 430) 0 4 % (1 in 250)
Lifetime risk 0 5 % (1 in 200) 0 5 % (1 in 190)
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¹ data for mortality for 2008 only
Figure 3.6.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C22, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C22, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
In Germany, about 5,300 new cases of malignant 
tumours of the gall bladder (approx. 40 %) and of 
the biliary tract outside the liver (60 %) were diag-
nosed in 2010. Women develop gall bladder carcino-
mas more frequently, whereas tumours in the extra 
hepatic biliary tracts are diagnosed more frequently 
in men. 
Histologically, the majority of these are adenocar-
cinomas. Other histological variants such as squa-
mous-cell carcinomas or hybrid forms are rare. As 
with liver cancer, the risk of developing this type 
increases steadily with age. The lifetime risk is about 
0.6 % for women and 0.5 % for men.
Since 1999 the age-standardised incidence rate 
in Germany has declined for women and remained 
largely unchanged for men. However, because of 
demographic changes the absolute number of new 
cases has increased significantly among men. The 
age-standardised mortality rates for the same period 
have decreased constantly in both genders. 
The survival prospects with malignant tumours 
of the gall bladder and biliary tract are generally 
poor, yet better than for liver cancer. The relative 
5-year survival rate for women is 18 % and 19 % for 
men. Details with regard to tumour stage at point of 
diagnosis exist for approximately 50 % of gall blad-
der cases registered, most of which were diagnosed 
in stage T2 and T3.
Risk factors and early detection
The triggers for gall bladder carcinomas are not 
absolutely clear. In the current scientific debate, the 
presence of gallstones, chronic inflammatory disea-
ses of the biliary tract, such as a primary sclerosing 
cholangitis (PSC), the inflammatory bowel disease 
ulcerative colitis, liver diseases as a result of the high 
consumption of alcohol, hepatitis-C virus infection, 
and HIV infection are all deemed to be possible risk 
factors. As lifestyle related risk factors, obesity and 
smoking are suspected of increasing the risk of bili-
ary tract carcinomas. Diabetes can also increase the 
risk, however, available studies do not show clearly 
enough whether this applies for both type 1 and type 
2 diabetes. A further risk factor, especially in Asia, is 
an infection with the parasitic liver flukes Clonorchis 
sinensis or Opisthorchis viverrini.  
Various markers are being tested for their suitabi-
lity for early detection among persons at risk, howe-
ver, without any practical consequences. There is no 
screening programme on offer for the general popu-
lation. Often, however, early stage diagnosis is made 
upon removing the gall bladder for other reasons.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 2,210 3,080 2,240 3,070 2,400 2,700
Crude incidence rate1 5 5 7 4 5 6 7 4 6 0 6 6
Standardised incidence rate1,² 3 8 3 7 3 8 3 7 3 7 3 0
Median age at diagnosis 72 76 72 76
Deaths 1,190 2,035 1,234 2,041
Crude mortality rate1 3 0 4 9 3 1 4 9
Standardised mortality rate1,² 2 0 2 3 2 1 2 3
5-year prevalence 3,600 4,200 3,600 4,200
Absolute 5-year survival rate (2009-2010)3 16 (7-27) 15 (12-19)
Relative 5-year survival rate (2009-2010)3 19 (8-31) 18 (14-23)
Table 3.7.1
Overview of key epidemiological parameters for Germany, ICD-10 C23 – C24
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.7  Gall bladder and biliary tract
 Cancer in Germany | Gall bladder and biliary tract
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C23 – C24, Germany 1999 – 2010
Figure 3.7.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C23 – C24, Germany 1999 – 2010
per 100,000 (European standard)
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Age group












Age-specific incidence rates by sex, ICD-10 C23 – C24, Germany 2009 – 2010
per 100,000
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Table 3.7.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C23 – C24, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C23 – C24, Germany 2009 – 2010
Figure 3.7.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C23 – C24, Germany 2009 – 2010
Figure 3.7.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 only C23, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 17,000) 0 5 % (1 in 200) <0 1 % (1 in 42,000) 0 3 % (1 in 360)
45 years <0 1 % (1 in 5,000) 0 5 % (1 in 200) <0 1 % (1 in 9,700) 0 3 % (1 in 360)
55 years 0 1 % (1 in 1,500) 0 5 % (1 in 200) <0 1 % (1 in 2,900) 0 3 % (1 in 360)
65 years 0 2 % (1 in 640) 0 5 % (1 in 210) 0 1 % (1 in 1,100) 0 3 % (1 in 370)
75 years 0 2 % (1 in 410) 0 4 % (1 in 240) 0 1 % (1 in 720) 0 2 % (1 in 430)
Lifetime risk 0 5 % (1 in 200) 0 3 % (1 in 370)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 26,000) 0 6 % (1 in 160) <0 1 % (1 in 41,000) 0 4 % (1 in 240)
45 years <0 1 % (1 in 4,400) 0 6 % (1 in 160) <0 1 % (1 in 8,400) 0 4 % (1 in 240)
55 years 0 1 % (1 in 1,400) 0 6 % (1 in 160) <0 1 % (1 in 2,700) 0 4 % (1 in 240)
65 years 0 2 % (1 in 650) 0 6 % (1 in 170) 0 1 % (1 in 1,000) 0 4 % (1 in 250)
75 years 0 3 % (1 in 380) 0 5 % (1 in 210) 0 2 % (1 in 520) 0 3 % (1 in 290)
Lifetime risk 0 6 % (1 in 160) 0 4 % (1 in 240)
11 % 41 % 37 % 11 %
11 % 37 % 42 % 10 %
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C23 – C24, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C23 – C24, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
The pancreas produces hormones (endocrinal func-
tion of islet cells) as well as digestive juices (exocrine 
function). The vast majority of malignant tumours 
in the pancreas originate in the exocrine portion of 
the pancreas. In 2010 more than 16,000 people were 
diagnosed with pancreatic cancer. In line with the 
unfavourable prognosis, almost that many people 
also died of the disease. The age-standardised inci-
dence and mortality rates have remained almost 
constant since the late 1990s, whereas the absolute 
number of new cases and deaths has risen steadily.
In the early stages, malignant neoplasms of the 
pancreas frequently cause no or only nonspecific 
symptoms, thus the tumour is frequently only detec-
ted late. Accordingly, the relative 5-year survival rate 
is extremely unfavourable. In Germany it is 8 % for 
both men and women, although the rare malignant 
islet cell tumours have a significantly better progno-
sis. The pancreatic carcinoma thus has the lowest 
survival rate of all forms of cancer and is the fourth 
most frequent cause of death due to cancer.
The median age at diagnosis is 71 years for men 
and 75 years for women. The mean lifetime risk of 
developing pancreatic cancer is 1.6 % for both sexes.
Risk factors
Smoking tobacco is a proven risk factor, and passive 
smoking also plays a part. Obesity (adiposity) is ano-
ther risk factor. Further lifestyle-related factors and 
in particular the influence of diet, have not been con-
clusively proven. It is believed that high consumpti-
on of processed meat goods can increase the risk. 
High consumption of alcohol similarly appears to 
increase the risk. 
The risk of developing pancreatic cancer is also 
higher for patients with type 2 diabetes mellitus. 
Patients with long-term chronic inflammation of the 
pancreas (pancreatitis) also have an increased risk.
First-degree relatives of patients with a pancreatic 
carcinoma have a statistically higher risk of develo-
ping the cancer themselves, although it is not clear 
whether this is due to a hereditary predisposition or 
a shared lifestyle. An inheritable risk does indeed 
appear to play a part for some patients at least. Peo-
ple with two or more first-degree relative patients are 
at a significantly higher risk of also developing the 
disease compared to the normal population. 
Research is being conducted to analyse which genes 
are involved. The risk of developing this cancer is 
also high for people affected by one of the known, 
rare, genetic cancer syndromes.
It is not yet clear what role is played by environ-
mental factors or occupational exposure to harmful 
substances.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 7,790 7,840 8,020 8,060 8,500 8,900
Crude incidence rate1 19 4 18 8 20 0 19 4 21 4 21 6
Standardised incidence rate1,² 13 7 9 9 13 8 10 0 13 5 10 5
Median age at diagnosis 70 74 71 75
Deaths 7,410 7,748 7,537 7,950
Crude mortality rate1 18 5 18 6 18 8 19 1
Standardised mortality rate1,² 12 9 9 4 12 8 9 5
5-year prevalence 7,100 7,200 7,300 7,400
Absolute 5-year survival rate (2009-2010)3 7 (3-9) 7 (4-11)
Relative 5-year survival rate (2009-2010)3 8 (4-11) 8 (5-12)
Table 3.8.1
Overview of key epidemiological parameters for Germany, ICD-10 C25
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.8  Pancreas
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C25, Germany 1999 – 2010
Figure 3.8.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C25, Germany 1999 – 2010
per 100,000 (European standard)
WomenMen
Age  group












Age-specific incidence rates by sex, ICD-10 C25, Germany 2009 – 2010
per 100,000
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Table 3.8.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C25, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C25, Germany 2009 – 2010
Figure 3.8.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C25, Germany 2009 – 2010
Figure 3.8.3
Distribution of T-stages at first diagnosis by sex
Not presented due to the large proportion of missing data.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 4,900) 1 7 % (1 in 60) <0 1 % (1 in 6,000) 1 6 % (1 in 62)
45 years 0 1 % (1 in 1,000) 1 7 % (1 in 60) 0 1 % (1 in 1,200) 1 6 % (1 in 62)
55 years 0 3 % (1 in 300) 1 6 % (1 in 61) 0 3 % (1 in 360) 1 6 % (1 in 63)
65 years 0 6 % (1 in 170) 1 5 % (1 in 69) 0 6 % (1 in 180) 1 5 % (1 in 68)
75 years 0 8 % (1 in 130) 1 1 % (1 in 90) 0 8 % (1 in 130) 1 2 % (1 in 86)
Lifetime risk 1 6 % (1 in 61) 1 6 % (1 in 63)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 8,100) 1 6 % (1 in 61) <0 1 % (1 in 10,000) 1 6 % (1 in 62)
45 years 0 1 % (1 in 1,500) 1 6 % (1 in 61) 0 1 % (1 in 1,800) 1 6 % (1 in 62)
55 years 0 2 % (1 in 470) 1 6 % (1 in 63) 0 2 % (1 in 550) 1 6 % (1 in 62)
65 years 0 4 % (1 in 230) 1 5 % (1 in 68) 0 4 % (1 in 240) 1 5 % (1 in 67)
75 years 0 7 % (1 in 150) 1 2 % (1 in 85) 0 7 % (1 in 140) 1 2 % (1 in 82)
Lifetime risk 1 6 % (1 in 62) 1 6 % (1 in 62)
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C25, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
Figure 3.8.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C25, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
Men are affected by laryngeal cancer considerably 
more frequently than women due to their higher 
consumption of tobacco and alcohol. Currently one 
in 170 men in Germany develops laryngeal cancer 
during their lifetime, but only one in 1,200 women 
(lifetime risk). The median age of diagnosis in 
women is 63 years and in men 66 years. 
The incidence and mortality rates for men have 
continued to decline since the turn of the millen-
nium, very markedly among younger individuals. 
For the same period, the rates for women have not 
increased further. Here too, incidence rates among 
the under 50 year-olds are in decline. In the first 
decade of this century this resulted in a decrease in 
the mortality and incidence rates among men, with 
the number of cases among women remaining 
unchanged. 
The relative 5-year survival rates for men and 
women do not differ, each with a rate of 65 %. 
Tumours of the larynx are diagnosed at an early 
stage (T1) in approximately one third of all cases. 
The vast majority of all cases of laryngeal cancer are 
squamous-cell carcinomas.
Risk factors 
Smoking is the most important risk factor for the 
development of laryngeal cancer. Alcohol consump-
tion also increases the probability of developing this 
cancer, whereby the combination of both factors is 
particularly harmful. The influences of lifestyle, diet, 
or environmental factors are not yet completely clear, 
because in the majority of cases the influence of 
tobacco and alcohol consumption overshadows other 
effects. However, there are indications that increased 
consumption of red meat, as well as a vitamin-defici-
ent diet may increase risk. There is a known link bet-
ween tumours of the larynx and occupational expo-
sure to asbestos, nickel or polycyclic aromatic hydro-
carbons. The role of infections with human 
papilloma viruses (HPV) has not been completely 
clarified to date. There are indications that infections 
with Helicobacter pylori may also be of significance.
First-degree relatives of patients have a higher 
risk of developing laryngeal cancer, but it is not clear 
in detail, whether this is attributable to risk-genes 
which are directly involved in the development of the 
tumour or to genes which determine the individual 
susceptibility to carcinogens.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 3,330 510 3,230 460 3,300 600
Crude incidence rate1 8 3 1 2 8 1 1 1 8 3 1 4
Standardised incidence rate1,² 6 3 0 9 6 0 0 8 5 7 1 0
Median age at diagnosis 66 64 66 63
Deaths 1,215 162 1,261 188
Crude mortality rate1 3 0 0 4 3 1 0 5
Standardised mortality rate1,² 2 2 0 3 2 2 0 3
5-year prevalence 12,100 1,700 12,000 1,700
Absolute 5-year survival rate (2009-2010)3 58 (50-62) 59
Relative 5-year survival rate (2009-2010)3 65 (56-70) 65
Table 3.9.1
Overview of key epidemiological parameters for Germany, ICD-10 C32
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.9  Larynx
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C32, Germany 1999 – 2010
Figure 3.9.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C32, Germany 1999 – 2010
per 100,000 (European standard)
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Age-specific incidence rates by sex, ICD-10 C32, Germany 2009 – 2010
per 100,000
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Table 3.9.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C32, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C32, Germany 2009 – 2010
Figure 3.9.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C32, Germany 2009 – 2010
33 % 27 % 26 % 14 %
34 % 29 % 20 % 17 %
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Figure 3.9.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C32, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 9,000) 0 6 % (1 in 160) <0 1 % (1 in 49,000) 0 3 % (1 in 390)
45 years 0 1 % (1 in 1,400) 0 6 % (1 in 160) <0 1 % (1 in 4,500) 0 3 % (1 in 380)
55 years 0 2 % (1 in 550) 0 6 % (1 in 180) 0 1 % (1 in 1,700) 0 2 % (1 in 400)
65 years 0 2 % (1 in 440) 0 4 % (1 in 240) 0 1 % (1 in 1,200) 0 2 % (1 in 480)
75 years 0 2 % (1 in 570) 0 2 % (1 in 420) 0 1 % (1 in 980) 0 2 % (1 in 640)
Lifetime risk 0 6 % (1 in 170) 0 3 % (1 in 390)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 38,000) 0 1 % (1 in 1,200) <0 1 % (1 in 181,000) <0 1 % (1 in 2,800)
45 years <0 1 % (1 in 7,200) 0 1 % (1 in 1,200) <0 1 % (1 in 28,000) <0 1 % (1 in 2,800)
55 years <0 1 % (1 in 3,600) 0 1 % (1 in 1,400) <0 1 % (1 in 14,000) <0 1 % (1 in 3,100)
65 years <0 1 % (1 in 4,900) <0 1 % (1 in 2,300) <0 1 % (1 in 8,800) <0 1 % (1 in 3,700)
75 years <0 1 % (1 in 5,400) <0 1 % (1 in 3,700) (1 in 9,100) (1 in 5,700)
Lifetime risk 0 1 % (1 in 1,200) <0 1 % (1 in 2,800)
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C32, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C32, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 35,500 16,550 35,040 17,030 36,000 19,600
Crude incidence rate1 88 5 39 6 87 4 40 9 90 6 47 6
Standardised incidence rate1,² 62 6 26 0 60 7 26 5 57 8 29 2
Median age at diagnosis 69 68 70 68
Deaths 29,158 13,103 29,381 13,627
Crude mortality rate1 72 7 31 4 73 3 32 7
Standardised mortality rate1,² 50 6 19 3 49 9 19 8
5-year prevalence 49,200 26,200 49,000 27,100
Absolute 5-year survival rate (2009-2010)3 14 (12-16) 19 (16-25)
Relative 5-year survival rate (2009-2010)3 16 (14-19) 21 (17-28)
Table 3.10.1
Overview of key epidemiological parameters for Germany, ICD-10 C33 – C34
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.10  Lung
Epidemiology
In 2010 about 17,000 women and 35,000 men were 
diagnosed with malignant lung tumours and about 
13,600 woman and 29,400 men died of the disease. 
Lung cancer therefore remains by far the commo-
nest cause of death due to cancer among men in 
Germany, accounting for 25 % of deaths due to can-
cer, while it is the second most common among 
women (14 %).
The age-standardised incidence and mortality 
rates show opposing trends for men and for women. 
Among women they have risen by some 30 % since 
the end of the 1990s, while for men the rates over 
the same period have fallen by about 20 %. These 
differing trends for the two sexes can be attributed 
to a change in smoking habits dating back some 
time and will probably continue in future. In terms 
of prognosis, lung cancer is one of the more unfavo-
urable cancers, with relatively low 5-year survival 
rates of about 21 % for women and 16 % for men. 
Histologically, three main types are distinguished. 
Adenocarcinomas account for a third of all cases, 
while squamous-cell and small-cell lung carcinomas 
each account for about a quarter of cases. Due to the 
tendency to metastasise early, small cell carcinomas 
have the worst prognosis.
Risk factors and early detection
Exposure to tobacco smoke has long been recognised 
as the main risk factor for lung cancer. Up to nine 
out of ten cases of lung cancer in men, and at least 
six out of ten cases in women are attributable to acti-
ve smoking. Passive smoke inhalation also increases 
the risk of cancer and is a major contributor to indoor 
pollution.
Other risk factors play a comparatively minor 
role. About 9 to 15 out of 100 cases of lung cancer are 
attributable to exposure to various carcinogenic sub-
stances, including asbestos, polycyclic aromatic hyd-
rocarbons and quartz and nickel dust. In areas with 
a high natural exposure to radon in buildings, the 
risk of lung cancer is higher for occupants, particu-
larly in lower storeys. This also applies for occupati-
onal exposure to radon or other sources of ionising 
radiation. Diesel exhaust fumes are the most impor-
tant risk factor among air pollutants. Other environ-
mental pollutants (e.g. particulate matter) are presu-
med to have an effect, but the extent of this is still the 
subject of research. The same applies for the influ-
ence of genetic factors. There is also a relationship 
between infection with human papilloma virus 
(HPV) or Epstein-Barr virus (EBV) and the develop-
ment of lung carcinomas.
To date there is no established means of scree-
ning for lung cancer. The role that examinations, 
such as a regular computed tomography, could have 
for risk groups is being explored in clinical trials.
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C33 – C34, Germany 1999 – 2010
Figure 3.10.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C33 – C34, Germany 1999 – 2010
per 100,000 (European standard)
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Age-specific incidence rates by sex, ICD-10 C33 – C34, Germany 2009 – 2010
per 100,000
58 Cancer in Germany | Lung
Table 3.10.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C33 – C34, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C33 – C34, Germany 2009 – 2010
Figure 3.10.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C33 – C34, Germany 2009 – 2010
Figure 3.10.3
Distribution of T-stages at first diagnosis by sex
Not presented due to the large proportion of missing data.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,400) 7 1 % (1 in 14) <0 1 % (1 in 2,500) 6 1 % (1 in 16)
45 years 0 5 % (1 in 210) 7 1 % (1 in 14) 0 3 % (1 in 300) 6 2 % (1 in 16)
55 years 1 5 % (1 in 67) 6 9 % (1 in 14) 1 1 % (1 in 88) 6 1 % (1 in 16)
65 years 2 7 % (1 in 37) 6 0 % (1 in 17) 2 2 % (1 in 45) 5 5 % (1 in 18)
75 years 3 0 % (1 in 33) 4 2 % (1 in 24) 2 9 % (1 in 34) 4 2 % (1 in 24)
Lifetime risk 7 0 % (1 in 14) 6 0 % (1 in 17)
Women aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,400) 3 2 % (1 in 31) <0 1 % (1 in 2,700) 2 6 % (1 in 38)
45 years 0 3 % (1 in 310) 3 2 % (1 in 31) 0 2 % (1 in 470) 2 6 % (1 in 38)
55 years 0 8 % (1 in 130) 2 9 % (1 in 34) 0 6 % (1 in 180) 2 5 % (1 in 41)
65 years 1 0 % (1 in 96) 2 2 % (1 in 45) 0 8 % (1 in 130) 2 0 % (1 in 50)
75 years 1 0 % (1 in 100) 1 4 % (1 in 73) 0 9 % (1 in 110) 1 4 % (1 in 72)
Lifetime risk 3 2 % (1 in 31) 2 6 % (1 in 38)
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C33 – C34, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C33 – C34, 2009 – 2010
per 100,000 (European standard)
60 Cancer in Germany | Malignant melanoma of the skin
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 9,640 9,660 9,640 9,580 10,100 9,600
Crude incidence rate1 24,0 23,1 24,0 23,0 25,4 23,4
Standardised incidence rate1,² 18,2 17,9 18,0 17,8 18,0 17,8
Median age at diagnosis 66 59 66 58
Deaths 1,454 1,203 1,568 1,143
Crude mortality rate1 3,6 2,9 3,9 2,7
Standardised mortality rate1,² 2,6 1,7 2,8 1,6
5-year prevalence 35,900 38,800 38,200 40,700
Absolute 5-year survival rate (2009-2010)3 78 (70-83) 86 (80-90)
Relative 5-year survival rate (2009-2010)3 89 (83-95) 94 (88-98)
Table 3.11.1
Overview of key epidemiological parameters for Germany, ICD-10 C43
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.11  Malignant melanoma of the skin
Epidemiology
The introduction of clinical screening for skin can-
cer in 2008 led to a marked increase in the inci-
dence of malignant melanoma that year. Since then 
the incidence has been approximately 20 % higher 
than the previous level. Approximately 9,600 men 
and a similar number of women were diagnosed 
with a malignant melanoma of the skin in 2010. In 
addition, about 6,000 in situ melanomas were 
detected even earlier predominantly in women.
The median age of women at diagnosis is cur-
rently 58 years, which is lower than previously. The 
median age of men at diagnosis is eight years later. 
This corresponds to a higher risk of developing the 
disease and to significantly higher incidence rates 
among younger women (under 55 years) and older 
men (over 55 years).
Since the 1980s, the age-standardised incidence 
rates have risen significantly in western industria-
lised nations and in some cases have more than tri-
pled. The highest incidence rates in Europe are cur-
rently found in Denmark, and within Germany a 
clear geographical pattern is evident. Since 1990 
mortality rates in Germany have remained nearly 
constant. 
Currently, the relative 5-year survival rate in Ger-
many for women with malignant melanoma of the 
skin is 94 % and for men is 89 %. These favourable 
survival rates are due in part to the fact that more 
than half of the melanomas were discovered at an 
early stage (T1). This proportion has risen markedly 
since 2008.
 
Risk factors and early detection
People with a light skin type, which tans poorly or 
not at all, and people with a large number of skin pig-
mentations (acquired, congenital, and dysplastic 
naevi) have a higher risk of developing a melanoma, 
and genetic factors can therefore also play a part. 
High-risk genes have been identified, which are 
linked to rare familial clusters of melanoma, as well 
as medium-risk genes and hereditary dispositions, 
which increase the likelihood of “spontaneously” 
developing malignant melanomas as a result of 
other risk factors.
The most important exogenous risk factor is 
exposure to natural sunlight or artificial UV-radia-
tion during childhood and youth. Particularly recur-
rent, intense exposure to UV-radiation, such as 
during summer holidays, increases the risk of deve-
loping a melanoma. A further risk factor is the expo-
sure to ultraviolet radiation at the workplace, e.g. 
during welding.
In mid-2008, new screening regulations were int-
roduced in Germany for all forms of skin cancer 
within the framework of legislation on the early 
detection of cancer. Men and women above 35 years 
of age with statutory health insurance are entitled to 
a skin examination every two years by a suitably trai-
ned doctor (dermatologist, general practitioner, etc.).
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C43, Germany 1999 – 2010
Figure 3.11.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C43, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C43 | Cancer in Germany 
WomenMen
Age group












Age-specific incidence rates by sex, ICD-10 C43, Germany 2009 – 2010
per 100,000
62 Cancer in Germany | Malignant melanoma of the skin
Table 3.11.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C43, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C43, Germany 2009 – 2010
Figure 3.11.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C43, Germany 2009 – 2010
61 % 23 % 9 % 7 %
56 % 25 % 11 % 8 %





T1       T2       T3       T4       
Figure 3.11.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C43, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 760) 1 8 % (1 in 57) <0 1 % (1 in 8,000) 0 3 % (1 in 310)
45 years 0 2 % (1 in 490) 1 7 % (1 in 60) <0 1 % (1 in 3,600) 0 3 % (1 in 320)
55 years 0 4 % (1 in 270) 1 5 % (1 in 66) 0 1 % (1 in 1,900) 0 3 % (1 in 330)
65 years 0 6 % (1 in 160) 1 3 % (1 in 78) 0 1 % (1 in 1,100) 0 3 % (1 in 360)
75 years 0 6 % (1 in 160) 0 9 % (1 in 120) 0 2 % (1 in 670) 0 2 % (1 in 440)
Lifetime risk 1 8 % (1 in 54) 0 3 % (1 in 310)
Women aged in the next ten years ever in the next ten years ever
35 years 0 2 % (1 in 440) 1 6 % (1 in 64) <0 1 % (1 in 8,800) 0 2 % (1 in 450)
45 years 0 3 % (1 in 370) 1 3 % (1 in 75) <0 1 % (1 in 5,100) 0 2 % (1 in 470)
55 years 0 3 % (1 in 340) 1 1 % (1 in 91) <0 1 % (1 in 3,300) 0 2 % (1 in 510)
65 years 0 4 % (1 in 260) 0 8 % (1 in 120) <0 1 % (1 in 2,100) 0 2 % (1 in 570)
75 years 0 4 % (1 in 280) 0 5 % (1 in 190) 0 1 % (1 in 1,300) 0 1 % (1 in 690)
Lifetime risk 1 8 % (1 in 57) 0 2 % (1 in 450)
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C43, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard)











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C43, 2009 – 2010
per 100,000 (European standard)
64 Cancer in Germany | Mesothelioma
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 1,280 310 1,320 350 1,600 300
Crude incidence rate1 3 2 0 7 3 3 0 8 4 1 0 8
Standardised incidence rate1,² 2 1 0 4 2 1 0 5 2 5 0 5
Median age at diagnosis 72 73 73 73
Deaths 1,012 264 1,099 298
Crude mortality rate1 2 5 0 6 2 7 0 7
Standardised mortality rate1,² 1 7 0 3 1 8 0 4
5-year prevalence 1,700 500 1,700 500
Absolute 5-year survival rate (2009-2010)3 8 (4-23) 14
Relative 5-year survival rate (2009-2010)3 9 (5-28) 15
Table 3.12.1
Overview of key epidemiological parameters for Germany, ICD-10 C45
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.12  Mesothelioma
Epidemiology
Malignant mesothelioma refer to a rare soft tissue 
tumour (in the cells of the mesothelium), mainly 
occurring in men of advanced age. The most fre-
quently affected site is the pleura (pleural mesothe-
lioma) – around 90 %.
Clear regional differences with high incidence 
and mortality rates, especially in Hamburg and Bre-
men can be explained by high exposure to asbestos 
among former shipyard workers and comparatively 
high rates in England and the Netherlands can be 
interpreted in a similar way.
Because of the long-term latency, no evidence of 
a reduction in age-standardised incidence rates is to 
be noted in spite of the ban on asbestos processing 
(see below). Meanwhile, the incidence and mortality 
rates in men under the age of 65 years are falling, 
whilst in the higher age groups they are still tending 
to increase. The absolute incidence and mortality 
figures are also still increasing, at least among men. 
In Germany, in 2010 approximately 1,320 men and 
350 women were diagnosed.
With relative 5-year survival rates of 9 % in men 
and 15 % in women, mesothelomia belong to the 
types of cancer with very unfavourable prognosis, 
which to date has not been significantly affected by 
screening (early detection programmes) of occupati-
onally at-risk persons. 
Risk factors 
Even today, asbestos and above all the inhalation of 
asbestos fibres is still responsible for the majority of 
newly diagnosed cases. Admittedly the processing of 
asbestos is banned in Germany since 1995, however 
there is a latency period of on average 30 years bet-
ween exposure beginning and the manifestation of 
the illness. Approximately 900 newly diagnosed 
cases per year are being recognised by employers‘ 
liability insurance associations. The occupational 
groups affected include metalworkers, welders, elec-
tricians, installers, roofers, bricklayers, construction 
workers, automotive engineers and tilers. Even if 
there is no known vocational exposure to asbestos, 
mesotheliomas are often asbestos-related. In autop-
sy studies high concentrations of asbestos fibres are 
often found in the lung tissue even without any cor-
responding vocational history.
Loosely bound asbestos with high fibre content is 
particularly dangerous. In contrast, asbestos cement 
(commonly referred to as ‘Eternit’, after a manufac-
turer), which is to be found even today both in and 
on buildings, is deemed to be largely safe, provided 
it remains intact and does not weather.
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C45, Germany 1999 – 2010
Figure 3.12.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C45, Germany 1999 – 2010
per 100,000 (European standard)
WomenMen
Age group












Age-specific incidence rates by sex, ICD-10 C45, Germany 2009 – 2010
per 100,000
66 Cancer in Germany | Mesothelioma
Table 3.12.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C45, database 2010

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C45, Germany 2009 – 2010
Figure 3.12.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C45, Germany 2009 – 2010
Figure 3.12.3
Distribution of T-stages at first diagnosis by sex
Not presented due to the large proportion of missing data.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 129,000) 0 3 % (1 in 350) <0 1 % (1 in 116,000) 0 2 % (1 in 420)
45 years <0 1 % (1 in 13,000) 0 3 % (1 in 350) <0 1 % (1 in 19,000) 0 2 % (1 in 410)
55 years <0 1 % (1 in 2,700) 1 3 % (1 in 350) <0 1 % (1 in 3,500) 0 2 % (1 in 410)
65 years 0 1 % (1 in 890) 0 3 % (1 in 360) 0 1 % (1 in 1,100) 0 2 % (1 in 420)
75 years 0 1 % (1 in 690) 0 2 % (1 in 470) 0 1 % (1 in 770) 0 2 % (1 in 530)
Lifetime risk 0 3 % (1 in 360) 0 2 % (1 in 430)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 49,000) 0 1 % (1 in 1,500) <0 1 % (1 in 94,000) 0 1 % (1 in 1,700)
45 years <0 1 % (1 in 33,000) 0 1 % (1 in 1,500) <0 1 % (1 in 48,000) 0 1 % (1 in 1,700)
55 years <0 1 % (1 in 10,000) 0 1 % (1 in 1,500) <0 1 % (1 in 12,000) 0 1 % (1 in 1,700)
65 years <0 1 % (1 in 4,500) 0 1 % (1 in 1,700) <0 1 % (1 in 5,700) 0 1 % (1 in 1,900)
75 years <0 1 % (1 in 3,800) <0 1 % (1 in 2,500) <0 1 % (1 in 4,000) <0 1 % (1 in 2,500)
Lifetime risk 0 1 % (1 in 1,500) 0 1 % (1 in 1,700)
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¹ no comparable data for incidence
Figure 3.12.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C45, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C45, 2009 – 2010
per 100,000 (European standard)
68 Cancer in Germany | Breast
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 560 73,340 610 70,340 600 75,200
Crude incidence rate1 1 4 175 7 1 5 168 9 1 5 182 5
Standardised incidence rate1,² 1 0 125 6 1 1 119 6 1 0 123 3
Median age at diagnosis 69 64 69 64
Deaths 131 17,066 107 17,466
Crude mortality rate1 0 3 40 9 0 3 41 9
Standardised mortality rate1,² 0 2 24 0 0 2 24 0
5-year prevalence 2,300 301,500 2,300 307,800
Absolute 5-year survival rate (2009-2010)3 61 (42-74) 79 (78-80)
Relative 5-year survival rate (2009-2010)3 74 (51-88) 87 (86-88)
Table 3.13.1
Overview of key epidemiological parameters for Germany, ICD-10 C50
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.13  Breast
Epidemiology
With some 70,000 new cases currently being diag-
nosed annually, breast cancer is by far the most com-
mon form of cancer among women. There are also 
an additional 6,500 in situ tumours annually. Accor-
ding to current incidence figures, about one woman 
in eight will develop breast cancer in the course of 
her life. One in every four women is younger than 55 
years at diagnosis, and one in ten is younger than 45 
years of age.
The incidence and mortality rates in Europe fol-
low an East to West gradient, and both are still sig-
nificantly lower in eastern than in western Germany. 
Following the introduction of mammography scree-
ning in 2005, the incidence rates in Germany initi-
ally spiked, although since 2009 they have started to 
fall again slightly. This indicates that in the first 
phase of the programme many tumours were diag-
nosed at an earlier stage than they would have been 
without screening. Among those, some tumours 
might have been diagnosed that would otherwise 
have gone unrecognised for the entire life of the 
patient (over-diagnosis). The proportion of smaller 
tumours (T1) in the screening age group is conside-
rably higher than before screening was introduced. 
Despite the increased incidence, fewer women 
die of breast cancer now than ten years ago. The pro-
spects of survival have improved considerably due to 
advances in therapy. It will not be possible to tell if 
screening leads to a further reduction in breast can-
cer mortality before 2015 at the earliest.
Risk factors and early detection
Early first menses and late last menses, childless-
ness, and having a first child late are all associated 
with an increased risk of breast cancer. Conversely, 
numerous or early births and longer periods of 
breast-feeding reduce the risk of breast cancer. Hor-
mone replacement therapy during and after meno-
pause increases the risk of breast cancer, especially if 
it involves a combination of oestrogen and progesto-
gen. Ovulation inhibitors containing hormones (“the 
pill”), on the other hand, have only a minor influence 
on the incidence rate. Studies have shown an increa-
sed risk associated with being overweight and with 
lack of exercise after menopause, and alcohol is also 
a proven risk factor. There are indications that active 
and passive smoking increase the risk.
In addition, women with very dense breast tissue 
or with certain benign breast neoplasms (lobular 
neoplasias and atypical ductal hyperplasias) have an 
increased risk. Having family clusters of breast or 
ovarian cancer is also a risk factor. In approximately 
half of these cases (5 - 10 % of all cases of breast can-
cer) the high family incidence results from a muta-
tion in the “classic” breast cancer genes BRCA1 and 
BRCA2.
The statutory early detection programme offers 
women above 30 years of age an annual palpation 
examination by a physician. Between 2005 and 
2009 the quality assured Mammography Screening 
Programme was introduced in Germany, and women 
between 50 and 69 years of age are invited to an 
X-ray examination of the breasts every two years.
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C50, Germany 1999 – 2010
Figure 3.13.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C50, Germany 1999 – 2010
per 100,000 (European standard)
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Age-specific incidence rates by sex, ICD-10 C50, Germany 2009 – 2010
per 100,000
70 Cancer in Germany | Breast
Table 3.13.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C50, database 2010

















Relative survival rates up to 5 years after first diagnosis, 
women, ICD-10 C50, Germany 2009 – 2010
Figure 3.13.4a
Absolute survival rates up to 5 years after first diagnosis, 
women, ICD-10 C50, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 25,000) 0 1 % (1 in 800) <0 1 % (1 in 192,000) <0 1 % (1 in 4,200)
45 years <0 1 % (1 in 15,000) 0 1 % (1 in 820) <0 1 % (1 in 108,000) <0 1 % (1 in 4,300)
55 years <0 1 % (1 in 4,100) 0 1 % (1 in 830) <0 1 % (1 in 21,000) <0 1 % (1 in 4,300)
65 years <0 1 % (1 in 2,300) 0 1 % (1 in 930) <0 1 % (1 in 14,000) <0 1 % (1 in 4,800)
75 years 0 1 % (1 in 1,700) 0 1 % (1 in 1,200) <0 1 % (1 in 9,900) <0 1 % (1 in 5,800)
Lifetime risk 0 1 % (1 in 810) <0 1 % (1 in 4,300)
Women aged in the next ten years ever in the next ten years ever
35 years 0 9 % (1 in 110) 12 9 % (1 in 8) 0 1 % (1 in 1,000) 3 5 % (1 in 29)
45 years 2 1 % (1 in 47) 12 2 % (1 in 8) 0 3 % (1 in 370) 3 4 % (1 in 30)
55 years 3 2 % (1 in 31) 10 5 % (1 in 10) 0 5 % (1 in 190) 3 2 % (1 in 31)
65 years 3 7 % (1 in 27) 7 8 % (1 in 13) 0 9 % (1 in 120) 2 8 % (1 in 36)
75 years 3 1 % (1 in 32) 4 9 % (1 in 21) 1 2 % (1 in 84) 2 2 % (1 in 46)
Lifetime risk 12 9 % (1 in 8)  3 4 % (1 in 29)
61 % 31 % 4 % 4 %
52 % 37 % 5 % 6 %
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Women all ages
Women 50 - 69 years
Women all ages
Women 50 - 69 years
T1       T2        T3       T4       no information DCO
Figure 3.13.3
Distribution of T-stages at first diagnosis for women at all ages and women between 50 and 69 years (top: all cases; bottom: only 
valid reports) ICD-10 C50, Germany 2009 – 2010
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International comparison of age-standardised incidence and mortality rates, women, 
ICD-10 C50, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 























Registered age-standardised incidence and mortality rates in German federal states, women, 
ICD-10 C50, 2009 – 2010
per 100,000 (European standard)
72 Cancer in Germany | Vulva
 2009 2010 Prediction for 2014
 Women Women Women
Incident cases 2,950 3,190 4,000
Crude incidence rate1 7 1 7 7 9 8
Standardised incidence rate1,² 4 3 4 6 5 8
Median age at diagnosis 72 72
Deaths 768 749
Crude mortality rate1 1 8 1 8
Standardised mortality rate1,² 0 9 0 8
5-year prevalence 9,700 10,500
Absolute 5-year survival rate (2009-2010)3 60 (52-65)
Relative 5-year survival rate (2009-2010)3 71 (62-79)
Table 3.14.1
Overview of key epidemiological parameters for Germany, ICD-10 C51
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.14  Vulva
Epidemiology
A significant increase in the number of vulvar carci-
nomas has been observed in Germany in recent 
years. In 2010 some 3,200 women were diagnosed 
with this carcinoma. Just ten years ago there were 
fewer than half as many cases. The mortality rate 
has not decreased in recent years, in contrast to the 
mortality rates for most other gynaecological 
tumours. Latest data shows that about 750 women 
die of this disease every year.
The increase in the incidence rate is observed in 
young women in particular, although the majority of 
the burden of disease is still accounted for by women 
over 70 years of age. Median age at diagnosis is 72 
years. The relative 5-year survival rate after diagnosis 
of a malignant vulvar tumour is 71 %. The vast majo-
rity of invasive carcinomas are diagnosed at an early 
tumour stage (T1), although lymph nodes are already 
affected in one of every five of these cases. There are 
significant regional differences in both the inci-
dence and the mortality rates. The Saarland has by 
far the highest incidence and mortality rates among 
Germany’s federal states. Germany has a broadly 
comparable mortality rate at a higher incidence rate 
than its neighbours, although data was not available 
for comparison in all neighbouring countries.
Risk factors and prevention
The majority of vulvar carcinomas are squamous-cell 
carcinomas (90 %). A distinction is made between 
two types of these carcinomas: non-keratinising and 
keratinising squamous-cell carcinomas. The former 
involve chronic infection with the human Papilloma-
virus (HPV), while the keratinising carcinomas deve-
lop independent of HPV. 
HPV-dependent vulvar carcinomas and their pre-
cancerous conditions (usual-type vulvar intraepithe-
lial neoplasia, uVIN) occur predominantly in 
younger women (median age approximately 55 
years). In contrast, HPV-independent carcinomas 
usually occur in older women (median age approxi-
mately 70 years), and these are the commonest type 
of vulvar carcinoma (65 % to 80 % of cases). Signifi-
cant risk factors for this type of carcinoma and its 
precancerous conditions (differentiated VIN, dVIN) 
are in particular degenerative and chronic inflamm-
atory skin diseases such as Lichen sclerosus.
Further risk factors are smoking and alcohol 
abuse. Long-standing immunosuppression, e.g. fol-
lowing organ transplants or in case of HIV infection, 
can facilitate infection with HPV and thus increase 
the risk. The presence of other cancers or their pre-
cursors in the genital area, for example cervical can-
cer, also constitutes a risk factor for vulvar carci-
noma. The incidence in particular of HPV-related 
precursors to vulvar carcinoma has increased in 
recent years. One possible means of preventing 
these precancerous conditions and carcinomas is 
HPV vaccination.
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Absolute numbers of incident cases and deaths,
ICD-10 C51, Germany 1999 – 2010
Figure 3.14.1a
Age-standardised incidence and mortality rates,
ICD-10 C51, Germany 1999 – 2010
per 100,000 (European standard)
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Age-specific incidence rates, ICD-10 C51, Germany 2009 – 2010
per 100,0000
74 Cancer in Germany | Vulva
Table 3.14.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C51, database 2010

















Relative survival rates up to 5 years after first diagnosis,
ICD-10 C51, Germany 2009 – 2010
Figure 3.14.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C51, Germany 2009 – 2010
Figure 3.14.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C51, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 2,800) 0 6 % (1 in 160) <0 1 % (1 in 48,000) 0 2 % (1 in 630)
45 years 0 1 % (1 in 1,700) 0 6 % (1 in 170) <0 1 % (1 in 22,000) 0 2 % (1 in 630)
55 years 0 1 % (1 in 1,200) 0 5 % (1 in 190) <0 1 % (1 in 8,100) 0 2 % (1 in 640)
65 years 0 2 % (1 in 660) 0 5 % (1 in 210) <0 1 % (1 in 3,400) 0 2 % (1 in 660)
75 years 0 2 % (1 in 450) 0 4 % (1 in 280) 0 1 % (1 in 1,500) 0 1 % (1 in 720)
Lifetime risk 0 6 % (1 in 160) 0 2 % (1 in 630)
87 % 10 % 3 %
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information
DCO
T1       T2       T3       T4       Women
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¹ incl. C52, C57.7, C57.8 and C57.9   ² no comparable data for mortality
³ no comparable data   4 data for mortality for 2008 only
Figure 3.14.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C51, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 























Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C51, 2009 – 2010
per 100,000 (European standard)
76 Cancer in Germany | Cervix
Epidemiology
In 2010 about 4,700 women were diagnosed with 
cervical carcinoma in Germany. About three quarters 
of cervical carcinomas are of squamous-cell origin. 
Adenocarcinomas (approx. 20 %) have a more proxi-
mate origin at the transition from uterus to cervix.
The incidence rates for invasive cervical carcino-
mas have remained largely stable since the late 
1990s at a markedly lower level than in the 1980s. 
The highest incidence rates are currently found 
among women between 40 and 59 years of age. The 
age distribution is slightly distorted by cases registe-
red by death certificate only (DCO) which are found 
in the eldest age groups in particular. The median 
age at diagnosis for invasive cancer is 53 years. The 
median age at diagnosis for in situ carcinomas is 
just 34 years. These are diagnosed some two to three 
times more often than invasive carcinomas, a result 
of the cervical cancer early detection examinations, 
aimed at identifying and treating cancer precursors. 
International comparison shows there are signifi-
cant differences between countries like Switzerland 
and Finland with low incidence rates on the one 
hand and Denmark, the Czech Republic and Poland 
on the other, with significantly higher incidence 
rates.
Currently, about 1,500 women in Germany die of 
cervical cancer every year. 30 years ago this figure 
was more than twice as high. The relative 5-year sur-
vival rate after diagnosis of an invasive cervical 
tumour is 69 %. Over half of invasive carcinomas 
are diagnosed at an early tumour stage (T1).
Risk factors and early detection
The main cause of cervical cancer is infection with 
the human Papillomavirus (HPV). The majority of 
women are infected with HPV at some point in their 
life. Usually the infection is transient and disap-
pears without further effects, but in some cases it 
persists and a cervical carcinoma can develop, espe-
cially with virus subtypes from the high risk group 
(e.g. HPV 16 or 18). Further risk factors are smoking, 
infections in the genital area with sexually transmit-
ted pathogens such as herpes simplex or chlamydia, 
becoming sexually active at a young age, numerous 
births, and a severely impaired immune system. 
Taking oral contraceptives (“the pill”) over a long 
period of time is also associated with a slightly high-
er risk of developing cervical cancer. However, the 
risk falls again when oral contraceptives are discon-
tinued, and after approximately ten years these 
women seem no more at-risk than women who 
never took oral contraceptives. 
Women in Germany aged 20 years and above are 
entitled to an annual cervical smear test (PAP smear). 
In March 2007, the German Standing Committee on 
Vaccination Recommendations (STIKO) proposed 
vaccinating girls between 12 and 17 years of age 
against HPV 16 and 18, which are responsible for 
about 70 % of all cervical carcinomas. It has been 
proved that the vaccination can prevent the develop-
ment of preliminary stages of cervical cancer. Howe-
ver, the vaccination does not supersede the PAP 
smear, as it only protects against two of the most 
common high-risk Papillomaviruses.
 2009 2010 Prediction for 2014
 Women Women Women
Incident cases 4,780 4,660 4,600
Crude incidence rate1 11 5 11 2 11 2
Standardised incidence rate1,² 9 5 9 3 9 6
Median age at diagnosis 52 53
Deaths 1,581 1,524
Crude mortality rate1 3 8 3 7
Standardised mortality rate1,² 2 6 2 5
5-year prevalence 17,800 17,800
Absolute 5-year survival rate (2009-2010)3 66 (61-69)
Relative 5-year survival rate (2009-2010)3 69 (65-73)
Table 3.15.1
Overview of key epidemiological parameters for Germany, ICD-10 C53
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.15  Cervix
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Absolute numbers of incident cases and deaths,
ICD-10 C53, Germany 1999 – 2010
Figure 3.15.1a
Age-standardised incidence and mortality rates,
ICD-10 C53, Germany 1999 – 2010
per 100,000 (European standard)


















Cancer incidence and mortality risks in Germany by age, ICD-10 C53, database 2010
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Relative survival rates up to 5 years after first diagnosis,
ICD-10 C53, Germany 2009 – 2010
Figure 3.15.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C53, Germany 2009 – 2010
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Figure 3.15.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C53, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
15 years <0 1 % (1 in 16,000) 0 8 % (1 in 120) <0 1 % (1 in 186,000) 0 3 % (1 in 350)
25 years 0 1 % (1 in 1,200) 0 8 % (1 in 120) <0 1 % (1 in 16,000) 0 3 % (1 in 350)
35 years 0 2 % (1 in 580) 0 8 % (1 in 130) <0 1 % (1 in 4,200) 0 3 % (1 in 360)
45 years 0 2 % (1 in 620) 0 6 % (1 in 170) <0 1 % (1 in 2,100) 0 3 % (1 in 390)
55 years 0 2 % (1 in 620) 0 4 % (1 in 230) 0 1 % (1 in 1,800) 0 2 % (1 in 460)
65 years 0 1 % (1 in 790) 0 3 % (1 in 350) 0 1 % (1 in 1,700) 0 2 % (1 in 590)
75 years 0 1 % (1 in 850) 0 2 % (1 in 550) 0 1 % (1 in 1,400) 0 1 % (1 in 800)
Lifetime risk 0 8 % (1 in 120)  0 3 % (1 in 350)
79 ICD-10 C53 | Cancer in Germany 


















International comparison of age-standardised incidence and mortality rates,
ICD-10 C53, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 























Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C53, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Women Women Women
Incident cases 11,650 11,550 11,900
Crude incidence rate1 27 9 27 7 28 9
Standardised incidence rate1,² 18 0 17 7 17 7
Median age at diagnosis 69 69
Deaths 2,360 2,432
Crude mortality rate1 5 7 5 8
Standardised mortality rate1,² 2 9 3 0
5-year prevalence 46,700 46,800
Absolute 5-year survival rate (2009-2010)3 72 (69-78)
Relative 5-year survival rate (2009-2010)3 81 (78-88)
Table 3.16.1
Overview of key epidemiological parameters for Germany, ICD-10 C54 – C55
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.16  Uterus
Epidemiology
With approximately 11,550 newly diagnosed cases 
every year, accounting for 5.1 % of all malignant neo-
plasms, uterine cancer is the fourth most common 
form of cancer among women and the most com-
mon cancer of the female genital organs. Due to the 
good prognosis, the proportion of all deaths the can-
cer accounts for is markedly lower, at just 2.4 %.
One in 46 women (2.2 %) develops cancer of the 
uterus in the course of her life, and one in 200 dies 
of it. As with the mortality rate for cancer of the cer-
vix, the mortality rate for cancer of the uterus has 
fallen slightly, while the age-standardised incidence 
rate has recently remained almost constant. The 
median age at diagnosis is 69 years. Histologically, 
cancers of the uterus are mostly endometrial (i.e. 
originating from the lining of the uterus) adenocar-
cinomas. Approximately 70 % of the carcinomas are 
diagnosed at an early stage (T1).
Uterine carcinomas are one of the types of cancer 
with a favourable prognosis. The relative 5-year sur-
vival rate in Germany is approximately 81 %. 
Regional differences within Germany are rela-
tively small. Internationally, higher incidence and 
mortality rates have been observed in Eastern 
Europe, Scandinavia and also in the USA.
Risk factors 
Independent of and in addition to age, the long-term 
influence of oestrogen is a risk factor. Thus early first 
menses (menarche), late onset of menopause (cli-
macterium), childlessness, and diseases of the ovari-
es, such as polycystic ovary syndrome (PCOS), all 
have the effect of increasing the risk. Oestrogen as 
monotherapy during menopause also increases the 
risk, although when combined with progesterone it 
does not. Oral contraceptives (“the pill”), in particu-
lar oestrogen-progesterone combinations, reduce 
the risk. For hormone-dependent tumours, lifestyle 
risk factors also play a role, particularly overweight 
and lack of exercise. Women with type 2 diabetes 
mellitus are more frequently affected. 
Women with breast cancer who have been treated 
with tamoxifen often develop endometrial hyperpla-
sia and thus have a higher risk of developing a ute-
rine carcinoma. Gene mutations that can lead to 
hereditary nonpolyposis colorectal carcinoma 
(HNPPC) also contribute to an increased risk of ute-
rine cancer. 
For the rarer oestrogen-independent types of this 
tumour, advanced age is also a risk. Exposure of the 
uterus to radiation can also increase the risk. Study 
results available do not permit conclusive interpreta-
tion of the roles played by lifestyle and genetic factors 
in oestrogen-independent tumours.
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Absolute numbers of incident cases and deaths,
ICD-10 C54 – C55, Germany 1999 – 2010
Figure 3.16.1a
Age-standardised incidence and mortality rates,
ICD-10 C54 – C55, Germany 1999 – 2010
per 100,000 (European standard)














Age-specific incidence rates, ICD-10 C54 – C55, Germany 2009 – 2010
per 100,000
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Table 3.16.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C54 – C55, database 2010









Relative survival rates up to 5 years after first diagnosis,
ICD-10 C54 – C55, Germany 2009 – 2010
Figure 3.16.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C54 – C55, Germany 2009 – 2010








70 % 19 % 10 % 1 %
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information
DCO
T1       T2       T3       T4       Women
Figure 3.16.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C54 – C55, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 2,000) 2 2 % (1 in 46) <0 1 % (1 in 27,000) 0 5 % (1 in 200)
45 years 0 2 % (1 in 470) 2 2 % (1 in 46) <0 1 % (1 in 5,800) 0 5 % (1 in 200)
55 years 0 5 % (1 in 200) 2 0 % (1 in 50) 0 1 % (1 in 1,700) 0 5 % (1 in 200)
65 years 0 7 % (1 in 140) 1 6 % (1 in 64) 0 1 % (1 in 750) 0 5 % (1 in 220)
75 years 0 7 % (1 in 140) 1 0 % (1 in 100) 0 2 % (1 in 500) 0 4 % (1 in 270)
Lifetime risk 2 2 % (1 in 46)  0 5 % (1 in 200)
83 ICD-10 C54 – C55 | Cancer in Germany 

















¹ incl. C58   ² only C54  
Figure 3.16.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C54 – C55, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 























Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C54 – C55, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Women Women Women
Incident cases 7,910 7,790 7,500
Crude incidence rate1 19 0 18 7 18 2
Standardised incidence rate1,² 12 3 12 1 11 2
Median age at diagnosis 69 69
Deaths 5,623 5,599
Crude mortality rate1 13 5 13 4
Standardised mortality rate1,² 7 7 7 5
5-year prevalence 22,800 22,400
Absolute 5-year survival rate (2009-2010)3 38 (28-43)
Relative 5-year survival rate (2009-2010)3 42 (31-47)
Table 3.17.1
Overview of key epidemiological parameters for Germany, ICD-10 C56
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.17  Ovaries
Epidemiology
Ovarian cancer accounts for 3.5 % of all malignant 
neoplasms among women and 5.6 % of all female 
deaths due to cancer. The incidence rates increase 
continually up to the age of 85 years, while the medi-
an age at diagnosis is 69 years. Histologically, mali-
gnant tumours of the ovaries are predominantly 
adenocarcinomas. The rare germ cell tumours of 
the ovaries occur in younger women. One in appro-
ximately 68 women develops ovarian cancer in the 
course of her lifetime.
Since the millennium, the incidence and morta-
lity rates in Germany have continued to fall signifi-
cantly. Both the incidence and mortality rates are 
higher in eastern than in western Germany.
Since diagnosis often only occurs at a late tumour 
stage, the survival prospects for patients with ova-
rian cancer are relatively unfavourable. The relative 
5-year survival rate is currently around 42 %.
Risk factors
The risk of developing ovarian cancer increases with 
age in particular. Of the lifestyle-related risk factors, 
obesity (adipositas) plays a part. There are important 
relationships with hormonal factors: childlessness 
and infertility increase the risk of developing ovarian 
cancer, while numerous births and longer periods of 
breast-feeding reduce the risk. It has not been con-
clusively proved whether early first menses (menar-
che) or late onset of menopause (climacterium) also 
lead to an increased risk. Hormonal factors probably 
also increase the risk for women with polycystic ova-
ries. Hormone replacement therapy (particularly 
with oestrogen monotherapy) for women after 
menopause is also a risk factor. In contrast, hormo-
nal ovulation inhibitors (“the pill”) protect against 
ovarian cancer. Sterilisation by means of tubal ligati-
on also reduces the risk of developing this cancer.
The risk of ovarian cancer is higher for women 
with first-degree relatives diagnosed with breast or 
ovarian cancer and for women who themselves have 
been diagnosed with breast, uterine or colorectal 
cancer. Underlying genetic mutations, above all of 
BRCA1 and BRCA2, considerably increase the risk, 
but they only play a part in a small proportion of 
cases. 
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Absolute numbers of incident cases and deaths,
ICD-10 C56, Germany 1999 – 2010
Figure 3.17.1a
Age-standardised incidence and mortality rates,
ICD-10 C56, Germany 1999 – 2010
per 100,000 (European standard)
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Relative survival rates up to 5 years after first diagnosis,
ICD-10 C56, Germany 2009 – 2010
Figure 3.17.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C56, Germany 2009 – 2010
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Figure 3.17.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C56, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,700) 1 4 % (1 in 70) <0 1 % (1 in 5,600) 1 1 % (1 in 91)
45 years 0 2 % (1 in 590) 1 4 % (1 in 72) 0 1 % (1 in 1,400) 1 1 % (1 in 92)
55 years 0 3 % (1 in 360) 1 2 % (1 in 80) 0 2 % (1 in 600) 1 0 % (1 in 96)
65 years 0 4 % (1 in 230) 1 0 % (1 in 98) 0 3 % (1 in 320) 0 9 % (1 in 110)
75 years 0 4 % (1 in 230) 0 7 % (1 in 150) 0 4 % (1 in 230) 0 7 % (1 in 150)
Lifetime risk 1 5 % (1 in 68)  1 1 % (1 in 91)
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¹ incl. C57.0 - C57.4
Figure 3.17.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C56, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 























Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C56, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Men Men Men
Incident cases 64,960 65,830 70,100
Crude incidence rate1 161 9 164 2 176 4
Standardised incidence rate1,² 111 6 111 4 111 4
Median age at diagnosis 70 70
Deaths 12,217 12,676
Crude mortality rate1 30 4 31 6
Standardised mortality rate1,² 20 0 20 0
5-year prevalence 273,100 279,000
Absolute 5-year survival rate (2009-2010)3 78 (73-80)
Relative 5-year survival rate (2009-2010)3 93 (88-95)
Table 3.18.1
Overview of key epidemiological parameters for Germany, ICD-10 C61
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.18  Prostate
Epidemiology
Prostate cancer is the most common cancer and the 
third most common cause of death due to cancer 
among men in Germany. The number of new cases 
has risen steadily in recent years and in 2010 was 
65,800. After increasing for almost two decades, the 
age-standardised incidence rate has remained large-
ly constant since 2003. Similar trends can also be 
observed in most other Western industrialised 
nations and may be attributable to the introduction 
of the prostate specific antigen test (PSA test) in the 
late 1980s as an (unorganised) screening method. In 
contrast to the incidence rate, the age-standardised 
mortality rate has been falling since approximately 
the mid-1990s.
Prostate cancer occurs seldom in people under 
50 years of age. For a 35-year old man, the risk of 
being diagnosed with prostate cancer within the 
next ten years is less than 0.1 %, while for a 75-year 
old man it is approximately 6 %.
Most tumours are discovered in the early stages 
T1 and T2. The relative 5-year survival rate for pros-
tate cancer is currently 93 %. Deaths may, however, 
still occur after a longer course of the disease, e.g. 
through recurrence. 
Risk factors and early detection
Little is known about the causes of prostate carcino-
ma development and the factors influencing its 
course. The presence of clustered cases among close 
relatives has now been adequately proved as a risk 
factor, although there is no understanding of the 
hereditary gene mutations involved. The male sex 
hormone (testosterone) also clearly plays a part.
Despite extensive research, there are few reliable 
findings relating to lifestyle, diet, or the environ-
ment. However, it is thought that diet may have an 
influence on the development of the prostate carci-
noma. A large-scale cancer prevention study has 
shown that taking vitamin E as a dietary supplement 
increases the risk of developing prostate cancer.
For men above 45 years of age, the cancer early 
detection directive in Germany currently recom-
mends an annual interview focusing on complaints 
and other health-related changes, an examination of 
the external sexual organs, as well as a palpation exa-
mination of the prostate and the lymph nodes. The 
test for PSA in the blood is not covered by the statu-
tory health insurance, as to date the benefit of the 
PSA test has not been irrefutably proven.
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Absolute numbers of incident cases and deaths,
ICD-10 C61, Germany 1999 – 2010
Figure 3.18.1a
Age-standardised incidence and mortality rates,
ICD-10 C61, Germany 1999 – 2010
per 100,000 (European standard)
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Cancer incidence and mortality risks in Germany by age, ICD-10 C61, database 2010
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Relative survival rates up to 5 years after first diagnosis,
ICD-10 C61, Germany 2009 – 2010
Figure 3.18.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C61, Germany 2009 – 2010
Figure 3.18.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C61, Germany 2009 – 2010
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
25 % 52 % 22 % 2 %
no information
DCO
Men T1       T2       T3       T4       
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 4,200) 13 4 % (1 in 7) <0 1 % (1 in 108,000) 3 3 % (1 in 30)
45 years 0 5 % (1 in 220) 13 6 % (1 in 7) <0 1 % (1 in 4,200) 3 4 % (1 in 30)
55 years 2 7 % (1 in 37) 13 8 % (1 in 7) 0 2 % (1 in 560) 3 5 % (1 in 29)
65 years 6 3 % (1 in 16) 12 6 % (1 in 9) 0 7 % (1 in 140) 3 7 % (1 in 27)
75 years 5 9 % (1 in 17) 8 5 % (1 in 12) 1 9 % (1 in 52) 3 8 % (1 in 26)
Lifetime risk 13 2 % (1 in 8)  3 3 % (1 in 30)
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Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C61, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Men Men Men
Incident cases 3,900 3,820 4,000
Crude incidence rate1 9 7 9 5 9 9
Standardised incidence rate1,² 9 5 9 4 10 0
Median age at diagnosis 38 38
Deaths 170 166
Crude mortality rate1 0 4 0 4
Standardised mortality rate1,² 0 4 0 4
5-year prevalence 18,900 18,800
Absolute 5-year survival rate (2009-2010)3 95 (93-96)
Relative 5-year survival rate (2009-2010)3 97 (94-98)
Table 3.19.1
Overview of key epidemiological parameters for Germany, ICD-10 C62
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.19  Testicle
Epidemiology
In 2010 some 3,820 men in Germany were diag-
nosed with testicular cancer. It accounts for 1.5 % of 
all cases of cancer in men, making it a relatively rare 
tumour. 
In contrast to almost all other types of cancer, 
most cases are diagnosed at a comparatively young 
age, namely between 25 and 45 years of age. In this 
age group, testicular cancer is the most common 
malignant tumour in men. Correspondingly, the 
median age at diagnosis is 38 years.
The age-standardised incidence rate has remai-
ned almost constant recently, levelling out after 
decades during which a steady increase was obser-
ved in Germany and other European countries. Over 
90 % of testicular tumours are diagnosed in the 
early stages T1 or T2. Histologically, testicular can-
cers are predominantly germ cell tumours, of which 
approximately two thirds are seminomas. Approxi-
mately one case in six is a malignant teratoma or a 
combination of the latter types. 
Since the introduction of cis-platinum in chemo-
therapy for testicular cancer over 30 years ago, this 
disease has become one of the malignant neoplasms 
with more favourable prognoses (5-year survival rate 
most recently 97 %) and a low mortality (166 deaths 
in 2010).
Risk factors and early detection
A proven risk factor for testicular cancer is cryptor-
chidism (undescended testis), even after this has 
been properly treated. Men who have already had 
cancer or a preliminary stage of cancer in one testicle 
have an increased risk of developing a tumour in the 
other testicle. Infertility and rare, genetic disturban-
ces to sexual development, such as Klinefelter’s syn-
drome, also increase the likelihood of developing tes-
ticular cancer.
In a small proportion of cases there may be a 
genetic predisposition. Sons and brothers (especially 
twin brothers) of patients with testicular cancer have 
a significantly higher risk of developing the disease.
A hypothesis is that the predisposition for the 
most frequently occurring germ cell tumours in the 
testes may have its origin in cells which are scattered 
during the embryonic stage, and which then undergo 
a malignant development in puberty. A birth weight 
below 2500g or above 4500g as well as tall stature 
are also being discussed as possible risk factors. The 
causes of the increase in incidence observed in for-
mer decades are not clearly understood. The current 
view is that lifestyle and environmental factors play 
no part in the development of testicular cancer. Since 
an early diagnosis is correlated with a better progno-
sis, men between 20 and 40 years of age are advised 
to carry out regular self-examination by palpation of 
the testes.
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Absolute numbers of incident cases and deaths,
ICD-10 C62, Germany 1999 – 2010
Figure 3.19.1a
Age-standardised incidence and mortality rates,
ICD-10 C62, Germany 1999 – 2010
per 100,000 (European standard)














Age-specific incidence rates, ICD-10 C62, Germany 2009 – 2010
per 100,000
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Table 3.19.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C62, database 2010

















Relative survival rates up to 5 years after first diagnosis,
ICD-10 C62, Germany 2009 – 2010
Figure 3.19.4a
Absolute survival rates up to 5 years after first diagnosis,
ICD-10 C62, Germany 2009 – 2010
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Figure 3.19.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C62, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years 0 1 % (1 in 1,300) 0 7 % (1 in 150) <0 1 % (1 in 67,000) <0 1 % (1 in 3,300)
25 years 0 2 % (1 in 470) 0 6 % (1 in 170) <0 1 % (1 in 16,000) <0 1 % (1 in 3,500)
35 years 0 2 % (1 in 490) 0 4 % (1 in 260) <0 1 % (1 in 16,000) <0 1 % (1 in 4,400)
45 years 0 1 % (1 in 860) 0 2 % (1 in 550) <0 1 % (1 in 19,000) <0 1 % (1 in 6,000)
55 years <0 1 % (1 in 2,500) 0 1 % (1 in 1,400) <0 1 % (1 in 32,000) <0 1 % (1 in 8,400)
65 years <0 1 % (1 in 5,000) <0 1 % (1 in 3,000) <0 1 % (1 in 23,000) <0 1 % (1 in 10,000)
75 years <0 1 % (1 in 9,300) <0 1 % (1 in 5,800) <0 1 % (1 in 21,000) <0 1 % (1 in 15,000)
Lifetime risk 0 7 % (1 in 150)  <0 1 % (1 in 3,300)
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International comparison of age-standardised incidence and mortality rates,
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Registered age-standardised incidence and mortality rates in German federal states,
ICD-10 C62, 2009 – 2010
per 100,000 (European standard)
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 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 9,040 5,630 8,950 5,570 9,500 6,000
Crude incidence rate1 22 5 13 5 22 3 13 4 23 9 14 5
Standardised incidence rate1,² 16 4 8 3 16 2 8 2 15 9 8 2
Median age at diagnosis 68 71 68 71
Deaths 3,088 2,015 3,096 2,151
Crude mortality rate1 7 7 4 8 7 7 5 2
Standardised mortality rate1,² 5 3 2 4 5 2 2 4
5-year prevalence 33,300 20,900 33,600 21,100
Absolute 5-year survival rate (2009-2010)3 65 (54-70) 69 (56-78)
Relative 5-year survival rate (2009-2010)3 75 (62-81) 77 (63-89)
Table 3.20.1
Overview of key epidemiological parameters for Germany, ICD-10 C64
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.20  Kidney
 Cancer in Germany | Kidney
Epidemiology
Malignant neoplasms of the kidney can develop 
from various tissues. Among all types of kidney 
tumours in adults, renal cell carcinomas (hyperne-
phromas) occur most frequently, account for 90 % 
of all cases. In contrast, nephroblastomas (Wilms‘ 
tumours), lymphomas or sarcomas of the kidney are 
more frequent in children.
The age-standardised incidence rates have remai-
ned at a fairly constant level for men and women 
since the end of the 1990s, although the incidence 
rate for men is twice as high as in women.  As far as 
the age-standardised mortality rates are concerned, 
a slightly downward trend is observed for both sexes, 
whereas the absolute number of new cases in the 
last ten years has increased by a good 10 %. 
The median age at diagnosis is 68 years for men 
and 71 years for women.
The prognosis for kidney carcinoma is compara-
tively favourable, the relative 5-year survival rate for 
kidney tumours is approx. 75 % in men and 77 % in 
women. Around three-quarters of all tumours are 
diagnosed at a relatively early stage (T1 and T2). In 
regional and/or international comparison, relatively 
high incidence and mortality rates are apparent in 
the eastern federal states, as well as in Germany’s 
eastern European neighbouring countries. 
Risk factors
Smoking and passive smoking, as well as hyperten-
sion and obesity are the most important risk factors. 
A relationship appears to exist between being over-
weight and developing kidney cancer, especially in 
women. In men, the nature of the fat distribution 
may possibly be decisive. Studies have also found 
that alcohol consumption is a potential risk factor.
Occupational exposure to substances which may 
damage the kidneys, e.g. halogenated hydrocarbons 
and cadmium, can also increase cancer risk. On the 
whole, chronic renal insufficiency, regardless of 
cause, may promote carcinogenesis in the kidney. 
Also following a kidney transplant, the immuno-sup-
pressed patient has an increased risk of developing a 
renal cell carcinoma.
Familial predisposition probably only plays a role 
in relatively few cases. Approximately three per cent 
of renal cell carcinomas occur in patients with com-
plex hereditary diseases such as those affected by 
Hippel-Lindau syndrome. These genetic renal cell 
carcinomas are often multifocal and occur more 
often at a younger age than kidney cancers in pati-
ents without a genetic disposition.
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C64, Germany 1999 – 2010
Figure 3.20.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C64, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C64 | Cancer in Germany 


















Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C64, database 2010
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C64, Germany 2009 – 2010
Figure 3.20.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C64, Germany 2009 – 2010
Figure 3.20.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C64, Germany 2009 – 2010
67 % 11 % 20 % 2 %
63 % 10 % 25 % 2 %





T1       T2       T3       T4       
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,900) 1 7 % (1 in 58) <0 1 % (1 in 15,000) 0 7 % (1 in 150)
45 years 0 2 % (1 in 580) 1 7 % (1 in 59) <0 1 % (1 in 3,000) 0 7 % (1 in 150)
55 years 0 4 % (1 in 240) 1 6 % (1 in 63) 0 1 % (1 in 1,000) 0 7 % (1 in 150)
65 years 0 6 % (1 in 160) 1 3 % (1 in 76) 0 2 % (1 in 490) 0 6 % (1 in 160)
75 years 0 6 % (1 in 150) 0 9 % (1 in 120) 0 4 % (1 in 280) 0 6 % (1 in 180)
Lifetime risk 1 7 % (1 in 58) 0 7 % (1 in 150)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 3,800) 1 0 % (1 in 95) <0 1 % (1 in 51,000) 0 4 % (1 in 220)
45 years 0 1 % (1 in 1,300) 1 0 % (1 in 97) <0 1 % (1 in 7,700) 0 4 % (1 in 220)
55 years 0 2 % (1 in 520) 1 0 % (1 in 100) <0 1 % (1 in 2,900) 0 4 % (1 in 230)
65 years 0 3 % (1 in 300) 0 8 % (1 in 120) 0 1 % (1 in 980) 0 4 % (1 in 230)
75 years 0 4 % (1 in 250) 0 6 % (1 in 180) 0 2 % (1 in 460) 0 4 % (1 in 270)
Lifetime risk 1 1 % (1 in 94) 0 4 % (1 in 230)
99


































International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C64, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C64, 2009 – 2010
per 100,000 (European standard)
 ICD-10 C64 | Cancer in Germany 
100
Epidemiology
Some 15,500 people, two third of them men, were 
newly diagnosed with an invasive bladder carcino-
ma in Germany in 2010. In addition, more than 
13,000 were diagnosed with non-invasive papillary 
carcinoma or in situ tumours of the bladder. The lat-
ter in particular, exhibit a high tendency of progres-
sion and recurrence and are thus of particular clini-
cal relevance, despite the fact that they currently do 
not rank among malignant tumours according to 
ICD-10. The majority of bladder cancer cases are car-
cinomas of the urothelium, which frequently occur 
simultaneously at various places in the bladder and 
urinary tract. 
Incidence rates increase steadily with age, with 
only about one in four being diagnosed before the 
age of 65. The age-standardised incidence and mor-
tality rates for men show a clear downward trend 
since the 1990s, probably due to a decline in tobacco 
consumption, but possibly also because of a reduc-
tion in occupational exposure to carcinogens (see 
below). For women, the age-standardised incidence 
rate has recently been constant, while the mortality 
rate reduced slightly. The mortality rate for bladder 
cancer is higher in the eastern federal states than in 
the western parts of Germany, above all among men.
The higher relative 5-year survival rates for men 
(59 %) compared with women (50 %) relate to the 
more favourable distribution of tumour stages at 
diagnosis (47 % vs. 37 % T1 tumours). 
Risk factors
Tobacco consumption is a key risk factor for the 
development of cancer of the bladder. Passive smo-
king also contributes to an increase in risk. The risk 
is further increased by exposure to some chemical 
substances such as aromatic amines, which play a 
role especially for certain occupational groups. The 
known hazardous substances have largely been eli-
minated from industrial processes and workplaces 
in Europe. However, there is a long latency period 
between exposure and the development of cancer, so 
that bladder carcinomas caused by occupational 
exposure will continue to be registered. Cytostatic 
drugs used in chemotherapy and local radiation the-
rapy can increase the risk. The risk potential for 
some other pharmaceuticals is currently being deba-
ted. In 2013 the International Agency for Research 
on Cancer (IARC) classified pioglitazone hydrochlo-
ride, an anti-diabetic agent, as probably carciongenic 
to humans (Class 2A) with regard to cancer of the 
bladder. Chronic inflammatory damage to the muco-
sa of the bladder also increases the risk of bladder 
cancer.
Family clusters have been observed. Furthermore, 
there are indications that genetic factors play a direct 
role in the occurrence of bladder cancer, by increa-
sing the susceptibility to carcinogens. 
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 11,550 4,050 11,350 4,150 11,900 4,500
(21,380)4 (6,970)4 (21,550)4 (7,240)4
Crude incidence rate1 28 8 (53 3)4 9 7 (16 7)4 28 3 (53 7)4 10 0 (17 4)4 30 0 10 8
Standardised incidence rate1,² 19 7 (36 6)4 5 0 (9 1)4 18 9 (36 1)4 5 0 (9 3)4 18 2 5 2
Median age at diagnosis 73 (72)4 76 (74)4 73 (72)4 77 (74)4
Deaths 3,587 1,766 3,631 1,885
Crude mortality rate1 8 9 4 2 9 1 4 5
Standardised mortality rate1,² 6 0 1 8 5 9 1 9
5-year prevalence 35,400 11,300 35,500 11,200
Absolute 5-year survival rate (2009-2010)3 47 (33-50) 41 (34-49)
Relative 5-year survival rate (2009-2010)3 59 (43-62) 50 (41-60)
Table 3.21.1
Overview of key epidemiological parameters for Germany, ICD-10 C67
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states) 
4 in parentheses: including in situ tumours and neoplasms of uncertain or unknown behavior (D09 0, D41 4)
3.21  Bladder
 Cancer in Germany | Bladder
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C67, Germany 1999 – 2010
Figure 3.21.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C67, Germany 1999 – 2010
per 100,000 (European standard)


















Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C67, database 2010
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C67, Germany 2009 – 2010
Figure 3.21.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C67, Germany 2009 – 2010
Figure 3.21.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C67, Germany 2009 – 2010
37 % 39 % 17 % 7 %
47 % 34 % 12 % 7 %





T1       T2       T3       T4       
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 6,400) 2 6 % (1 in 39) <0 1 % (1 in 48,000) 0 9 % (1 in 110)
45 years 0 1 % (1 in 980) 2 6 % (1 in 39) <0 1 % (1 in 5,400) 1 0 % (1 in 110)
55 years 0 4 % (1 in 280) 2 6 % (1 in 39) 0 1 % (1 in 1,500) 1 0 % (1 in 100)
65 years 0 8 % (1 in 130) 2 5 % (1 in 41) 0 2 % (1 in 500) 1 0 % (1 in 100)
75 years 1 3 % (1 in 78) 2 1 % (1 in 47) 0 5 % (1 in 190) 1 0 % (1 in 98)
Lifetime risk 2 5 % (1 in 40) 0 9 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 11,000) 0 8 % (1 in 120) <0 1 % (1 in 53,000) 0 4 % (1 in 240)
45 years <0 1 % (1 in 3,200) 0 8 % (1 in 120) <0 1 % (1 in 13,000) 0 4 % (1 in 240)
55 years 0 1 % (1 in 1,100) 0 8 % (1 in 120) <0 1 % (1 in 4,400) 0 4 % (1 in 240)
65 years 0 2 % (1 in 480) 0 8 % (1 in 130) 0 1 % (1 in 1,600) 0 4 % (1 in 240)
75 years 0 4 % (1 in 280) 0 7 % (1 in 150) 0 2 % (1 in 550) 0 4 % (1 in 250)
Lifetime risk 0 8 % (1 in 120) 0 4 % (1 in 240)
103 ICD-10 C67 | Cancer in Germany 


































International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C67, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C67, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
Cancers of the central nervous system (CNS) predo-
minantly affect the brain, including the brain stem. 
The remaining 5 % are cancers of the meninges, cra-
nial nerves, and the spinal nerves in the cauda equi-
na. Malignant neoplasms of the central nervous sys-
tem originate from glial cells, nerve sheaths and 
meninges. Histologically, approximately two thirds 
are accounted for by glioblastomas, as well as astro-
cytomas in particular (15 %) and other gliomatous 
tumours.
In 2010 nearly 7,000 people developed cancer of 
the central nervous system in Germany, of whom 
around 3,000 were women and 4,000 men. Men 
show higher incidence and mortality rates in all age 
groups than women and have a median age at diag-
nosis of 61 years, 6 years younger than for women, 
though CNS tumours do occur at earlier age in both 
sexes as well. 
Following increases in mortality rates through 
the 1980s to the mid-1990s, especially among the 
more advanced age groups, since the millennium 
have the incidence rates remained constant and the 
mortality rates have fallen in Germany. However, 
with the demographic change, the absolute number 
of malignant neoplasms occurring in men has con-
tinued to rise, and is significantly higher than in 
women. 
The relative 5-year survival rates for patients with 
cancer of the central nervous system have improved 
slightly and are currently 22 % for both sexes, alt-
hough the prognosis for glioblastomas of the brain 
is at 8 % considerably worse. 
Risk factors
The causes of the various brain tumours are still lar-
gely unclear. The only exception are the rare heredi-
tary tumour syndromes, who are associated with a 
significantly higher risk of brain tumours. Following 
therapeutic radiation of the head in childhood (from 
1910 - late 1950s due to tinea capitis) there is a slight-
ly higher risk of developing a brain tumour after a 
long period of latency. Computed tomography 
during childhood can also marginally increase the 
risk of a brain tumour. In contrast, there is no indica-
tion from available data that either the use of ionis-
ing radiation in diagnostic imaging procedures or 
exposure to radiation in other contexts causes any 
discernible risk. Further, current thinking is that 
neither environmental factors nor electromagnetic 
radiation (mobile telephones) contribute to an incre-
ased risk. There is similarly no evidence that viruses 
or toxic substances cause brain tumours in humans. 
First-degree relatives of patients with brain 
tumours have a slightly higher risk of themselves 
developing a brain tumour. Genetic mutations are 
presumably also involved in this marginal familial 
increased risk.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 3,990 3,050 3,890 3,030 4,200 3,200
Crude incidence rate1 9 9 7 3 9 7 7 3 10 6 7 7
Standardised incidence rate1,² 8 1 5 3 7 9 5 2 8 1 5 3
Median age at diagnosis 62 67 61 67
Deaths 3,130 2,609 3,087 2,559
Crude mortality rate1 7 8 6 3 7 7 6 1
Standardised mortality rate1,² 6 0 4 1 5 8 3 9
5-year prevalence 6,900 5,400 6,900 5,300
Absolute 5-year survival rate (2009-2010)3 21 (14-25) 21 (17-31)
Relative 5-year survival rate (2009-2010)3 22 (15-27) 22 (18-32)
Table 3.22.1
Overview of key epidemiological parameters for Germany, ICD-10 C70 – C72
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.22  Central nervous system
 Cancer in Germany | Central nervous system
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C70 – C72, Germany 1999 – 2010
Figure 3.22.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C70 – C72, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C70 – C72 | Cancer in Germany 


















Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C70 – C72, database 2010
 Cancer in Germany | Central nervous system

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C70 – C72, Germany 2009 – 2010
Figure 3.22.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C70 – C72, Germany 2009 – 2010
Figure 3.22.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for tumours of the central nervous system.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,700) 0 6 % (1 in 160) <0 1 % (1 in 3,200) 0 6 % (1 in 180)
45 years 0 1 % (1 in 1,200) 0 6 % (1 in 170) 0 1 % (1 in 1,500) 0 5 % (1 in 190)
55 years 0 2 % (1 in 660) 0 5 % (1 in 190) 0 1 % (1 in 760) 0 5 % (1 in 200)
65 years 0 2 % (1 in 500) 0 4 % (1 in 240) 0 2 % (1 in 520) 0 4 % (1 in 250)
75 years 0 2 % (1 in 460) 0 3 % (1 in 350) 0 2 % (1 in 510) 0 3 % (1 in 380)
Lifetime risk 0 7 % (1 in 130) 0 6 % (1 in 170)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 2,700) 0 5 % (1 in 190) <0 1 % (1 in 5,300) 0 5 % (1 in 210)
45 years 0 1 % (1 in 1,800) 0 5 % (1 in 200) <0 1 % (1 in 2,500) 0 5 % (1 in 220)
55 years 0 1 % (1 in 1,000) 0 5 % (1 in 220) 0 1 % (1 in 1,100) 0 4 % (1 in 240)
65 years 0 2 % (1 in 620) 0 4 % (1 in 270) 0 1 % (1 in 690) 0 4 % (1 in 280)
75 years 0 2 % (1 in 630) 0 2 % (1 in 420) 0 2 % (1 in 610) 0 2 % (1 in 420)
Lifetime risk 0 6 % (1 in 170) 0 5 % (1 in 200)
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¹ only C71   2 no comparable data for incidence
Figure 3.22.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C70 – C72, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C70 – C72, 2009 – 2010
per 100,000 (European standard)
 ICD-10 C70 – C72 | Cancer in Germany 
108
Epidemiology
Annually in Germany approximately 4,200 women 
and 1,700 men are diagnosed with thyroid cancer. 
The median age at diagnosis is 52 years for women 
and 56 for men, though the cancer does also occur 
at a younger age, especially in women.
Histologically, cases most frequently are papillary 
adenocarcinomas (72 %) and follicular adenocarci-
nomas (12 %), rarer forms are medullary and ana-
plastic carcinoma (each 2-3 %).
In the period from 1999 to 2010, the mortality 
rates in both men and women in Germany have 
decreased slightly, whilst the age-standardised inci-
dence rates for both sexes have increased conside-
rably. Papillary carcinomas – very favourable from 
the point of view of prognosis – were exclusively res-
ponsible for this increase, predominantly in younger 
adults. This trend is observed in other countries to a 
similar extent and is most likely attributable to 
improved examination methods (e.g. ultrasound) 
which are used in the course of clarifying other thy-
roid disorders or other internal illnesses. Within 
Germany, the highest incidence rates by far are to be 
observed in Bavaria, which corresponds with simi-
larly high rates in Austria. 
The majority of cancers of the thyroid gland are 
diagnosed at an early stage, especially among 
women (T1) and have a favourable prognosis with 
relative 5-year survival rates of 93 % among women 
and 88 % among men. Anaplastic carcinomas cons-
titute an exception to this (12 %).  
Risk factors
The only proven, albeit comparatively rare environ-
mental risk factor is exposure to ionising radiation, 
particularly in childhood. This would also include 
radiotherapy which extends to the thyroid gland. 
There is no clear proof of other environmental, die-
tary or lifestyle factors. It is also unclear why women 
are more frequently affected than men. Many pati-
ents have a history of iodine deficiency or benign 
thyroid complaints such as struma (goitre) and ade-
noma, which increase the risk of developing thyroid 
carcinomas. About a fifth of patients with a rare 
medullary thyroid carcinoma have hereditary genetic 
mutations with autosomal dominant inheritance. 
Medullary thyroid carcinomas can also occur 
together with other endocrine tumours – as part of 
a so-called type 2 multiple endocrine neoplasia 
(MEN 2). A genetic component is also suspected for 
papillary thyroid carcinomas.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 1,800 4,340 1,670 4,220 2,100 5,100
Crude incidence rate1 4 5 10 4 4 2 10 1 5 2 12 4
Standardised incidence rate1,² 3 7 9 0 3 5 8 7 4 2 10 9
Median age at diagnosis 56 52 56 52
Deaths 262 429 275 431
Crude mortality rate1 0 7 1 0 0 7 1 0
Standardised mortality rate1,² 0 5 0 5 0 5 0 5
5-year prevalence 6,900 17,600 7,200 18,500
Absolute 5-year survival rate (2009-2010)3 82 (70-89) 89 (74-92)
Relative 5-year survival rate (2009-2010)3 88 (76-95) 93 (78-96)
Table 3.23.1
Overview of key epidemiological parameters for Germany, ICD-10 C73
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.23  Thyroid gland
 Cancer in Germany | Thyroid gland
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C73, Germany 1999 – 2010


















Age-standardised incidence and mortality rates, by sex, 
ICD-10 C73, Germany 1999 – 2010
per 100,000 (European standard)
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Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C73, database 2010
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C73, Germany 2009 – 2010
Figure 3.23.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C73, Germany 2009 – 2010
58 % 20 % 18 % 4 %
49 % 20 % 25 % 6 %





T1       T2       T3       T4       
Figure 3.23.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C73, Germany 2009 – 2010
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
25 years <0 1 % (1 in 4,900) 0 3 % (1 in 350) <0 1 % (1 in 245,000) 0 1 % (1 in 1,800)
35 years <0 1 % (1 in 2,600) 0 3 % (1 in 370) <0 1 % (1 in 82,000) 0 1 % (1 in 1,800)
45 years 0 1 % (1 in 1,700) 0 2 % (1 in 420) <0 1 % (1 in 32,000) 0 1 % (1 in 1,800)
55 years 0 1 % (1 in 1,400) 0 2 % (1 in 540) <0 1 % (1 in 11,000) 0 1 % (1 in 1,800)
65 years 0 1 % (1 in 1,400) 0 1 % (1 in 800) <0 1 % (1 in 4,900) 0 1 % (1 in 2,000)
75 years 0 1 % (1 in 1,900) 0 1 % (1 in 1,500) <0 1 % (1 in 3,600) <0 1 % (1 in 2,600)
Lifetime risk 0 3 % (1 in 330) 0 1 % (1 in 1,800)
Women aged in the next ten years ever in the next ten years ever
25 years 0 1 % (1 in 1,200) 0 7 % (1 in 140) <0 1 % (1 in 228,000) 0 1 % (1 in 1,100)
35 years 0 1 % (1 in 740) 0 6 % (1 in 160) <0 1 % (1 in 107,000) 0 1 % (1 in 1,100)
45 years 0 1 % (1 in 700) 0 5 % (1 in 200) <0 1 % (1 in 48,000) 0 1 % (1 in 1,100)
55 years 0 2 % (1 in 660) 0 4 % (1 in 270) <0 1 % (1 in 11,000) 0 1 % (1 in 1,100)
65 years 0 1 % (1 in 800) 0 2 % (1 in 420) <0 1 % (1 in 5,000) 0 1 % (1 in 1,200)
75 years 0 1 % (1 in 1,000) 0 1 % (1 in 790) <0 1 % (1 in 2,600) 0 1 % (1 in 1,400)
Lifetime risk 0 8 % (1 in 130) 0 1 % (1 in 1,200)
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International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C73, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C73, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
Hodgkin’s lymphoma is distinguished from non-
Hodgkin lymphomas histologically by the presence 
of Reed-Sternberg giant cells in the bone marrow. 
Hodgkin’s lymphoma is a rare disease, and in Ger-
many some 1,260 men and 940 women were diag-
nosed with it in 2010. It can occur at any age, and 
about one patient in ten was under 20 years of age at 
diagnosis. The risk of developing Hodgkin’s lym-
phoma at any stage in life is 0.2 % for both men and 
women.
In recent years the incidence rates, and the abso-
lute number of new cases annually, have shown no 
discernible trends, while ever fewer people are dying 
of Hodgkin’s lymphoma. The mortality rate in Ger-
many in 2010 was just over 300, almost 200 fewer 
than ten years previously. The prognosis is corres-
pondingly favourable, with some 80 % of adult pati-
ents still alive 5 years after diagnosis. Due to the 
chronic relapsing nature of the disease, the long-
term prognosis is also determined by side effects of 
therapy (including secondary tumours).
Risk factors 
The risk factors for Hodgkin’s lymphoma are not 
completely understood. It remains unclear whether 
lifestyle-related risk factors or environmental risks 
are responsible for the development of Hodgkin’s 
lymphoma. It is possible that the risk is increased by 
a long-term cigarette smoking habit.
As with non-Hodgkin lymphomas, congenital 
and acquired characteristics of the immune system 
and viral infections are topics of debate, although 
their influence cannot be quantified and it is not pos-
sible to ascribe a definite cause for any individual 
patient.
It has long been suspected that the Epstein-Barr 
virus (EBV), the cause of glandular fever (infectious 
mononucleosis), and retroviruses (e.g. HTLV and 
HIV) are involved. The results of recent studies con-
firm that EBV infection plays an important part in 
the development of Hodgkin’s lymphoma. Other 
viruses, such as the hepatitis B virus, may also be 
involved in the development of Hodgkin’s lym-
phoma.
The children and siblings of patients with 
Hodgkin’s lymphoma have a much higher risk of 
developing the disease themselves. Researchers are 
therefore paying increasing attention to hereditary 
factors. However, research has not yet identified any 
risk-enhancing and inheritable gene mutations.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 1,260 950 1,260 940 1,300 900
Crude incidence rate1 3 1 2 3 3 1 2 3 3 2 2 3
Standardised incidence rate1,² 2 9 2 2 2 9 2 2 3 0 2 2
Median age at diagnosis 43 40 45 41
Deaths 173 139 169 147
Crude mortality rate1 0 4 0 3 0 4 0 4
Standardised mortality rate1,² 0 3 0 2 0 3 0 2
5-year prevalence 5,100 3,900 5,200 3,900
Absolute 5-year survival rate (2009-2010)3 79 (70-87) 82 (69-89)
Relative 5-year survival rate (2009-2010)3 83 (75-92) 85 (72-92)
Table 3.24.1
Overview of key epidemiological parameters for Germany, ICD-10 C81
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.24  Hodgkin’s lymphoma
 Cancer in Germany | Hodgkin’s lymphoma
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C81, Germany 1999 – 2010
Figure 3.24.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C81, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C81 | Cancer in Germany 


















Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C81, database 2010
 Cancer in Germany | Hodgkin’s lymphoma

















Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C81, Germany 2009 – 2010
Figure 3.24.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C81, Germany 2009 – 2010
Figure 3.24.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for Hodgkin’s lymphoma.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years <0 1 % (1 in 2,600) 0 2 % (1 in 450) <0 1 % (1 in 210,000) <0 1 % (1 in 2,800)
25 years <0 1 % (1 in 2,700) 0 2 % (1 in 540) <0 1 % (1 in 75,000) <0 1 % (1 in 2,800)
35 years <0 1 % (1 in 2,800) 0 1 % (1 in 670) <0 1 % (1 in 54,000) <0 1 % (1 in 2,900)
45 years <0 1 % (1 in 3,200) 0 1 % (1 in 860) <0 1 % (1 in 37,000) <0 1 % (1 in 3,100)
55 years <0 1 % (1 in 3,600) 0 1 % (1 in 1,100) <0 1 % (1 in 25,000) <0 1 % (1 in 3,200)
Lifetime risk 0 2 % (1 in 420) <0 1 % (1 in 2,800)
Women aged in the next ten years ever in the next ten years ever
15 years <0 1 % (1 in 2,300) 0 2 % (1 in 570) <0 1 % (1 in 129,000) <0 1 % (1 in 3,400)
25 years <0 1 % (1 in 2,700) 0 1 % (1 in 760) <0 1 % (1 in 96,000) <0 1 % (1 in 3,500)
35 years <0 1 % (1 in 5,300) 0 1 % (1 in 1,100) <0 1 % (1 in 95,000) <0 1 % (1 in 3,600)
45 years <0 1 % (1 in 6,600) 0 1 % (1 in 1,300) <0 1 % (1 in 56,000) <0 1 % (1 in 3,700)
55 years <0 1 % (1 in 5,300) 0 1 % (1 in 1,600) <0 1 % (1 in 48,000) <0 1 % (1 in 3,900)
Lifetime risk 0 2 % (1 in 550) <0 1 % (1 in 3,400)
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Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C81, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
Non-Hodgkin lymphomas originate from cells of 
the lymphatic system, mostly from B-lymphocytes. 
A distinction is made between high-grade and low-
grade malignancy forms. In 2010, some 16,000 peo-
ple were diagnosed with non-Hodgkin lymphoma in 
Germany. The disease occurs as early as in child-
hood and the risk of developing it rises almost stea-
dily with increasing age. The median age at diagno-
sis for men was 69 years, and for women 71 years.
The significant increases in the age-standardised 
incidence rates should be seen within the context of 
falling rates for leukaemias, since chronic lymphatic 
leukaemias are now classified clinically under the 
low-grade malignancy non-Hodgkin lymphomas. 
The age-standardised mortality rates increased until 
the 1990s, but have fallen in the last ten years. 
Approximately 6,000 people in Germany die of this 
disease annually. 
With a relative 5-year survival rate for both men 
and women of 67 %, the prognosis for non-Hodgkin 
lymphomas is generally favourable, although in 
individual cases it depends on age, as well as on type 
and distribution of the disease. Some forms, even 
highly malignant ones, can now be treated with the 
prospect of a permanent cure.
Risk factors
Risk factors for non-Hodgkin lymphoma can only 
rarely be conclusively identified. Immunodeficiency 
(hereditary, because of HIV infection, or due to 
immunosuppressive treatment) is associated with an 
increased risk, as are a number of rare autoimmune 
diseases. Nuclear radiation can also cause malign 
lymphomas. Viruses and other pathogens also con-
tribute to the development of some lymphomas. For 
example, the link between infection with the Epstein-
Barr virus (EBV, glandular fever) and Burkitt’s lym-
phoma, which occurs predominantly in Africa, has 
been proven. Chronic infection of the stomach with 
the Helicobacter pylori bacterium can lead to a lym-
phoma of the gastric mucosa (MALT lymphoma). 
Certain T-cell lymphomas that are rare in Europe are 
found clustered in carriers of the human T-cell leuka-
emia virus (HTLV-1). Studies suggest that certain 
types of lymphoma are more likely to develop in peo-
ple chronically infected with hepatitis viruses (type B 
or C). Environmental pollutants such as heavy 
metals, organic solvents as well as some herbicides, 
insecticides and fungicides are being discussed as 
causes of malign lymphomas. Smoking and being 
overweight appear to play a role, particularly for 
aggressive lymphomas. Regular exercise may reduce 
the risk. New studies suggest that hereditary genetic 
variations could affect the risk of developing the 
disease, without being a direct cause of the lympho-
mas. 
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 8,480 7,360 8,590 7,640 9,400 7,900
Crude incidence rate1 21 1 17 6 21 4 18 3 23 7 19 1
Standardised incidence rate1,² 15 6 10 7 15 5 11 2 16 0 11 1
Median age at diagnosis 68 71 69 71
Deaths 2,998 2,658 3,082 2,921
Crude mortality rate1 7 5 6 4 7 7 7 0
Standardised mortality rate1,² 5 1 3 1 5 2 3 3
5-year prevalence 27,400 24,800 28,200 25,300
Absolute 5-year survival rate (2009-2010)3 58 (49-64) 59 (53-63)
Relative 5-year survival rate (2009-2010)3 67 (57-74) 67 (61-71)
Table 3.25.1
Overview of key epidemiological parameters for Germany, ICD-10 C82 – C85
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.25  Non-Hodgkin lymphomas
 Cancer in Germany | Non-Hodgkin lymphomas
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C82 – C85, Germany 1999 – 2010
Figure 3.25.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C82 – C85, Germany 1999 – 2010
per 100,000 (European standard)
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C82 – C85, Germany 2009 – 2010
Figure 3.25.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C82 – C85, Germany 2009 – 2010
Figure 3.25.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for non-Hodgkin lymphomas.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0 1 % (1 in 1,200) 1 7 % (1 in 60) <0 1 % (1 in 8,400) 0 7 % (1 in 140)
45 years 0 1 % (1 in 720) 1 6 % (1 in 62) <0 1 % (1 in 3,500) 0 7 % (1 in 150)
55 years 0 3 % (1 in 340) 1 5 % (1 in 66) 0 1 % (1 in 1,200) 0 7 % (1 in 150)
65 years 0 6 % (1 in 180) 1 4 % (1 in 73) 0 2 % (1 in 510) 0 7 % (1 in 150)
75 years 0 7 % (1 in 140) 1 0 % (1 in 97) 0 4 % (1 in 270) 0 6 % (1 in 170)
Lifetime risk 1 7 % (1 in 58) 0 7 % (1 in 150)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 2,100) 1 4 % (1 in 69) <0 1 % (1 in 21,000) 0 6 % (1 in 170)
45 years 0 1 % (1 in 920) 1 4 % (1 in 71) <0 1 % (1 in 6,700) 0 6 % (1 in 170)
55 years 0 3 % (1 in 400) 1 3 % (1 in 75) 0 1 % (1 in 2,100) 0 6 % (1 in 170)
65 years 0 4 % (1 in 240) 1 1 % (1 in 88) 0 1 % (1 in 760) 0 6 % (1 in 170)
75 years 0 5 % (1 in 190) 0 8 % (1 in 120) 0 3 % (1 in 330) 0 5 % (1 in 190)
Lifetime risk 1 5 % (1 in 68) 0 6 % (1 in 170)
C82¹ C83² C843 C854
Men 18 % 46 % 10 % 26 %
Women 24 % 42 % 7 % 28 %
Table 3.25.3
Proportion of the various non-Hodgkin lymphomas for all new diagnoses C82 – C85,  
by sex, Germany 2009 – 2010
1 Follicular/nodular non-Hodgkin lymphoma
2 Diffuse non-Hodgkin lymphoma
3 Peripheral and cutaneous T-cell lymphomas
4 Other and unspecified types of non-Hodgkin lymphomas
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¹ incl. C88   ² incl. C96   ³ incl. C86 and C96   4 no comparable data for incidence   5 data for mortality incl. C96
Figure 3.25.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C82 – C85, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C82 – C85, 2009 – 2010
per 100,000 (European standard)
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Epidemiology 
Plasmacytoma is a malignant proliferation of anti-
body-producing plasma cells. The disease mostly 
occurs initially in the bone marrow where it forms 
multiple myeloma with corresponding complica-
tions such as bone fractures and bone pain or blood 
count changes. In approximately 5 % of cases 
involvement of other organs not associated with 
bone marrow leads to diagnosis.
In Germany, in 2010 approximately 3,360 men 
and 2,780 women were newly diagnosed with the 
illness. The risk of developing the disease increases 
significantly in advanced years with cases being ext-
remely rare before the age of 45 years (approxi-
mately 2 % of all cases). Following age-standardisa-
tion the incidence rates for women and men were 
almost constant with the mortality rates in contrast 
for both genders declining slightly. 
Given a relative 5-year survival rate of approxi-
mately 45 % in both women and men, the prognosis 
is relatively unfavourable. Even after maximum the-
rapy, e.g. autologous stem cell transplant, a perma-
nent cure is not to be expected. However, the course 
of the illness may in some cases be asymptomatic 
for a relatively long period, and during therapy tem-
porary remissions may be possible.
Risk factors
The causes of the development of plasmacytomas 
(multiple myeloma) are largely still not yet under-
stood. A monoclonal gammopathy of undetermined 
significance (MGUS) is considered to be the prelimi-
nary stage of the multiple myeloma. Recognised risk 
factors for multiple myeloma are advanced age and 
the male sex. Chronic infections such as HIV-infec-
tion or infection with the hepatitis C virus are associ-
ated with an increased risk of developing a multiple 
myeloma. There are currently conflicting opinions 
as to whether certain lifestyle habits or exposure to 
environmental toxins or radiation significantly incre-
ase the risk of developing a myeloma.  According to 
more recent study data, being very overweight is 
linked with increased risk. Familial clustering has 
been observed though there is no definite evidence 
of heredity to date. However, variations in incidence 
within different population groups also point to 
genetic factors. People of black African origin are 
probably more frequently affected than white North 
Americans, Europeans or Asians.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 3,260 2,910 3,360 2,780 3,600 3,000
Crude incidence rate1 8 1 7 0 8 4 6 7 9 2 7 4
Standardised incidence rate1,² 5 6 3 9 5 7 3 7 5 7 3 9
Median age at diagnosis 71 74 71 74
Deaths 1,809 1,828 1,981 1,850
Crude mortality rate1 4 5 4 4 4 9 4 4
Standardised mortality rate1,² 3 0 2 1 3 2 2 2
5-year prevalence 9,000 8,200 9,200 8,100
Absolute 5-year survival rate (2009-2010)3 39 (31-49) 40 (32-46)
Relative 5-year survival rate (2009-2010)3 45 (37-57) 45 (36-52)
Table 3.26.1
Overview of key epidemiological parameters for Germany, ICD-10 C90
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.26  Multiple myeloma
 Cancer in Germany | Multiple myeloma
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C90, Germany 1999 – 2010
Figure 3.26.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C90, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C90 | Cancer in Germany 
Figure 3.26.2
Age-specific incidence rates by sex, ICD-10 C90, Germany 2009 – 2010
per 100,000
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C90, Germany 2009 – 2010
Figure 3.26.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C90, Germany 2009 – 2010
Figure 3.26.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for multiple myeloma.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 7,300) 0 7 % (1 in 140) <0 1 % (1 in 34,000) 0 4 % (1 in 230)
45 years <0 1 % (1 in 2,300) 0 7 % (1 in 150) <0 1 % (1 in 7,700) 0 4 % (1 in 220)
55 years 0 1 % (1 in 800) 0 7 % (1 in 150) 0 1 % (1 in 1,900) 0 5 % (1 in 220)
65 years 0 2 % (1 in 420) 0 6 % (1 in 160) 0 1 % (1 in 690) 0 4 % (1 in 230)
75 years 0 3 % (1 in 300) 0 5 % (1 in 210) 0 2 % (1 in 420) 0 4 % (1 in 270)
Lifetime risk 0 7 % (1 in 150) 0 4 % (1 in 230)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 13,000) 0 5 % (1 in 190) <0 1 % (1 in 58,000) 0 4 % (1 in 270)
45 years <0 1 % (1 in 2,900) 0 5 % (1 in 190) <0 1 % (1 in 11,000) 0 4 % (1 in 270)
55 years 0 1 % (1 in 1,200) 0 5 % (1 in 190) <0 1 % (1 in 2,600) 0 4 % (1 in 270)
65 years 0 2 % (1 in 610) 0 5 % (1 in 220) 0 1 % (1 in 990) 0 4 % (1 in 280)
75 years 0 2 % (1 in 430) 0 3 % (1 in 300) 0 2 % (1 in 540) 0 3 % (1 in 340)
Lifetime risk 0 5 % (1 in 190) 0 4 % (1 in 270)
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¹ incl. C88   ² no comparable data for incidence   ³ data for mortality incl. C88
Figure 3.26.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C90, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 
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Figure 3.26.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C90, 2009 – 2010
per 100,000 (European standard)
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Epidemiology
In 2010, some 11,500 people in Germany were diag-
nosed with leukaemia, 6 % of whom were under 15 
years of age. The incidence risk for leukaemia falls 
with increasing age among children and young 
adults independent of gender. Above the age of 30 
the risk increases again continuously, with a higher 
incidence among men than women. More than a 
third of the diagnosed cases were chronic lymphatic 
leukaemia (CLL) and over a quarter of the cases were 
acute myeloid leukaemia (AML). 
The age-standardised incidence rates are decli-
ning among both sexes. However, in view of the 
vague distinction between CLL and non-Hodgkin 
lymphomas (C82-C85), this trend should be inter-
preted carefully, especially since the incidence of the 
latter has increased to a similar extent. The age-stan-
dardised mortality rates for both sexes have declined 
continuously in recent years.
The prognosis for leukaemia depends on its form 
and the age of the subject at diagnosis. It is most 
favourable by far for the leukaemia forms in child-
hood, whereas in adults the acute forms still have a 
poorer prognosis. 
Overall, about half of adult patients are still alive 
five years after diagnosis. However, a permanent 
cure is rarely achieved, e.g. after a risky stem cell 
transplantation.
Risk factors
The risk factors known to cause acute leukaemia 
include ionising radiation in radiotherapy, cytostatic 
drugs in chemotherapy for cancer, and probably also 
various chemicals (e.g. at the workplace). If, for 
example, occupational contact with benzene is a cau-
sal factor, then leukaemia can be recognised as an 
occupational disease.
However, none of these risk factors is found in the 
medical history of most patients. In particular the 
causes of chronic leukaemias are unclear. 
The possible influence of dietary habits and life-
style is under discussion, particularly for chronic 
lymphatic leukaemias. So far, however, there is no 
proof of such influences for this or for other chronic 
and acute forms of leukaemia. 
A number of comparatively rare genetic muta-
tions can increase the incidence risk for leukaemia, 
including trisomy of chromosome 21. Research is 
being carried out into other genetic changes.
The influence of viruses has not been conclusi-
vely proved and is also the subject of research. There 
is also a debate as to whether insufficient training of 
the immune system in childhood contributes 
towards increased risk, with no conclusion having 
yet been reached. No link to exposure to electromag-
netic fields of any origin has been proved.
 2009 2010 Prediction for 2014
 Men Women Men Women Men Women
Incident cases 6,550 5,180 6,640 4,920 6,800 5,300
Crude incidence rate1 16 3 12 7 16 6 11 8 17 2 12 9
Standardised incidence rate1,² 12 4 8 3 12 4 7 7 12 0 8 0
Median age at diagnosis 69 72 70 72
Deaths 3,799 3,308 3,942 3,304
Crude mortality rate1 9 5 7 9 9 8 7 9
Standardised mortality rate1,² 6 5 4 1 6 5 4 0
5-year prevalence 20,100 15,400 20,200 15,100
Absolute 5-year survival rate (2009-2010)3 47 (35-54) 47 (37-54)
Relative 5-year survival rate (2009-2010)3 55 (41-62) 53 (42-61)
Table 3.27.1
Overview of key epidemiological parameters for Germany, ICD-10 C91 – C95
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.27  Leukaemias
 Cancer in Germany | Leukaemias
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Absolute numbers of incident cases and deaths, by sex,
ICD-10 C91 – C95, Germany 1999 – 2010
Figure 3.27.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C91 – C95, Germany 1999 – 2010
per 100,000 (European standard)
 ICD-10 C91 – C95 | Cancer in Germany 
Figure 3.27.2
Age-specific incidence rates by sex, ICD-10 C91 – C95, Germany 2009 – 2010
per 100,000
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Relative survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C91 – C95, Germany 2009 – 2010
Figure 3.27.4a
Absolute survival rates up to 5 years after first diagnosis,  
by sex, ICD-10 C91 – C95, Germany 2009 – 2010
Figure 3.27.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for leukaemias.
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 2,300) 1 3 % (1 in 79) <0 1 % (1 in 9,000) 0 9 % (1 in 110)
45 years 0 1 % (1 in 1,200) 1 2 % (1 in 81) <0 1 % (1 in 3,200) 0 9 % (1 in 110)
55 years 0 2 % (1 in 490) 1 2 % (1 in 83) 0 1 % (1 in 1,200) 0 9 % (1 in 110)
65 years 0 4 % (1 in 250) 1 1 % (1 in 90) 0 3 % (1 in 400) 0 9 % (1 in 110)
75 years 0 6 % (1 in 160) 0 9 % (1 in 110) 0 5 % (1 in 200) 0 8 % (1 in 120)
Lifetime risk 1 4 % (1 in 72) 0 9 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
35 years <0 1 % (1 in 3,300) 0 9 % (1 in 110) <0 1 % (1 in 10,000) 0 7 % (1 in 150)
45 years 0 1 % (1 in 1,500) 0 9 % (1 in 120) <0 1 % (1 in 5,000) 0 7 % (1 in 150)
55 years 0 1 % (1 in 770) 0 8 % (1 in 120) 0 1 % (1 in 1,700) 0 7 % (1 in 150)
65 years 0 2 % (1 in 430) 0 7 % (1 in 140) 0 1 % (1 in 690) 0 6 % (1 in 160)
75 years 0 3 % (1 in 290) 0 6 % (1 in 180) 0 3 % (1 in 330) 0 6 % (1 in 180)
Lifetime risk 1 0 % (1 in 100) 0 7 % (1 in 150)
ALL¹ CLL² AML3 CML4 others5
Men 8 % 40 % 24 % 10 % 18 %
Women 8 % 34 % 30 % 10 % 18 %
Table 3.27.3
Proportion of the various leukaemia forms for all new diagnoses C91 – C95, by sex,  
Germany 2009 – 2010
1 Acute lymphatic leukaemia (C91 0)    2 Chronic lymphatic leukaemia (C91 1)   3 Acute myeloid leukaemia (C92 0)   
4 Chronic myeloid leukaemia (C92 1)    5 incl  unspecified leukaemia forms
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¹ no comparable data for incidence
Figure 3.27.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C91 – C95, 2009 – 2010 or latest available year (details and sources, see appendix)
per 100,000 (European standard) 











































Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C91 – C95, 2009 – 2010
per 100,000 (European standard)
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Rare malignant tumours
A good 5 % of all malignant neoplasms excluding 
non-melanoma skin cancer affect sites which have 
not been covered in the preceding chapters. Of the-
se, approximately half again are malignant tumours 
of unspecified site (C80) or other and ill-defined 
sites (C26, C76). The remainder are presented in 
Table 3.28.1. Detailled results regarding estimated 
nationwide incidence and mortality, for instance 
according to age group and year of diagnosis, can be 
found at www.krebsdaten.de.
Cancer site ICD-10 Incident cases Deaths Ø age at diagnosis rel. 5-Y-SR¹
 Men Women Men Women Men Women total
Small intestine C17 990 840 255 254 68 70 57
Nasal cavity, nasal sinuses and middle ear C30 – C31 510 320 125 56 64 65 58
Mediastinum and other intrathoracic organs C37 – C39 300 210 189 138 67 70 46
Bone and articular cartilage C40 – C41 400 350 239 197 51 57 62
Soft tissue (without Mesothelioma) C46 – C49 2,010 1,870 660 760 66 68 57
Vagina and other female genital organs C52, C57 – C58 1,020 478 71 53
Penis and other male genital organs C60, C63 890 199 70 70
Urinary tract exc  kidney and bladder C65 – C66, C68 1,480 940 1,878 883 73 75 44
Eye C69 440 410 117 120 65 65 65
Adrenal gland and other endocrine glands C74 – C75 160 200 263 252 55 60 46
Waldenström macroglobulinaemia² C88, C96 170 140 86 70 69 72 78
Table 3.28.1
Frequency, median age at diagnosis and survival rates for rare malignant tumours in Germany (2010)
3.28  Rare cancer sites and non-melanoma skin cancer
Non-melanoma skin cancer
Non-melanoma skin cancers can mainly be divided 
into basal cell carcinomas (basaliomas) and  squa-
mous-cell carcinomas, both of which occur particu-
larly in advanced age (Table 3.28.2). The most impor-
tant risk factor for both forms is the long-term 
impact of the ultraviolet part of sunshine, which is 
why they are particularly located on the face or on the 
head and neck.
The basalioma metastasises only in very rare 
exceptional circumstances and therefore is not usu-
ally life-threatening. It can however grow destruc-
tively in the surrounding tissue and can considerably 
affect quality of life given an unfavourable site. The 
relative survival rate of over 100 % for basalioma can 
be probably be  explained by the fact that suspicious 
skin changes especially in old age are more likely to 
heal completely in otherwise healthy people. 
In the case of squamous-cell carcinoma, metasta-
ses occur somewhat more frequently, the prognosis 
is however generally good. An acquired immune 
deficiency and/or supression through medication, 
for example following transplant surgery, can encou-
rage the occurrence of this tumour. 
Rare forms of skin cancer include, amongst 
others, Merkel-cell tumours, fibrosarcoma and carci-
noma of the  sebaceous and sweat glands. In cause 
of death statistics, no differentiation can be made 
between the various forms of non-melanoma skin 
cancer.  
1 relative 5-year survival rate in percentage, men and women, period 2009-2010  
2 and other malignant neoplasms of lymphoid, haematopoietic and related tissue 170 890
Cancer site ICD-O-3 Incident cases Deaths Ø age at diagnosis rel. 5-Y-SR¹
 Men Women Men Women Men Women total
Basaliomas 809-811 77,800 73,800 71 71 104
Squamous cell carcinomas 805-808 22,000 14,700 76 79 95
unspecific histology 800-804 400 300 75 78 80
other types other 900 700 73 75 81
total all 101,100 89,500 346 275 72 72 102
Table 3.28.2
Frequency, median age at diagnosis and survival rates for types of non-melanoma skin cancer in Germany (2010)
1 relative 5-year survival rate in percentage, men and women, period 2009-2010
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4  Cancer in children
The German Childhood Cancer Registry (GCCR) 
has been based at the Institute of Medical Biostatis-
tics, Epidemiology and Informatics at the University 
Medical Centre of the Johannes Gutenberg Univer-
sity Mainz, since beginning its work in 1980. Close 
cooperation with the Society for Paediatric Oncology 
and Haematology (GPOH) and its associated hospi-
tals was part of the GCCR‘s original conception. 
This is a characteristic feature of the registry which 
cannot be easily applied to adult oncology. This nati-
onwide, population based childhood cancer registry 
with a high level of data quality and a degree of com-
pleteness of over 95 % (since about 1987) has been 
built up covering the whole of Germany. The GCCR 
thus meets international standards for population 
based cancer registries. A further characteristic of 
the GCCR is that it has implemented an active, 
open-end, long-term follow-up observation system 
which continues long into adulthood. In this way, 
the registry also provides the basis for research into 
long-term effects and secondary tumours, and for 
studies with long-term survivors in general. The 
registry population comprises children who are dia-
gnosed with a malignant disease or a histologically 
benign brain tumour before their 15th birthday and 
are part of the resident population of the Federal 
Republic of Germany when diagnosed. Cancer cases 
in eastern Germany have also been registered since 
1991. The current data pool consists of over 52,000 
cancer cases. Since 1 January 2009, the GCCR has 
been registering all children and adolescents up to 
the age of 18 years (i.e. who are diagnosed before 
their 18th birthday) on the basis of the ”Agreement 
of the Joint Federal Committee on Quality-Assu-
rance Measures for the In-Patient Care of Children 
and Adolescents with Haemato-Oncological Disea-
ses (GBA)”. This will make it possible to better con-
sider the needs of the collaborating hospitals which 
have been combining paediatric and adolescent 
medicine for several years now and thus also treat 
cancer patients aged 15 years and over. 
Incidence of childhood cancers
About 1,800 cases of childhood cancer are newly dia-
gnosed every year in Germany. With an overall 
population of approx. 11 million children under the 
age of 15 years, this means an annual incidence of 
about 16.0 per 100,000 children in this age group. 
The likelihood that a newborn child will develop a 
malignant disease within the first 15 years of his/her 
life is 0.2 %. In other words, a malignant cancer is 
diagnosed in approx. one in 420 children up to their 
15th birthday.
Range of diagnoses
The pattern of cancer diagnoses in children is com-
pletely different from that of adults. For example, 
children are mostly affected by embryonal tumours 
(neuroblastomas, retinoblastomas, nephroblasto-
mas, medulloblastomas, embryonic rhabdomyosar-
comas or germ-cell tumours); carcinomas, by cont-
rast, are very rare in childhood (making up about 
2 % of all malignant diseases). The largest diag-
nostic groups are leukaemias (33.8 %), CNS tumours 
(24.0 %) and lymphomas (11.1 %). Overall cancer 
incidence among children under the age of five is 
about twice as high as in the 5- to 14-year-old age 
group. The median age at onset among the under-
15-year-olds is five years, eleven months. Boys are 
diagnosed with cancer 1.2 times more frequently 
than girls.
Leukaemias
Leukaemias make up more than a third of all can-
cers among the under-15-year-olds. The most com-
mon single diagnosis overall (26.3 %) is acute lym-
Lymphomas  11,1 %  
CNS tumours  24,0 %  
Peripheral nervous cell tumours  7,0 %  
Soft-tissue sarcomas  5,8 %
Kidney tumours  5,5 %  
Bone tumours  4,4 %  
Other diagnoses  5,4 %   
Germ-cell tumours  3,0 % 
Leukaemias  33,8 %
Figure 4.1
Cancer in children (determined for the period 2003 – 2012)
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phatic leukaemia (ALL). It occurs more than twice as 
frequently among children under the age of five as 
in the other age groups. 4.4 % of all childhood mali-
gnancies are acute myeloid leukaemias (AML). AML 
is most common among children under the age of 
two. The survival prospects for AML are markedly 
lower than for ALL. The causes of leukaemias in 
childhood remain largely uncertain, even today. For 
a long time, environmental influences were suspec-
ted of causing childhood leukaemias. Since then it 
has been shown that the number of cases caused by 
most environmental factors (low-dose ionising radi-
ation, non-ionising radiation and pesticides) is quite 
small after all, even if a weak association with leuka-
emias in childhood cannot be ruled out. A number 
of clues have meanwhile strengthened hypotheses 
that assign a key role to infectious pathogens in the 
development of childhood leukaemias. Especially 
children with an insufficiently modulated immune 
system in infancy can have a higher risk of develo-
ping leukaemia.
CNS tumours
The most common single diagnoses among CNS 
tumours are astrocytomas (total: 11.1 %), intracranial 
and intraspinal embryonal tumours (4.6 %) and 
ependymomas (2.4 %). The increase in the incidence 
of CNS tumours observed in a number of western 
countries over the past decades may be connected 
with general changes in environmental factors and 
related exposures. For example, a number of epide-
miological studies is looking into the possible influ-
ence of ionising radiation, electromagnetic fields, 
pesticides, the mother‘s diet and genetic aspects.
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Figuer 4.4
Trends of the incidence of selected diagnostic groups and for all childhood malignancies
Number of cases per 100,000 (age standardised), including eastern Germany since 1991
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nificantly more differentiated diagnostics and the 
use of multimodal therapy concepts. In the early 
1980s the chances of children with cancer being still 
alive five years after diagnosis were 67 %; this figure 
has risen to 84 % since then. Looking at all patients 
of the registry population who were diagnosed bet-
ween 2001 and 2010 and followed up, the overall 
chance of survival is 84 % after five years, 82 % after 
ten years, and 81 % after 15 years. The encouraging 
increase in the number of long-term survivors is 
increasingly focusing attention on the long-term 
observation of former paediatric cancer patients. The 
GCCR provides an ideal data basis for carrying out 
studies with long-term survivors. As the above figu-
res show, it is already possible to provide information 
on long-term survival (for example after 15 years) and 
to estimate the risk of developing a second malig-
nancy after cancer in childhood. Examples of further 
research possibilities include the incidence of other 
long-term effects, such as the possible effects of the-
rapy on fertility, and studies examining the health 
risks of the descendants of fathers and mothers who 
had childhood cancer. About 22,000 of the more 
than 37,000 patients currently known to be alive 
have been under observation by the registry for at 
least ten years. About three quarters of these patients 
are at least 18 years old.
 
Table 4.1
Incidence and survival rates for the most common diagnoses, determined for the period 2001 – 2010
Cancer sites Incidence* Survival rate in %**
after 5 years after 10 years after 15 years
Hodgkin‘s lymphomas 0 6 98 98 97
Retinoblastomas 0 4 98 97 97
Germ-cell tumours 0 5 95 94 94
Nephroblastomas 1 0 93 92 92
Lymphoid leukaemias 4 4 91 89 88
Non-Hodgkin lymphomas 0 6 89 88 86
Astrocytomas 1 7 81 79 77
Neuroblastomas and ganglioneuroblastomas 1 4 79 76 75
Osteosarcomas 0 3 76 72 71
Rhabdomyosarcomas 0 5 72 71 69
Acute myeloid leukaemias 0 7 72 70 69
Ewing’s tumours and related bone sarcomas 0 3 70 66 65
Intracranial and intraspinal embryonal tumours 0 8 67 60 56
All malignancies 16 4 84 82 81
*  Related to 100,000 children under the age of 15, age standardised (standard: Segi world population), children diagnosed 2003 – 2012
** Brenner H, Spix C  Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates  Br J Cancer 89, 
1260-1265, 2003
Lymphomas
The most common lymphomas are non-Hodgkin 
lymphomas (NHL), including Burkitt‘s lymphoma 
(total: 6.4 %) and Hodgkin’s lymphoma (4.7 %). The 
chances of survival with Hodgkin’s lymphoma are 
among the best in paediatric oncology. Children with 
congenital or acquired immunodeficiency and those 
who have had immunosuppressive therapy are at 
increased risk of developing NHL. An association is 
suspected between lymphomas and ionising radiati-
on; this has not, however, been substantiated.
Other common malignant diseases
Other common malignant diseases in childhood 
include neuroblastomas (nerve-cell tumours), neph-
roblastomas (kidney tumours), germ-cell tumours, 
bone tumours and rhabdomyosarcomas (tumours of 
the skeletal musculature). Among these malignan-
cies, the prognosis for children with nephroblastoma 
or a germ-cell tumour is much more favourable than 
for the others.
Survival
Children with cancer make up fewer than 1 % of all 
cancer patients. However, malignant neoplasms are 
the second most common cause of death among 
children. Fortunately, the survival rates have impro-
ved dramatically over the last 30 years thanks to sig-
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After the Federal Cancer Registry Data Act (Bundes-
krebsregisterdatengesetz – BKRG) came into force 
in August 2009, the German Centre for Cancer 
Registry Data was set up as an independent division 
within the Robert Koch Institute’s Department of 
Epidemiology and Health Reporting to perform the 
tasks laid down in the Act:
 ▶ to check the completeness of case finding and of 
the variables included in the anonymised data 
submitted by the epidemiological (population-
based) state cancer registries
 ▶ to analyse these data
 ▶ to publish the findings on cancer incidence in 
Germany and its development over time together 
with the Association of Population based Cancer 
Registries in Germany (GEKID)
 ▶ to conduct a nationwide record linkage with the 
data from the different state cancer registries to 
discover any duplicate notifications and to 
inform the cancer registries accordingly
 ▶ to compile, update and extrapolate a dataset 
from the reviewed data from the state cancer 
registries
 ▶ to regularly estimate and analyse survival rates, 
stage distribution at diagnosis of the respective 
cancer, and other indicators, particularly on pre-
valence, the risk of developing and dying of the 
disease, and how these indicators develop over 
time
 ▶ to examine data from various states to determine 
any regional differences in selected cancer sites
 ▶ to provide a dataset for evaluating health-policy 
measures of cancer prevention, cancer scree-
ning, cancer treatment and healthcare
 ▶ to conduct analyses and studies on all aspects of 
cancer
 ▶ to write a comprehensive report on cancer in 
Germany every five years
 ▶ to further enhance methods and standardisation 
rules on data collection and data transfer, and to 
analyse the data together with the state cancer 
registries
 ▶ to collaborate in scientific bodies as well as Euro-
pean and international organisations on
 ▶ cancer registration and cancer epidemiology
The work of the German Centre for Cancer Regis-
try Data is supported by a scientific advisory board 
with an office at the RKI. This advisory board can 
also give permission for the dataset at the Centre 
for Cancer Registry Data to be made available to 
third parties on application – i.e. in addition to the 
state cancer registries – if a justified and, in parti-
cular, scientific interest can be substantiated. 
Further information on the German Centre for Can-
cer Registry Data is available on the Internet at 
www.krebsdaten.de. 
Staff of the German Centre for Cancer Registry 
Data:















The German Centre for Cancer Registry Data (Zentrum für Krebsregisterdaten, ZfKD)
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The Association of Population-based Cancer Regist-
ries in Germany (GEKID) was formed in 2004 as a 
registered, non-profit-making association. GEKID’s 
members include not only all Germany’s populati-
on-based cancer registries, but also a tumour centre 
and interested scientists working in the field of can-
cer epidemiology. In the field of cancer control, 
GEKID cooperates closely with the Federal Ministry 
of Health, particularly in the context of the National 
Cancer Plan, and the German Centre for Cancer 
Registry Data based at the Robert Koch Institute 
(RKI). GEKID also participates actively in a wide 
range of scientific committees especially in working 
groups preparing the establishment of nationwide 
clinical cancer registration.
The association’s primary task is to standardise 
as far as possible the content and methodology of 
cancer registration, despite the differences in legis-
lation between the federal states. The comparability 
of results from the cancer registries can only be 
assured by nationwide cooperation. To promote 
such cooperation, GEKID published ”The Manual of 
Population-based Cancer Registration” in 2008. 
Furthermore, GEKID is a joint point of contact for 
the population-based cancer registries on all issues 
of common interest and represents the registries at 
the European level, e.g. in the European Network of 
Cancer Registries (ENCR). In its charter, GEKID has 
set itself the following tasks:
 ▶ to be the point of contact both for national and 
international cooperation partners and for the 
interested public
 ▶ to provide information on the status of cancer 
registration in Germany and explain the aims of 
population-based cancer registration
 ▶ to engage in joint information activities and thus 
help the individual cancer registries achieve and 
maintain complete registration
 ▶ to define standards on content as a basis for the 
comparability of population-based cancer regist-
ries
 ▶ to coordinate tasks involving all the registries 
and foster contacts with clinical tumour docu-
mentation
 ▶ to initiate joint research activities 
 ▶ to promote the scientific use of the population 
based cancer registries
 ▶ to use the data to advance quality assurance in 
oncological care 
Information on GEKID can be obtained on the 
Internet at www.gekid.de or from the respective 
regional member registries (see address section).
Contacts for the Association of Population-based 
Cancer Registries in Germany (Gesellschaft der epi-
demiologischen Krebsregister in Deutschland e.V., 
GEKID) (see address section):
Prof Dr Alexander Katalinic 
(Chair of GEKID, Schleswig-Holstein Cancer 
Registry)
Dr Stefan Hentschel 
(1st Vice-chair, Hamburg Cancer Registry)
Roland Stabenow 
(2nd Vice-chair, Joint Cancer Registry)
Association of Population-based Cancer Registries in Germany
136 Cancer in Germany | Appendix
The cancer Information service ”KID” was set up in 
1986 to provide personal telephone contacts for pati-
ents and their relatives with questions regarding can-
cer. Nowadays, medical staff provides up-to-the 
minute, scientifically sound answers to around 
30,000 questions every year by phone, by e-mail and 
in consultation surgeries in both Heidelberg and 
Dresden. This encompasses not only patients, relati-
ves and interested citizens - even representatives 
from expert groups concerned with the care of can-
cer patients turn to the Cancer Information Service. 
The information on offer is individually tailored to 
the needs of the various target groups:
 ▶ Patients, their relatives and friends are provided 
with answers to their questions relating to diag-
nosis and cancer treatment options, on living 
with the disease and links to additional points of 
contact within the healthcare system. However, 
interested citizens with questions on risk fac-
tors, cancer prevention and early detection or on 
cancer research can also obtain comprehensive 
information by contacting the Cancer Informati-
on Service. This strengthens the health literacy 
of individuals and creates the basis for active 
interaction and joint decision-making between 
patients or beneficiaries and the attending phy-
sicians. 
 ▶ Specialists professionally concerned with the 
subject of cancer receive quick and reliable per-
tinent information on the basis of the best availa-
ble scientific evidence. Through clearly structu-
red preparation, research results are made trans-
parent and directly usable for patient care. 
Source references, individually compiled for 
experts in the written e-mail replies, enable 
more in-depth study of relevant literature. 
Via its website www.krebsinformationsdienst.de the 
Cancer Information Service conveys the latest know-
ledge about cancer, useful addresses and tips on 
further links and information material. Between 
200,000 and 300,000 individual visitors per month 
use this facility. For specialist groups, the website 
offers an introduction into a wealth of cancer-related 
topics and provides references to further scientific 
sources. On the social networking site Facebook, the 
service posts breaking news and invites discussion. 
The Cancer Information Service is provided by 
the German Cancer research Centre in Heidelberg, 
the largest bio-medical research establishment in 
Germany. The service is financed by funds from the 
Federal Ministry of Education and Research (BMBF), 
the State of Baden-Württemberg’s Ministry of Sci-
ence, Research and Art (MWK) and the Federal 
Ministry of Health. As a result, the service can pro-
vide information independently, free from conflicts 
of interest and free of charge. In its capacity as nati-
onal reference centre for cancer information, the 
Cancer Information Service is committed to provi-
ding the highest possible standard of information. 
Through its accompanying research the Cancer 
Information Service also provides feedback on how 
the care situation in Germany is directly experienced 
by cancer patients and their relatives.  
Further information on the remit and wor- 
kings of the Cancer Information Service can be 
found (in German) by following the link: 
www.krebsinformationsdienst.de/wirueberuns.php  
Cancer Information Service (KID) 
Telephone: + 49 (0) 800 – 420 30 40, (Free inside 
Germany) Daily from 08.00 to 20.00 hrs.
E-Mail:   krebsinformationsdienst@dkfz.de, 
Answers usually within 2 working days 
Internet: www.krebsinformationsdienst.de  and 
www.facebook.com/krebsinformationsdienst 
Contact partners at the Cancer Information Service 
- KID (also see address section):
Dr. Susanne Weg-Remers
Head of the Cancer Information Service (KID)
Dr. Regine Hagmann
Head of Working Group “Knowledge Manage-
ment” at KID
KID – The Cancer Information Service provided by the German Cancer Research Centre
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Addresses
Krebsregister Baden-Württemberg (Baden-Württemberg Cancer Registry)
Epidemiologisches Krebsregister (Population-based Cancer Registry)
Deutsches Krebsforschungszentrum (German Cancer Research Centre)
Im Neuenheimer Feld 581
69120 Heidelberg Telephone: 06221/42 42 20 Telefax: 06221/42 22 03 
 Email: ekr-bw@dkfz.de 
 Internet: www.krebsregister-bw.de
Vertrauensstelle* Baden-Württemberg (Baden-Württemberg Confidentiality Unit)
Deutsche Rentenversicherung (German Pension Insurance) Baden-Württemberg
Gartenstr. 105
76135 Karlsruhe Telephone:  0721/82 57 90 00 Telefax:  0721/82 59 97 90 99 
 Email:  vs@drv-bw.de
Klinische Landesregisterstelle* (Clinical State Registration Unit)
Baden-Württembergische Krankenhausgesellschaft e.V. (Baden-Württemberg Hospital Association)
Birkenwaldstr. 151
70191 Stuttgart Telephone: 0711/2 57 77 70 Telefax: 0711/2 57 77 79 
 Email: info@klr-krbw.de
Bevölkerungsbezogenes Krebsregister Bayern (Bavaria Population-based Cancer Registry)
Registerstelle* (Registry Unit)
Östliche Stadtmauerstr. 30






90419 Nürnberg Telephone: 0911/3 78 67 38 Telefax: 0911/3 78 76 19 
 Email: vertrauensstelle@klinikum-nuernberg.de 
 Internet: www.krebsregister-bayern.de
Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern,  
Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen (Joint Cancer Registry of Berlin, Brandenburg, 
Mecklenburg-West Pomerania, Saxony-Anhalt, Saxony and Thuringia), GKR
Brodauer Str. 16-22
12621 Berlin Telephone: 030/56 58 14 01 (R) Telefax: 030/56 58 14 44 (R) 
                030/56 58 13 15 (V)  030/56 58 13 33 (V)
 Email: registerstelle@gkr.berlin.de
              vertrauensstelle@gkr.berlin.de
 Internet: www.berlin.de/gkr/
Epidemiologisches Krebsregister Bremen (Bremen Cancer Registry)
Leibniz-Institut für Präventionsforschung und Epidemiologie (Leibniz Institute for Prevention Research 
and Epidemiology), BIPS GmbH
Achterstr. 30
28359 Bremen Telephone: 0421/2 18 569 61 (R) Telefax: 0421/2 18 569 41 (R)
  0421/2 18 569 99 (V)
 Email: krebsregister@bips.uni-bremen.de (R)
              vbkr.kvhb@t-online.de (V)
 Internet: www.krebsregister.bremen.de
R = Registerstelle (Registry Unit)        V = Vertrauensstelle (Confidentiality Unit)
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Hamburgisches Krebsregister (Hamburg Cancer Registry) 
Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz  
(State Ministry of Social Affairs, Family, Health and Consumer Protection) 
Billstr. 80A
20539 Hamburg Telephone: 040/4 28 37 22 11 Telefax: 040/4 27 31 00 94 
 Email: HamburgischesKrebsregister@bgv.hamburg.de 
 Internet: www.hamburg.de/krebsregister
Krebsregister Hessen (Hesse Cancer Registry) 
Registerstelle* (Registry Unit)
Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen  
(Hesse State Health Office), HLPUG
Wolframstr. 33
35683 Dillenburg Telephone: 02771/32 06 39 Telefax: 02771/3 66 71 
 Email: stefan.gawrich@hlpug.hessen.de 
 Internet: www.hlpug.de
Vertrauensstelle* (Confidentiality Unit) of Hesse Cancer Registry at
Landesärztekammer Hessen (Hesse State Medical Council)
Im Vogelsgesang 3
60488 Frankfurt/Main Telephone: 069/7 89 04 50 Telefax: 069/78 90 45 29
 Email:  vertrauensstelle@laekh.de
 Internet:  www.laekh.de
Epidemiologisches Krebsregister Niedersachsen (Lower Saxony Population-based Cancer Registry) 
OFFIS CARE GmbH 
Industriestr. 9
26121 Oldenburg Telephone: 0441/3 61 05 60 (R) Telefax: 0441/36 10 56 10 (R) 
  0511/4 50 53 56 (V)  0511/4 50 51 32 (V) 
 Email: registerstelle@krebsregister-niedersachsen.de (R)
  vertrauensstelle.ekn@nlga.niedersachsen.de (V)
 Internet: www.krebsregister-niedersachsen.de
Epidemiologisches Krebsregister Nordrhein-Westfalen gGmbH 
(North Rhine-Westphalia Population-based Cancer Registry) 
Robert-Koch-Str. 40
48149 Münster Telephone: 0251/8 35 85 71 Telefax: 0251/8 35 85 77 
 Email: info@krebsregister.nrw.de 
 Internet: www.krebsregister.nrw.de
 
Krebsregister Rheinland-Pfalz (Rhineland-Palatinate Cancer Registry)
Registerstelle* (Registry Unit)
Institut für Medizinische Biometrie, Epidemiologie und Informatik  
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI
Obere Zahlbacher Str. 69
55131 Mainz Telephone: 06131/17 29 68 Telefax: 06131/17 32 47
 Email: krebsregister@imbei.uni-mainz.de 
 Internet: www.krebsregister-rheinland-pfalz.de
Vertrauensstelle* (Confidentiality Unit) 
Am Pulverturm 13
55131 Mainz Telephone: 06131/17 30 02 Telefax: 06131/17 32 47
 Email: krebsregister@mail.uni-mainz.de 
 Internet: www.krebsregister-rheinland-pfalz.de
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Epidemiologisches Krebsregister Saarland (Saarland Population-based Cancer Registry)
Ministerium für Soziales, Gesundheit, Frauen und Familie  
(Ministry of Social Affairs, Health, Women and Family)
Präsident-Baltz-Str. 5
66119 Saarbrücken Telephone: 0681/5 01 59 82 (R) Telefax: 0681/5 01 59 98 (R)
  0681/5 01 58 05 (V)
 Email: krebsregister@gbe-ekr.saarland.de
 Internet: www.krebsregister.saarland.de
Krebsregister Schleswig-Holstein (Schleswig-Holstein Cancer Registry)
Institut für Krebsepidemiologie e.V. (Institute of Cancer Epidemiology)
Ratzeburger Allee 160, Haus 50
23538 Lübeck Telephone: 0451/5 00 54 40 Telefax: 0451/5 00 54 55
 Email: info@krebsregister-sh.de 
 Internet: www.krebsregister-sh.de
Vertrauensstelle* (Confidentiality Unit)
Ärztekammer Schleswig-Holstein (Schleswig-Holstein Medical Council)
Bismarckallee 8-12
23795 Bad Segeberg Telephone: 04551/80 31 04 Telefax: 04551/80 31 88 
 
Deutsches Kinderkrebsregister (German Childhood Cancer Registry)
Institut für Medizinische Biometrie, Epidemiologie und Informatik  
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI
Obere Zahlbacher Str. 69
55131 Mainz Telephone: 06131/17 31 11 Telefax: 06131/17 44 62
 Email: kinderkrebsregister@imbei.uni-mainz.de  
 Internet: www.kinderkrebsregister.de
Further contacts:
Zentrum für Krebsregisterdaten im Robert Koch-Institut  
(German Centre for Cancer Registry Data at the Robert Koch Institute) 
General-Pape-Str. 62-66
12101 Berlin Telephone: 030/1 87 54 33 82 Telefax: 030/1 87 54 33 54
 E-Mail: krebsdaten@rki.de
 Internet: www.krebsdaten.de
Bundesministerium für Gesundheit (Federal Ministry of Health) 
53107 Bonn
Referat 311 Telephone: 0228/9 94 41 15 10 Telefax: 0228/9 94 41 49 62
Referat 315 Telephone: 0228/9 94 41 31 08 Telefax: 0228/9 94 41 49 38
 E-Mail: poststelle@bmg.bund.de
 Internet: www.bmg.bund.de
Cancer Information Service 
German Cancer Research Centre
Im Neuenheimer Feld 280
69120 Heidelberg Telephone: 06221/42 28 90 (secretariat) 
 E-Mail: krebsinformationsdienst@dkfz.de 
 Internet: www.krebsinformationsdienst.de 
* To protect patients’ confidentiality, responsibility for cancer registration in Germany is often divided between Confidentiality Units (Vertrauensstellen, V) and 
Registry Units (Registerstellen, R)  Cancer morbidity and mortality notifications are sent to the Confidentiality Units, where personal information is anonymised  
Along with the corresponding medical data, these anonymised data are then sent to the Registration Units, which are responsible for maintaining and analysing 
the registry database 
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Sources for international comparison of cancer incidence and mortality rates 
(for the years 2009 – 2010, if not otherwise stated. Access date: June to October 2013)
Netherlands: Netherlands Cancer Registry
 http://www.cijfersoverkanker.nl/?language=en
Sweden, Finland,  Association of the Nordic Cancer Registries (ANCR) 
Denmark: http://www-dep.iarc.fr/NORDCAN/english/frame.asp
Poland: National Cancer Registry 
 http://epid.coi.waw.pl/krn/english/
 
Czech Republic: Institute of Health Information and Statistics of the Czech Republic (UZIS)
 Cancer Incidence 2009 (2010) in the Czech Republic (http://www.uzis.cz/)
 SVOD Web Portal (http://www.svod.cz/?sec=aktuality&lang=en)
Switzerland: Foundation National Institute for Cancer Epidemiology and Registration
 http://www.nicer.org/NicerReportFiles/report/atlas.html?&geog=0
 (mean value for the years 2006 to 2010)
 
Belgium: Incidence:
 Belgian Cancer Registry
 http://www.kankerregister.org/
 Mortality:
 Ministerie van den Vlaamse Gemeenschap
 https://www.wiv-isp.be/epidemio/spma/
 (Mortality data only for the year 2009)
 
France: Institut de veille sanitaire
 Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff A-S, Bossard N. 
 Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012. 
 Partie 1 - Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire; 2013.
 Alain Monnereau, Laurent Remontet, Marc Maynadié, Florence Binder-Foucard, Aurélien Belot,   
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The “Cancer in Germany” report is published every two years 
by the Association of Population-based Cancer Registries in 
Germany (GEKID) and the German Centre for Cancer Registry 
Data (ZfKD) at the Robert Koch Institute. The results contained 
in this, the ninth edition are based on data up to 2010. In the 
meantime, population-based cancer registration has achieved 
nationwide coverage in Germany. However, because reliable data 
is not yet available from all federal states, it is still  
necessary for the ZfKD to estimate figures in some areas. 
Included for the first time in this edition are chapters on pleura 
mesothelioma and vulvar cancer. Altogether, this report  
presents the most important epidemiological measured  
values and current trends for 26 different types of cancer.  
Details are contained with regard to disease incidence and  
mortality, along with regional and international comparisons,  
as well as illustrations of the distribution of tumour stages and 
of survival prospects. 
As in earlier editions, details on cancer in children are  
presented in a separate chapter by the German Childhood  
Cancer Registry. 
For the year 2010, the number of new cases of cancer in Germany 
was estimated by the ZfKD at approximately 477,300, of which 
252,400 cases were among men and 224,900 in women. This 
means the number of new cases annually has increased by around 
71,500 since the year 2000. This is primarily to be attributed to  
the continually growing proportion of older people within our  
population.  The most frequently occurring types of cancer are 
breast cancer with around 70,300 new cases, prostate cancer  
(just under 66,000) and bowel cancer (62,400).  Among women 
an increase is to be reported in the age-standardised incidence 
rates for breast cancer and malignant melanoma, as well as for 
tumours of the lung, thyroid, vulva, oral cavity and pharynx.   
Declining incidence rates were observed in cancerous diseases  
of the stomach, gall bladder and biliary tract, the bowel and the 
ovaries. In men, incidence rates since the year 2000 have  
increased with regard to malignant melanoma, prostate cancer 
and liver cancer whereas in contrast incidence rates fell in  
tumours of the stomach, lungs, oesophagus and the bladder.  
For 2014, the ZfKD estimates about half a million new cases of 
cancer in Germany. 
